



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 205 478 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC.

(43) Date of publication:
15.05.2002 Bulletin 2002/20

(51) Int Cl.7: **C07D 417/04**

(21) Application number: **00951874.7**

(86) International application number:
PCT/JP00/05198

(22) Date of filing: **03.08.2000**

(87) International publication number:
WO 01/10865 (15.02.2001 Gazette 2001/07)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

- **NARUO, Kenichi**
Sanda-shi, Hyogo 669-1535 (JP)
- **KIMURA, Hiroyuki**
Sakai-shi, Osaka 590-0975 (JP)
- **MIWATASHI, Seiji**
Kawabe-gun, Hyogo 666-0261 (JP)

(30) Priority: **06.08.1999 JP 22465199**

(71) Applicant: **Takeda Chemical Industries, Ltd.**
Osaka-shi, Osaka 541-0045 (JP)

(74) Representative:
von Kreisler, Alek, Dipl.-Chem. et al
Patentanwälte
von Kreisler-Selting-Werner
Postfach 10 22 41
50462 Köln (DE)

(72) Inventors:
• **OHKAWA, Shigenori**
Takatsuki-shi, Osaka 569-1121 (JP)

(54) **p38MAP KINASE INHIBITORS**

(57) A 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s) has a superior p38 MAP kinase inhibitory activity and TNF- α production inhibitory activity.

EP 1 205 478 A1

BEST AVAILABLE COPY

Description

Technical Field

[0001] The present invention relates to superior p38 MAP kinase inhibitors, selective phosphodiesterase IV (PDE IV) inhibitors and the like. More particularly, the present invention relates to a pharmaceutical agent containing a 1,3-thiazole compound having a prophylactic or therapeutic activity of cytokine-mediated diseases, based on a p38 MAP kinase inhibitory activity, a TNF- α production inhibitory activity, a phosphodiesterase (PDE) inhibitory activity and the like.


Background Art

[0002] Cytokines such as TNF- α (tumor necrosis factor- α), IL-1 (interleukin-1) and the like are biological substances which are produced by a variety of cells such as monocyte or macrophage in response to the infection and other cellular stress (Koj, A., Biochim. Biophys. Acta, 1317, 84-94 (1996)). Although these cytokines play important roles in the immune response when they are present at an appropriate amount, it is thought that the overproduction is associated with a variety of inflammatory diseases (Dinarello, C.A., Curr. Opin. Immunol., 3, 941-948 (1991)). p38 MAP kinase which was cloned as a homologue of MAP kinase is involved in the control of production of these cytokines and signal transduction system coupled with receptors, and there is a possibility that the inhibition of p38 MAP kinase provides a drug for treating inflammatory diseases (Stein, B., Anderson, D., Annual Report in Medicinal Chemistry, edited by Bristol, J.A., Academic Press, vol.31, pages 289-298, 1996).

[0003] As compounds having a p38 MAP kinase inhibitory activity, imidazole derivatives are described in JP-T 7-50317 (WO 93/14081) and oxazole derivatives are described in JP-T 9-505055 (WO 95/13067), respectively.


[0004] On the other hand, as thiazole compounds, the following compounds are known:

1) 1,3-thiazole derivatives represented by the formula:




wherein R¹ represents a cycloalkyl group, a cyclic amino group, an amino group optionally having, as substituent(s), 1 or 2 lower alkyl, phenyl, acetyl or lower alkoxyacetyl, an alkyl group optionally having, as substituent(s), hydroxyl, carboxyl or lower alkoxy, or a phenyl group optionally having, as substituent(s), carboxyl, 2-carboxyethenyl or 2-carboxy-1-propenyl, R² represents a pyridyl group optionally having, as substituent(s), lower alkyl, R³ represents a phenyl group optionally having, as substituent(s), lower alkoxy, lower alkyl, hydroxyl, halogen or methylenedioxy, or salts thereof, which have analgesic, antipyretic, anti-inflammatory, anti-ulcerative, thromboxane A₂ (TXA₂) synthase-inhibitory, and platelet coagulation-inhibitory activities (JP-A 60-58981),

2) 1,3-thiazole derivatives represented by the formula:




wherein R¹ represents an alkyl group, an alkenyl group, an aryl group, an aralkyl group, a cycloalkyl group, a heterocyclic group employing carbon as an attachment point or an amino group optionally having substituent(s), R² represents a pyridyl group optionally substituted with alkyl group(s), R³ represents a phenyl group optionally having substituent(s), or salts thereof, which have analgesic, antipyretic, anti-inflammatory, anti-ulcerative, TXA₂ synthase-inhibitory, and platelet coagulation-inhibitory activities (JP-A 61-10580),


3) 1,3-thiazole derivatives represented by the formula:




wherein R¹ represents an alkyl group, an alkenyl group, an aryl group, an aralkyl group, a cycloalkyl group, a heterocyclic group employing carbon as an attachment point or an amino group optionally having substituent(s), R² represents a pyridyl group optionally substituted with alkyl group(s), R³ represents an aryl group optionally having substituent(s), or salts thereof, which have analgesic, antipyretic, anti-inflammatory, anti-ulcerative, TXA₂ synthase-inhibitory, and platelet coagulation-inhibitory activities (USP 4,612,321),
4) a compound of the formula




wherein R¹ represents an optionally substituted phenyl, R² represents C₁₋₆ alkyl or (CH₂)_nAr, n represents 0-2, Ar represents an optionally substituted phenyl, R³ represents a hydrogen or C₁₋₄alkyl, R⁴ represents a hydrogen, C₁₋₄ alkyl and the like, R⁵ represents a hydrogen or C₁₋₄ alkyl, R⁶ represents a hydrogen, C₁₋₄ alkyl and the like, or a salt thereof, having an inhibitory activity of gastric acid secretion (JP-T 7-503023, WO93/15071),
5) a compound of the formula



wherein R¹ represents pyridyl and the like, R² represents phenyl and the like, R³ and R⁴ represent a hydrogen or methyl, R⁵ represents methyl and the like, and R⁶ represents a hydrogen, methyl and the like, or a salt thereof, which is an antiinflammatory agent and antiallergic agent (DE-A-3601411),
6) a compound of the formula



wherein R¹ represents a lower alkyl substituted by halogen, R² represents pyridyl and the like, and R³ represents phenyl and the like, or a salt thereof, having an antiinflammatory, antipyretic, analgesic and antiallergic activity (JP-A-5-70446), and
7) a thiazole compound of the formula




wherein R represents a lower alkyl group; a lower haloalkyl group; a lower hydroxyalkyl group; a lower alkoxy(lower) alkyl group; an aralkyloxy(lower)alkyl group and the like, R¹ represents a cycloalkyl group optionally substituted by lower alkyl group(s) and the like, and R² represents an optionally substituted aryl group and the like, or a pharmaceutically acceptable salt thereof, having a selective inhibitory activity of TNF- α production and/or IFN- γ production (JP-A-11-49762).

[0005] Inasmuch as a p38 MAP kinase inhibitor, TNF- α production inhibitor or PDE IV inhibitor satisfactory in the action effect, safety, metabolism stability and the like has not been found yet, the development of a p38 MAP kinase inhibitor, TNF- α production inhibitor or PDE IV inhibitor having superior property as a pharmaceutical agent effective for the prophylaxis or treatment of cytokine-mediated diseases and the like has been demanded.

Disclosure of the Invention

[0006] The present inventors studied variously and, as a result, have first found that a 1,3-thiazole compound (hereinafter sometimes to be briefly referred to as Compound (I)) characterized by a chemical structure where the 1,3-thiazole structure is substituted at the 5-position by a pyridyl group optionally having substituent(s) includes, for example, a compound of the formula (Ia)



wherein


R¹ represents a hydrogen atom, a hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an amino group optionally having substituent(s) or an acyl group;
 R² represents a pyridyl group optionally having substituent(s); and
 R³ represents an aromatic group optionally having substituent(s).

and a salt thereof [hereinafter sometimes to be briefly referred to as Compound (Ia)], and that they have, based on their specific chemical structure, an unexpectedly superior p38 MAP kinase-inhibitory activity, a TNF- α production-inhibitory activity, a PDE IV-inhibitory activity and the like, as well as superior properties as a pharmaceutical product, such as stability and the like, and are sufficiently satisfactory as a pharmaceutical, and completed the present invention based on these findings.


[0007] Accordingly, the present invention relates to

(1) a p38 MAP kinase inhibitory agent comprising a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof,

(2) a TNF- α production inhibitory agent comprising a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof, excluding a compound of the formula



wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of an aromatic ring, and R is a hydrogen atom, an acyl group, or a monovalent aromatic group having not more than 10 carbon atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring, and a salt thereof,
 (3) the agent of (1) or (2), wherein the 1,3-thiazole compound is a 1,3-thiazole compound substituted at the 4-position by an aromatic group optionally having substituent(s),
 (4) the agent of (1) or (2), wherein the 1,3-thiazole compound is a 1,3-thiazole compound substituted at the 2-position by an aryl group optionally having substituent(s) or an amino group optionally having substituent(s),
 (5) the agent of (1) or (2), wherein the 1,3-thiazole compound is a compound of the formula



wherein R¹ represents a hydrogen atom, a hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an amino group optionally having substituent(s) or an acyl group;
 R² represents a pyridyl group optionally having substituent(s); and
 R³ represents an aromatic group optionally having substituent(s), or a salt thereof,
 (6) the agent of (1) or (2), which is a prophylactic or therapeutic agent of cytokine-mediated diseases,
 (7) the compound of (5), wherein R¹ is

(i) a hydrogen atom,

(ii) a C₁₋₁₀ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₆ cycloalkyl group, a C₆₋₁₄ aryl group or a C₇₋₁₆ aralkyl group [these groups may have substituent(s) selected from the group (substituent group A) consisting of oxo, halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, C₆₋₁₄ aryl, optionally halogenated C₁₋₈ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, C₆₋₁₄ aryloxy, C₇₋₁₆ aralkyloxy, mercapto, optionally halogenated C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₇₋₁₆ aralkylthio, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino, formyl, carboxy, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5 or 6 membered heterocyclic carbonyl, carbamoyl, thiocarbamoyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5 or 6 membered heterocyclic carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfinyl, C₆₋₁₄ arylsulfinyl, formylamino, C₁₋₆ alkyl-carbonylamino, C₆₋₁₄ aryl-carbonylamino, C₁₋₆ alkoxy-carbonylamino, C₁₋₆ alkylsulfonylamino, C₆₋₁₄ arylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy, nicotinoyloxy, 5 to 7 membered saturated cyclic amino optionally having 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to one nitrogen atom and carbon atoms (this cyclic amino may have substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₁₋₆ alkyl-carbonyl, 5 to 10 membered aromatic heterocyclic group and oxo), 5 to 10 membered aromatic heterocyclic group containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom, in addition to carbon atoms, sulfo, sulfamoyl, sulfinamoyl and sulfenamoyl],

(iii) a monovalent heterocyclic group obtained by removing one arbitrary hydrogen atom from a 5 to 14 membered heterocycle containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms optionally having substituents selected from the above-mentioned substituent group A,

(iv) an acyl group represented by the formula:

-(C=O)-R⁵, -(C=O)-OR⁵, -(C=O)-NR⁵R⁶, -(C=S)-NHR⁵ or -SO₂-R⁷ wherein R⁵ represents (a) a hydrogen

atom, (b) a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₆ cycloalkyl group, a C₆₋₁₄ aryl group or a C₇₋₁₆ aralkyl group as defined in the above (ii) or (c) a heterocyclic group as defined in the above (iii), R⁶ represents a hydrogen atom or a C₁₋₆ alkyl group, R⁷ represents (a) a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₆ cycloalkyl group, a C₆₋₁₄ aryl group or a C₇₋₁₆ aralkyl group as defined in the above (ii), or (b) a heterocyclic group as defined in the above (iii),

(v) an amino group (this amino group may have substituent(s) selected from the group consisting of (a) a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₆ cycloalkyl group, a C₆₋₁₄ aryl group or a C₇₋₁₆ aralkyl group as defined in the above (ii), (b) a heterocyclic group as defined in the above (iii), (c) an acyl group as defined in the above (iv), and (d) a C₁₋₆ alkylidene group optionally having substituent(s) selected from the above substituent group A), or

(vi) a 5 to 7 membered non-aromatic cyclic amino group optionally containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to one nitrogen atom and carbon atoms (this cyclic amino group may have substituent(s) selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₁₋₆ alkyl-carbonyl, 5 to 10 membered aromatic heterocyclic group and oxo);

R² represents a pyridyl group optionally having substituent(s) selected from the above substituent group A; and

R³ represents (a) a C₆₋₁₄ monocyclic or fused polycyclic aromatic hydrocarbon group optionally having substituents selected from the substituent group A or (b) a monovalent aromatic heterocyclic group obtained by removing one arbitrary hydrogen atom from a 5 to 14 membered aromatic heterocycle containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, said 5 to 14 membered aromatic heterocycle optionally having substituent(s) selected from the substituent group A,

(8) the agent of (5), wherein

R¹ is (a) a C₆₋₁₄ aryl group (preferably C₆₋₁₀ aryl) optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbonylamino, C₁₋₃ alkylenedioxy, C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₁₋₆ alkylsulfinyl, C₆₋₁₄ arylsulfinyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl and nitro,

(b) a C₁₋₈ alkyl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino,

(c) a C₃₋₆ cycloalkyl group (e.g., cyclohexyl) optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino,

(d) a C₇₋₁₆ aralkyl group (e.g., phenyl-C₁₋₆ alkyl group),

(e) a 5 to 10 membered aromatic heterocyclic group containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms (e.g., 5 or 6 membered aromatic heterocyclic group such as pyridyl, thienyl and the like),

(f) a 5 to 10 membered non-aromatic heterocyclic group containing 1 or 2 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, said 5 to 14 membered aromatic heterocycle optionally having C₆₋₁₄ aryl (e.g., phenyl), C₁₋₆ alkyl-carbonyl or oxo (e.g., 5 or 6 membered non-aromatic cyclic amino group such as piperidino, piperazino and the like),

(g) an amino group optionally having 1 or 2 substituent(s) selected from the group consisting of the following (1) to (7) [(1) C₁₋₆ alkyl, (2) C₆₋₁₄ aryl, (3) C₇₋₁₆ aralkyl, (4) 5 or 6 membered heterocyclic group containing 1 or 2 heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms (e.g., pyridyl), (5) C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkyl-carbamoyl or 5 or 6 membered heterocyclic carbonyl group, optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy, C₁₋₆ alkoxy-carbonyl, cyano, tetrazine and the like, (6) C₆₋₁₄ aryl-carbamoyl group optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy, C₁₋₆ alkoxy-carbonyl, cyano, nitro, mono- or di-C₁₋₆ alkylamino and the like and (7) di-C₁₋₆ alkylamino-C₁₋₆ alkylidene], or

(h) a carboxy group,

(9) the agent of (5), wherein R¹ is a C₆₋₁₄ aryl group optionally having C₁₋₆ alkylsulfonyl,

- (10) the agent of (5), wherein R² is a 4-pyridyl group optionally having substituent(s),
 (11) the agent of (5), wherein R³ is a C₆₋₁₀ aryl group optionally having substituent(s),
 (12) the agent of (5), wherein R³ is a phenyl group optionally having substituent(s),
 (13) the agent of (5), wherein R³ is a C₆₋₁₄ aryl group optionally having substituent(s) selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₈ alkoxy, carboxy C₁₋₈ alkoxy, hydroxy, C₆₋₁₄ aryloxy, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkyl-carbonyloxy, mono- or di-C₁₋₆ alkylamino and C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy,
 (14) the agent of (5), wherein R³ is a phenyl group optionally having substituent(s) selected from the group consisting of halogen atom and C₁₋₆ alkyl group,
 (15) the agent of (5), wherein R¹ is (a) an amino group optionally having 1 or 2 acyl represented by the formula: -C(=O)-R⁵ or -C(=O)-NR⁵R⁶ wherein each symbol is as defined above, (b) C₆₋₁₄ aryl group optionally having 1 to 5 substituent(s) selected from C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₁₋₆ alkylsulfinyl, C₆₋₁₄ arylsulfinyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl and carboxy or (c) C₁₋₆ alkyl group optionally substituted by halogen atom, R² is a pyridyl group, and R³ is a C₆₋₁₄ aryl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy and carboxy,
 (16) the agent of (5), wherein R¹ is

- (i) C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₆₋₁₄ aryl optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino,
 (ii) a 5 membered heterocyclic group,
 (iii) an amino group optionally having 1 or 2 substituent(s) selected from (a) C₁₋₆ alkyl, (b) C₆₋₁₄ aryl, (c) C₇₋₁₆ aralkyl, (d) 6 membered heterocyclic group and (e) C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkyl-carbamoyl or 5 or 6 membered heterocyclic carbonyl, optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy and C₁₋₆ alkoxy-carbonyl, or an amino group optionally having di-C₁₋₆ alkylamino-C₁₋₆ alkylidene,
 (iv) a 5 or 6 membered non-aromatic cyclic amino group optionally substituted by C₁₋₆ alkyl-carbonyl or oxo, or
 (v) a carboxy group;

R² is a pyridyl group; and

R³ is a C₆₋₁₀ aryl group optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₈ alkoxy, hydroxy, C₇₋₁₆ aralkyloxy and C₁₋₆ alkyl-carbonyloxy (two adjacent alkyl groups as substituents may be bonded to form a 5 membered non-aromatic carbon ring),

(17) the agent of (5), wherein R¹ is a C₆₋₁₄ aryl group optionally having C₁₋₆ alkylsulfonyl, R² is a pyridyl group, and R³ is a C₆₋₁₄ aryl group optionally having halogen atom(s),

(18) the agent of (1) or (2), which is a prophylactic or therapeutic agent of asthma, chronic obstructive pulmonary disease (COPD), allergic disease (e.g., allergic dermatitis, allergic rhinitis), inflammation, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis (e.g., chronic rheumatoid arthritis, osteoarthritis), osteoporosis, toxemia (e.g., sepsis), Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis, AIDS encephalopathy, meningitis, angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney failure, nephritis, malignant tumor, transplantation, dialysis hypotension or disseminated intravascular coagulation,


(19) the agent of (1) or (2), which is a prophylactic or therapeutic agent of chronic rheumatoid arthritis or osteoarthritis,

(20) N-ethyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-269), N-propyl-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-276), N-butyl-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-280), N-benzyl-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-281), N-propyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-290), N-isopropyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-291), N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-phenylurea (Reference Example 23-296), 4-[[[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid (Reference Example 23-299),

methyl 4-[2-[4-(methylthio)phenyl]-5-(4-pyridyl)-1,3-thiazol-4-yl]phenyl ether (Reference Example 23-300),
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-302),
 4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-303),
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-305),
 4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-306),
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-308),
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-309),
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-310),
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-311),
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-312),
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-313),
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-314),
 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-phenylurea (Reference Example 23-315),
 2-hydroxy-N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide (Reference Example 23-325),
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-326),
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-327),
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-328),
 2-hydroxy-N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-329),
 4-[[[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid (Reference Example
 23-337),
 3-[[[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid (Reference Example
 23-342),
 4-(4-fluorophenyl)-2-phenyl-5-(4-pyridyl)-1,3-thiazole (Reference Example 44-1),
 methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfide (Reference Example 44-7),
 methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfoxide (Reference Example 44-8),
 methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfone (Reference Example 44-26), or a salt
 thereof,

(21) a method for inhibiting p38 MAP kinase, comprising administering an effective amount of a 1,3-thiazole com-
 pound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug
 thereof to a mammal,

(22) a method for inhibiting TNF- α production, comprising administering an effective amount of a 1,3-thiazole
 compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a pro-
 drug thereof, excluding a compound of the formula




wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of an aromatic
 ring, and R is a hydrogen atom, an acyl group, or a monovalent aromatic group having not more than 10 carbon
 atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring, and a salt thereof, to a mammal,
 (23) a method for prophylaxis or treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic
 disease (e.g., allergic dermatitis, allergic rhinitis), inflammation, Addison's disease, autoimmune hemolytic anemia,
 systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction,
 head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amy-
 trophic lateral sclerosis, diabetes, arthritis (e.g., chronic rheumatoid arthritis, osteoarthritis), osteoporosis, toxemia
 (e.g., sepsis), Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis,
 pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis,
 AIDS encephalopathy, meningitis, angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney
 failure, nephritis, malignant tumor, transplantation, dialysis hypotension or disseminated intravascular coagulation,
 which method comprises administering an effective amount of a 1,3-thiazole compound substituted at the 5-position
 by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof to a mammal,
 (24) a method for prophylaxis or treatment of chronic rheumatoid arthritis or osteoarthritis, which method comprises

administering an effective amount of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof to a mammal,

(25) use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof for the production of a p38 MAP kinase inhibitory agent,

(26) use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof, excluding a compound of the formula



wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of an aromatic ring, and R is hydrogen atom, acyl group, or a monovalent aromatic group having not more than 10 carbon atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring, and a salt thereof, for the production of a TNF- α production inhibitory agent,

(27) use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof for the production of an agent for the prophylaxis or treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic disease (e.g., allergic dermatitis, allergic rhinitis), inflammation, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis (e.g., chronic rheumatoid arthritis, osteoarthritis), osteoporosis, toxemia (e.g., sepsis), Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis, AIDS encephalopathy, meningitis, angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney failure, nephritis, malignant tumor, transplantation, dialysis hypotension or disseminated intravascular coagulation, and

(28) use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof for the production of an agent for the prophylaxis or treatment of chronic rheumatoid arthritis or osteoarthritis.

Best Mode to Practice the Invention

[0008] In the present specification, as "acyl group", for example, there are an acyl group represented by the formula: $-(C=O)-R^5$, $-(C=O)-OR^5$, $-(C=O)-NR^5R^6$, $-(C=S)-NHR^5$ or $-SO_2-R^7$ (wherein R^5 represents a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s), R^6 represents a hydrogen atom or a C_{1-6} alkyl, R^7 represents a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s)) and the like.

[0009] In the aforementioned formula, as "hydrocarbon group" of "hydrocarbon group optionally having substituent(s)" represented by R^5 , for example, there are an acyclic or cyclic hydrocarbon group (for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl and the like) and the like. Among them, acyclic or cyclic hydrocarbon groups having 1 to 16 carbon atom(s) are preferable.

[0010] As "alkyl", for example, C_{1-6} alkyl (for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like) and the like are preferable.

[0011] As "alkenyl", for example, C_{2-6} alkenyl (for example, vinyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl and the like) and the like are preferable.

[0012] As "alkynyl", for example, C_{2-6} alkynyl (for example, ethynyl, propargyl, 1-butyne, 2-butyne, 3-butyne, 1-hexynyl and the like) and the like are preferable.

[0013] As "cycloalkyl", for example, C_{3-6} cycloalkyl (for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like) and the like are preferable.

[0014] As "aryl", for example, C_{6-14} aryl (for example, phenyl, 1-naphthyl, 2-naphthyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, 2-anthryl and the like) and the like are preferable.

[0015] As "aralkyl", for example, C_{7-16} aralkyl (for example, benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl and the like) and the like are preferable.

erable.

[0016] As "substituent(s)" of "hydrocarbon group optionally having substituent(s)" represented by R⁵, for example, there are oxo, halogen atom (for example, fluorine, chlorine, bromine, iodine and the like), C₁₋₃ alkylenedioxy (for example, methylenedioxy, ethylenedioxy and the like), nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, carboxy C₂₋₆ alkenyl (for example, 2-carboxyethenyl, 2-carboxy-2-methylethenyl and the like), optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, C₆₋₁₄ aryl (for example, phenyl, 1-naphthyl, 2-naphthyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, 2-anthryl and the like), optionally halogenated C₁₋₈ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy (for example, ethoxycarbonylmethoxy and the like), hydroxy, C₆₋₁₄ aryloxy (for example, phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like), C₇₋₁₆ aralkyloxy (for example, benzyloxy, phenethyloxy and the like), mercapto, optionally halogenated C₁₋₆ alkylthio, C₆₋₁₄ arylthio (for example, phenylthio, 1-naphthylthio, 2-naphthylthio and the like), C₇₋₁₆ aralkylthio (for example, benzylthio, phenethylthio and the like), amino, mono-C₁₋₆ alkylamino (for example, methylamino, ethylamino and the like), mono-C₆₋₁₄ arylamino (for example, phenylamino, 1-naphthylamino, 2-naphthylamino and the like), di-C₁₋₆ alkylamino (for example, dimethylamino, diethylamino, ethylmethylamino and the like), di-C₆₋₁₄ arylamino (for example, diphenylamino and the like); formyl, carboxy, carboxy-C₂₋₆ alkenyl, carboxy-C₁₋₆ alkyl, C₁₋₆ alkyl-carbonyl (for example, acetyl, propionyl and the like), C₃₋₆ cycloalkyl-carbonyl (for example, cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl and the like), C₁₋₆ alkoxy-carbonyl (for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl and the like), C₆₋₁₄ aryl-carbonyl (for example, benzoyl, 1-naphthoyl, 2-naphthoyl and the like), C₇₋₁₆ aralkyl-carbonyl (for example, phenylacetyl, 3-phenylpropionyl and the like), C₆₋₁₄ aryloxy-carbonyl (for example, phenoxycarbonyl and the like), C₇₋₁₆ aralkyloxy-carbonyl (for example, benzyloxycarbonyl, phenethyloxycarbonyl and the like), 5 or 6 membered heterocyclic carbonyl (for example, nicotinoyl, isonicotinoyl, thenoyl, furoyl, morpholinocarbonyl, thiomorpholinocarbonyl, piperazin-1-ylcarbonyl, pyrrolidin-1-ylcarbonyl and the like), carbamoyl, thiocarbamoyl, mono-C₁₋₆ alkyl-carbamoyl (for example, methylcarbamoyl, ethylcarbamoyl and the like), di-C₁₋₆ alkyl-carbamoyl (for example, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl and the like), mono- or di-C₆₋₁₄ aryl-carbamoyl (for example, phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl and the like), mono- or di-5 or 6 membered heterocyclic carbamoyl (for example, 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-thienylcarbamoyl, 3-thienylcarbamoyl and the like), C₁₋₆ alkylsulfonyl (for example, methylsulfonyl, ethylsulfonyl and the like), C₁₋₆ alkylsulfinyl (for example, methylsulfinyl, ethylsulfinyl and the like), C₆₋₁₄ arylsulfonyl (for example, phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl and the like), C₆₋₁₄ arylsulfinyl (for example, phenylsulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl and the like), formylamino, C₁₋₆ alkyl-carbonylamino (for example, acetylamino and the like), C₆₋₁₄ aryl-carbonylamino (for example, benzoylamino, naphthoylamino and the like), C₁₋₆ alkoxy-carbonylamino (for example, methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino and the like), C₁₋₆ alkylsulfonylamino (for example, methylsulfonylamino, ethylsulfonylamino and the like), C₆₋₁₄ arylsulfonylamino (for example, phenylsulfonylamino, 2-naphthylsulfonylamino, 1-naphthylsulfonylamino and the like), C₁₋₆ alkyl-carbonyloxy (for example, acetoxy, propionyloxy and the like), C₆₋₁₄ aryl-carbonyloxy (for example, benzoyloxy, naphthylcarbonyloxy and the like), C₁₋₆ alkoxy-carbonyloxy (for example, methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy and the like), mono-C₁₋₆ alkyl-carbamoyloxy (for example, methylcarbamoyloxy, ethylcarbamoyloxy and the like), di-C₁₋₆ alkyl-carbamoyloxy (for example, dimethylcarbamoyloxy, diethylcarbamoyloxy and the like), C₆₋₁₄ aryl-carbamoyloxy (for example, phenylcarbamoyloxy, naphthylcarbamoyloxy and the like), nicotinoyloxy, 5 to 7 membered saturated cyclic amino optionally having substituent(s), 5 to 10 membered aromatic heterocyclic group (for example, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl and the like), sulfo and the like.

[0017] The "hydrocarbon group" may have 1 to 5, preferably 1 to 3 aforementioned substituent(s) at a substitutable position and, when the number of substituents is 2 or more, respective substituents may be the same or different.

[0018] As aforementioned "optionally halogenated C₁₋₆ alkyl", for example, there are C₁₋₆ alkyl (for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like) and the like optionally having 1 to 5, preferably 1 to 3 halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like). Examples thereof are methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, propyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl, 6,6,6-trifluorohexyl and the like.

[0019] As the aforementioned "optionally halogenated C₂₋₆ alkenyl", for example, there are C₂₋₆ alkenyl (for example, vinyl, propenyl, isopropenyl, 2-buten-1-yl, 4-penten-1-yl, 5-hexen-1-yl) and the like optionally having 1 to 5, preferably 1 to 3 halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like).

[0020] As the aforementioned "optionally halogenated C₂₋₆ alkynyl", there are C₂₋₆ alkynyl (for example, 2-butyne-1-yl, 4-pentyne-1-yl, 5-hexyne-1-yl and the like) and the like optionally having 1 to 5, preferably 1 to 3 halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like).

[0021] As the aforementioned "optionally halogenated C₃₋₆ cycloalkyl", for example, there are C₃₋₆ cycloalkyl (for

example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like) and the like optionally having 1 to 5, preferably 1 to 3 halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like). Examples thereof are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-dichlorocyclohexyl, 2,2,3,3-tetrafluorocyclopentyl, 4-chlorocyclohexyl and the like.

5 **[0022]** As the aforementioned "optionally halogenated C₁₋₈ alkoxy", for example, there are C₁₋₈ alkoxy (for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy and the like) and the like optionally having 1 to 5, preferably 1 to 3 halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like). Examples thereof are methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy and the like.

10 **[0023]** As the aforementioned "optionally halogenated C₁₋₆ alkylthio", for example, there are C₁₋₆ alkylthio (for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio and the like) and the like optionally having 1 to 5, preferably 1 to 3 halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like). Examples thereof are methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio, hexylthio and the like.

15 **[0024]** As "5 to 7 membered saturated cyclic amino" of the aforementioned "5 to 7 membered saturated cyclic amino optionally having substituent(s)", there are 5 to 7 membered saturated cyclic amino optionally containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to one nitrogen atom and carbon atoms and examples thereof are pyrrolidin-1-yl, piperidino, piperazin-1-yl, morpholino, thiomorpholino, hexahydroazepin-1-yl and the like.

20 **[0025]** As "substituents" of the "5 to 7 membered saturated cyclic amino optionally having substituent(s)", for example, there are 1 to 3 C₁₋₆ alkyl (for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like), C₆₋₁₄ aryl (for example, phenyl, 1-naphthyl, 2-naphthyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, 2-anthryl and the like), C₁₋₆ alkyl-carbonyl (for example, acetyl, propionyl and the like), 5 to 10 membered aromatic heterocyclic group (for example, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl and the like), oxo and the like.

25 **[0026]** As "heterocyclic group" of "heterocyclic group optionally having substituent(s)" represented by R⁵, for example, there is a monovalent group obtained by removing one arbitrary hydrogen atom from a 5 to 14 membered (monocyclic, bicyclic or tricyclic) heterocycle containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, preferably (i) a 5 to 14 membered (preferably 5 to 10 membered) aromatic heterocycle, (ii) a 5 to 10 membered non-aromatic heterocycle or (iii) a 7 to 10 membered bridged heterocycle.

30 **[0027]** As the aforementioned "5 to 14 membered (preferably 5 to 10 membered) aromatic heterocycle", there are an aromatic heterocycle such as thiophene, benzo[b]thiophene, benzo[b]furan, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, 4H-quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β -carboline, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, isoxazole, furazan, phenoxazine and the like, and a ring formed by fusing these rings (preferably monocyclic) with one or more (preferably 1 to 2) aromatic ring(s) (for example, benzene ring and the like).

40 **[0028]** As the aforementioned "5 to 10 membered non-aromatic heterocycle", for example, there are pyrrolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dioxazole, oxadiazoline, thiadiazoline, triazoline, thiadiazole, dithiazole and the like.

[0029] As the aforementioned "7 to 10 membered bridged heterocycle", for example, there are quinuclidine, 7-azabicyclo[2.2.1]heptane and the like.

45 **[0030]** The "heterocyclic group" is preferably a 5 to 14 membered (preferably 5 to 10 membered) (monocyclic or bicyclic) heterocyclic group containing preferably 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms. More particularly, examples thereof are an aromatic heterocyclic group such as 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 3-pyrrolyl, 2-imidazolyl, 3-pyridazinyl, 3-isothiazolyl, 3-isoxazolyl, 1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl and the like, and a non-aromatic heterocyclic group such as 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-imidazolyl, 4-imidazolyl, 2-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl, 1-piperazinyl, 2-piperazinyl, morpholino, thiomorpholino and the like.

50 **[0031]** Among them, for example, a 5 or 6 membered heterocyclic group containing 1 to 3 heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms is further preferable. More particularly, examples thereof are 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furyl, 3-furyl, pyrazinyl, 2-pyrimidinyl, 3-pyrrolyl, 3-pyridazinyl, 3-isothiazolyl, 3-isoxazolyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-imidazolyl, 4-imida-

zoliny, 2-pyrazolidiny, 3-pyrazolidiny, 4-pyrazolidiny, piperidino, 2-piperidy, 3-piperidy, 4-piperidy, 1-piperaziny, 2-piperaziny, morpholino, thiomorpholino and the like.

[0032] As "substituent(s)" of "heterocyclic group optionally having substituent(s)", for example, there are the same "substituent(s)" as substituent(s) of "hydrocarbon group optionally having substituent(s)" represented by R⁵.

5 [0033] The "heterocyclic group" may have 1 to 5, preferably 1 to 3 aforementioned substituent(s) at a substitutable position and, when the number of substituents is 2 or more, respective substituents may be the same or different.

[0034] As "C₁₋₆ alkyl" represented by R⁶, for example, there are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.

10 [0035] As "hydrocarbon group optionally having substituent(s)" and "heterocyclic group optionally having substituent(s)" represented by R⁷, for example, there are the aforementioned "hydrocarbon group optionally having substituent(s)" and "heterocyclic group optionally having substituent(s)" represented by R⁵, respectively.

[0036] As "hydrocarbon group optionally having substituent(s)" represented by R¹, for example, there are "hydrocarbon group optionally having substituent(s)" represented by R⁵.

15 [0037] As "heterocyclic group optionally having substituent(s)" represented by R¹, for example, there are "hydrocarbon group optionally having substituent(s)" represented by R⁵.

[0038] As "amino group optionally having substituent(s)" represented by R¹, for example, there are (1) an amino group optionally having 1 or 2 substituent(s) and (2) a cyclic amino group optionally having substituent(s), and the like.

20 [0039] As "substituent(s)" of "amino group optionally having 1 or 2 substituent(s)" of the aforementioned (1), for example, there are a hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an acyl group, an alkylidene group optionally having substituent(s), and the like. As these "hydrocarbon group optionally having substituent(s)" and "heterocyclic group optionally having substituent(s)", there are the same "hydrocarbon group optionally having substituent(s)" and "heterocyclic group optionally having substituent(s)" as those represented by R⁵ described above, respectively.

25 [0040] As "alkylidene group" of "alkylidene group optionally having substituent(s)", for example, there are a C₁₋₆ alkylidene group (for example, methylenedene, ethylenedene, propylenedene and the like) and the like. As "substituent(s)" of "alkylidene group optionally having substituent(s)", there are 1 to 5, preferably 1 to 3 same substituent(s) as "substituent(s)" of "hydrocarbon group optionally having substituent(s)" represented by R⁵.

[0041] When the number of the aforementioned "substituent(s)" of "amino group optionally having 1 or 2 substituent(s)" is 2, respective substituent(s) may be the same or different.

30 [0042] As "cyclic amino group" of "cyclic amino group optionally having substituent(s)" of the aforementioned (2), there are a 5 to 7 membered non-aromatic cyclic amino group optionally containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to one nitrogen atom and carbon atoms. More particularly, examples thereof are pyrrolidin-1-yl, piperidino, piperazin-1-yl, morpholino, thiomorpholino, hexahydroazepin-1-yl, imidazolidin-1-yl, 2,3-dihydro-1H-imidazol-1-yl, tetrahydro-1(2H)-pyrimidinyl, 3,6-dihydro-1(2H)-pyrimidinyl, 3,4-dihydro-1(2H)-pyrimidinyl and the like. As "substituent(s)" of "cyclic amino optionally having substituent(s)", there are 1 to 3 same ones as "substituent(s)" of "5 to 7 membered saturated cyclic amino group optionally having substituent(s)" which were described in detail as "substituent(s)" of "hydrocarbon group optionally having substituent(s)" represented by R⁵.

40 [0043] Examples of the 5 to 7 membered non-aromatic cyclic amino group having one oxo, there are 2-oxoimidazolidin-1-yl, 2-oxo-2,3-dihydro-1H-imidazol-1-yl, 2-oxotetrahydro-1(2H)-pyrimidinyl, 2-oxo-3,6-dihydro-1(2H)-pyrimidinyl, 2-oxo-3,4-dihydro-1(2H)-pyrimidinyl, 2-oxopyrrolidin-1-yl, 2-oxopiperidino, 2-oxopiperazin-1-yl, 3-oxopiperazin-1-yl, 2-oxo-2,3,4,5,6,7-hexahydroazepin-1-yl and the like.

45 [0044] As R¹, an amino group optionally having substituent(s) and an aryl group optionally having substituent(s) are preferable. As further preferable example of the "amino group optionally having substituent(s)" is an amino group optionally having 1 or 2 acyl represented by the formula: -(C=O)-R⁵, -(C=O)-OR⁵, -(C=O)-NR⁵R⁶, -(C=S)-NHR⁵ or -SO₂-R⁷ [wherein respective symbols represent the same meanings as described above].

[0045] More preferable example is an amino group optionally having 1 or 2 acyl represented by the formula: -C(C=O)-R⁵ or -(C=O)-NR⁵R⁶ [wherein respective symbols represent the same meanings as described above].

50 [0046] As the "aryl group optionally having substituent(s)", for example, there is preferably a C₆₋₁₄ aryl group (preferably a phenyl group and the like) optionally having 1 to 5 substituent(s) selected from C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₁₋₆ alkylsulfanyl, C₆₋₁₄ arylsulfanyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl and carboxy.

[0047] Particularly, as R¹, there are mentioned

55 (a) C₆₋₁₄ aryl group (preferably C₆₋₁₀ aryl) optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbonylamino, C₁₋₃ alkylenedioxy, C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₁₋₆ alkylsulfanyl, C₆₋₁₄ arylsulfanyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, nitro and the like,

- (b) C₁₋₆ alkyl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino,
- 5 (c) C₃₋₆ cycloalkyl group (e.g., cyclohexyl) optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino,
- (d) C₇₋₁₆ aralkyl group (e.g., phenyl-C₁₋₆ alkyl group),
- 10 (e) 5 to 10 membered aromatic heterocyclic group containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms (e.g., 5 or 6 membered aromatic heterocyclic group such as pyridyl, thienyl and the like),
- (f) 5 to 10 membered non-aromatic heterocyclic group containing 1 or 2 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, which may have
- 15 C₆₋₁₄ aryl (e.g., phenyl), C₁₋₆ alkyl-carbonyl or oxo, such as 5 or 6 membered non-aromatic cyclic amino group (e.g., piperidino, piperazino and the like),
- (g) amino group optionally having 1 or 2 substituent(s) selected from the group consisting of the following (1) to (7) [(1) C₁₋₆ alkyl, (2) C₆₋₁₄ aryl, (3) C₇₋₁₆ aralkyl, (4) a 5 or 6 membered heterocyclic group (e.g., pyridyl) containing 1 or 2 heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms,
- 20 (5) C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkyl-carbamoyl or 5 or 6 membered heterocyclic carbonyl group optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy, C₁₋₆ alkoxy-carbonyl, cyano, tetrazine and the like, (6) C₆₋₁₄ aryl-carbamoyl group optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy, C₁₋₆ alkoxy-carbonyl, cyano, nitro, mono- or di-C₁₋₆ alkylamino and the like, (7) di-C₁₋₆ alkylamino-C₁₋₆ alkylidene], or
- 25 (h) carboxy group and the like are preferable.

[0048] As the "pyridyl group" of the "pyridyl group optionally having substituent(s)" represented by R², 1-, 2-, 3- or 4-pyridyl group and the like are used.

30 [0049] As the "substituent(s)" of the "pyridyl group optionally having substituent(s)" represented by R², for example, those similar to the "substituent(s)" of the "hydrocarbon group optionally having substituent(s)" represented by the aforementioned R⁵ are used.

[0050] The "pyridyl group" may have 1 to 5, preferably 1 to 3, substituent(s) such as those mentioned above at substitutable position(s). When the number of substituent is 2 or more, the respective substituent(s) may be the same or different. In addition, the nitrogen atom in the ring of the "pyridyl group" may be N-oxidized.

35 [0051] R² is preferably a pyridyl group optionally having substituent(s) (e.g., 3-pyridyl group, 4-pyridyl group and the like, preferably 4-pyridyl group).

[0052] As R², pyridyl group optionally having 1 or 2 substituent(s) selected from the group consisting of C₁₋₆ alkyl (e.g., methyl), hydroxy and C₁₋₆ alkyl-carboxyloxy (e.g., acetyloxy) and the like are preferable.

40 [0053] As the "aromatic group" of "aromatic group optionally having substituent(s)" represented by R³, for example, there are an aromatic hydrocarbon group, an aromatic heterocyclic group and the like.

[0054] As the "aromatic hydrocarbon group", examples thereof include a C₆₋₁₄ monocyclic or fused polycyclic (bicyclic or tricyclic) aromatic hydrocarbon group. As examples, there are a C₆₋₁₄ aryl group and the like such as phenyl, 1-naphthyl, 2-naphthyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, 2-anthryl and the like.

45 [0055] As the "aromatic heterocyclic group", there are a 5 to 14 membered (preferably 5 to 10 membered) (monocyclic or bicyclic) aromatic heterocyclic group containing preferably 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms and the like and, more particularly, there are an aromatic heterocyclic group such as 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 3-pyrrolyl, 2-imidazolyl, 3-pyridazinyl, 3-isothiazolyl, 3-isoxazolyl, 1-indolyl, 2-indolyl,

50 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl and the like.


[0056] As the "substituent(s)" of the "aromatic group optionally having substituent(s)", there are 1 to 5, preferably 1 to 3 same substituent(s) as "substituent(s)" of "hydrocarbon group optionally having substituent(s)" represented by the aforementioned R⁵. When the number of substituents is 2 or more, respective substituents may be the same or different. The adjacent two substituents may form a 4 to 7 membered non-aromatic carbon ring. Preferably, it is a 5 membered

55 non-aromatic carbon ring.

[0057] R³ is preferably a C₆₋₁₀ aryl group optionally having substituent(s). More preferably, it is a phenyl group optionally having substituent(s). The substituent of these C₆₋₁₀ aryl group and phenyl group is preferably 1 to 3 substituent(s) selected from halogen atom, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, C₃₋₆ cy-

cloalkyl, optionally halogenated C₁₋₈ alkoxy, hydroxy, C₇₋₁₆ aralkyloxy, C₁₋₆ alkyl-carbonyloxy and carboxy. Particularly preferably, it is optionally halogenated C₁₋₆ alkyl (e.g., C₁₋₃ alkyl such as methyl, ethyl and the like), optionally halogenated C₁₋₈ alkoxy (e.g., C₁₋₃ alkoxy such as methoxy, ethoxy and the like). The two adjacent alkyl groups as substituents may be bonded to form a 5 membered non-aromatic carbon ring.

[0058] When compound (I) or compound (Ia) is used as a TNF- α production inhibitor, the compound (I) or compound (Ia) does not include a compound of the formula



wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of the aromatic ring, and R is a hydrogen atom, acyl group, or a monovalent aromatic group having not more than 10 carbon atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring.

[0059] As the compound (I), for example, compound (Ia) is preferable.

[0060] As compound (Ia), the following compounds of (A)-(B) and the like are preferable.

(A) A compound (Ia) wherein R¹ is (a) an amino group which may have 1 or 2 acyl of the formula: -(C=O)-R⁵ or -(C=O)-NR⁵R⁶ wherein each symbol is as defined above or (b) a C₆₋₁₄ aryl group optionally having 1 to 5 substituent(s) selected from C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₁₋₆ alkylsulfinyl, C₆₋₁₄ arylsulfinyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl and carboxy and the like; R² is pyridyl group optionally having 1 to 5 substituent(s) selected from C₁₋₆ alkyl, hydroxy and C₁₋₆ alkyl-carbonyloxy; and R³ is a C₆₋₁₄ aryl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy and carboxy.

(B) A compound (Ia) wherein R¹ is (i) C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₆₋₁₄ aryl (preferably C₆₋₁₀ aryl) optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino, (ii) a 5 membered heterocyclic group,

(iii) an amino group optionally having 1 or 2 substituent(s) selected from (1) C₁₋₆ alkyl, (2) C₆₋₁₄ aryl, (3) C₇₋₁₆ aralkyl, (4) 6 membered heterocyclic group and (5) C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkyl-carbamoyl or 5 or 6 membered heterocyclic carbonyl, each optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy and C₁₋₆ alkoxy-carbonyl, or an amino group optionally having di-C₁₋₆ alkylamino-C₁₋₆ alkylidene,

(iv) a 5 or 6 membered non-aromatic cyclic amino group optionally substituted by C₁₋₆ alkyl-carbonyl or oxo, or (v) a carboxy group;

R² is a pyridyl group optionally having 1 to 3 substituent(s) selected from C₁₋₆ alkyl, hydroxy and C₁₋₆ alkyl-carbonyloxy;

R³ is a C₆₋₁₀ aryl group optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₈ alkoxy, hydroxy, C₇₋₁₆ aralkyloxy and C₁₋₆ alkyl-carbonyloxy (two adjacent alkyl groups as substituents may be bonded to form a 5 membered non-aromatic carbon ring).

[0061] Moreover, preferable examples of compound (I) and compound (Ia) include:

[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-14),
 [4-phenyl-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-15),
 N-methyl [4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-16),
 N-methyl [4-phenyl-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-47),
 N-methyl [4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-69),
 N-methyl [4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-70),
 N-methyl [4-(4-bromophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 13-71),
 2-phenyl-N-[4-phenyl-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-29),
 3-phenyl-N-[4-phenyl-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide (Reference Example 23-30).

N-[4-(3-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-49),
 N-[4-(3-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide (Reference Example 23-50),
 N-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-51),
 N-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide (Reference Example 23-52),
 5 [4-(3-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-59),
 [4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-60),
 [4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-61),
 [4-(4-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-62),
 N-[4-phenyl-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-71),
 10 N-phenyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-80),
 N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]nicotinamide (Reference Example 23-101),
 N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]isonicotinamide (Reference Example 23-102),
 [4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-125),
 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-128),
 15 [4-(2-naphthyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-144),
 N-ethyl-N'-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]urea (Reference Example 23-156),
 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]isonicotinamide (Reference Example 23-200),
 N-ethyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-269),
 N-propyl-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-276),
 20 N-butyl-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-280),
 N-benzyl-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-281),
 N-propyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-290),
 N-isopropyl-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (Reference Example 23-291),
 N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-phenylurea (Reference Example 23-296),
 25 4-[[[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid (Reference Example 23-299),
 methyl 4-[2-[4-(methylthio)phenyl]-5-(4-pyridyl)-1,3-thiazol-4-yl]phenyl ether (Reference Example 23-300),
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-302),
 4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-303),
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-305),
 30 4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-306),
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-308),
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-309),
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-310),
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-311),
 35 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-312),
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-313),
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-314),
 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-phenylurea (Reference Example 23-315),
 2-hydroxy-N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide (Reference Example 23-325),
 40 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide (Reference Example 23-326),
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide (Reference Example 23-327),
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone (Reference Example 23-328),
 2-hydroxy-N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide (Reference Example 23-329),
 4-[[[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid (Reference Example
 45 23-337),
 3-[[[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid (Reference Example
 23-342), salts thereof and the like.

[0062] Preferable examples of compound (I) and compound (Ia) further include 4-(4-fluorophenyl)-2-phenyl-5-(4-pyridyl)-1,3-thiazole (Reference Example 44-1), methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfide (Reference Example 44-7), methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfoxide (Reference Example 44-8), methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfone (Reference Example 44-26) and the like.

[0063] Furthermore, as compound (I) and (Ia),

(S)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]nicotinamide,
 (R)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]nicotinamide,
 (S)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]-2-methylnicotinamide,

(R)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]-2-methylnicotinamide,
 (S)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]-2-chloronicotinamide,
 (R)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]-2-chloronicotinamide,
 (S)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]-2-methoxynicotinamide,
 5 (R)-N-[4-(3-methylphenyl)-5-(2-(1-phenylethylamino)-4-pyridyl)-1,3-thiazol-2-yl]-2-methoxynicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]nicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-methoxynicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-chloronicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-methylnicotinamide,
 10 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]nicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-methylnicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-chloronicotinamide,
 N-[5-(2-benzylamino-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-methoxynicotinamide,
 (S)-N-(1-phenylethyl)-4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 15 (R)-N-(1-phenylethyl)-4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 (S)-N-(1-phenylethyl)-4-[4-(3-methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridylamine,
 (R)-N-(1-phenylethyl)-4-[4-(3-methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridylamine,
 (S)-N-(1-phenylethyl)-4-[2-butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 (R)-N-(1-phenylethyl)-4-[2-butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 20 (S)-N-(1-phenylethyl)-4-[4-(3-methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 (R)-N-(1-phenylethyl)-4-[4-(3-methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 (S)-N-(1-phenylethyl)-4-[4-(3-methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 (R)-N-(1-phenylethyl)-4-[4-(3-methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 (S)-N-(1-phenylethyl)-4-[2-(4-fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine,
 25 (R)-N-(1-phenylethyl)-4-[2-(4-fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine, salts thereof and
 the like are preferable.

[0064] As the salt of Compounds (I) and (Ia), for example, there are a metal salt, ammonium salt, a salt with an organic base, salt with an inorganic acid, a salt with an organic acid, a salt with basic or acidic amino acid and the like.
 30 As a suitable metal salt, there are alkali metal salt such as sodium salt, potassium salt and the like; alkaline earth metal salt such as calcium salt, magnesium salt, barium salt and the like; aluminum salt and the like. As a suitable example of a salt with an organic base, for example, there are salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine and the like. As a suitable example of a salt with an inorganic acid, for example, there are salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like. As a suitable example of a salt with an organic acid, for example, there are salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like. As a suitable example of a salt with a basic amino acid, for example, there are salts with arginine, lysine, ornithine and the like. As a suitable example of a salt with an acidic amino acid, for example, there are salts with aspartic acid, glutamic acid and the like.


[0065] Among them, pharmaceutically acceptable salts are preferable. For example, when a compound has an acidic functional group therein, there are inorganic salts such as alkali metal salt (for example, sodium salt, potassium salt and the like), alkaline earth metal salt (for example, calcium salt, magnesium salt, barium salt and the like), ammonium salts and the like and, when a compound has a basic functional group therein, there are salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, and salts with organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid and the like.

[0066] A process for producing Compound (I) including Compound (Ia) will be described below.

[0067] Compound (I) can be obtained by a method shown by the following reaction formulas 1 and 2 or a similar method to that, and additionally, for example, it can be obtained according to the methods described in JP-A-60-58981, JP-A-61-10580, JP-T 7-503023, WO 93/15071, DE-A-3601411, JP-A-5-70446 and the like, a method similar to these methods and the like.

[0068] Respective symbols in the compounds in the following reaction formulas 1 and 2 have the same meanings as those described above. Compounds in the reaction formulas include salts thereof and, as the salts, for example, those similar to the salts of Compound (I) can be mentioned.

[Reaction formula 1]



[0069] Compounds (II), (III), (V), (VII), (XI), (XIII) and (XIV) can be used as they are when they are commercially available or can be prepared by a method known per se or according to the similar method to this.

[0070] Compound (IV) can be obtained by condensing Compound (II) and Compound (III) in the presence of a base.

[0071] In the compound (III), R⁸ is, for example, (a) C₁₋₆ alkoxy (e.g., methoxy, ethoxy and the like), (b) di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino and the like), (c) N-C₆₋₁₀ aryl-N-C₁₋₆ alkylamino (e.g., N-phenyl-N-methylamino and the like), (d) a 3 to 7 membered cyclic amino optionally substituted by C₆₋₁₀ aryl and/or C₁₋₆ alkyl (e.g., pyrrolidino, morpholino, methylaziridin-1-yl and the like) and the like.

[0072] An amount of Compound (III) to be used is about 0.5 to about 3.0 moles, preferably about 0.8 to about 2.0 moles relative to 1 mole of Compound (II).

[0073] An amount of a base to be used is about 1.0 to about 30 moles, preferably about 1.0 to about 10 moles relative to 1 mole of Compound (II).

[0074] As the "base", for example, there are a basic salt such as sodium carbonate, potassium carbonate, cesium carbonate and the like, an inorganic base such as sodium hydroxide, potassium hydroxide and the like, an aromatic amine such as pyridine, lutidine and the like, a tertiary amine such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like, an alkali metal hydride such as sodium hydride, potassium hydride and the like, a metal amide such as sodium amide, lithium diisopropylamide, lithium hexamethyldisilazide and the like, a metal alkoxide such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like.

[0075] It is advantageous that this reaction is conducted without a solvent or in the presence of an inert solvent. Although the solvent is not particularly limited as long as the reaction proceeds, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, amides, alcohols, water or a mixture of two or more of them are used.

[0076] A reaction temperature is usually about -5 to about 200°C, preferably about 5 to about 150°C. A reaction time

EP 1 205 478 A1

is usually about 5 minutes to about 72 hours, preferably about 0.5 to about 30 hours.

[0077] Although the reaction product can be used as the reaction solution itself or as a crude product in the next step, it can be isolated from the reaction mixture according to the conventional method and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0078] Compound (VIII) can be obtained by treating compound (IV) with an acid.

[0079] An amount of an acid to be used is about 1.0 to about 100 moles, preferably about 1.0 to about 30 moles, relative to 1 mole of Compound (IV).

[0080] As the "acid", for example, mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like are used.

[0081] This reaction is conducted in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, water, a mixture of water and amides, a mixture of water and alcohols and the like are used.

[0082] A reaction temperature is usually about 20 to about 200°C, preferably about 60 to about 150°C. A reaction time is generally about 30 minutes to about 72 hours, preferably about 1 to about 30 hours.

[0083] Although the reaction product can be used as the reaction solution itself or as a crude product in the next step, it can be isolated from the reaction mixture according to the conventional method and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0084] The compound (VIII) can be also obtained by condensing compound (VI) obtained by treating compound (V) with a base, and compound (VII).

[0085] In the compound (VI), M represents, for example, an alkali metal such as lithium, sodium, potassium and the like.

[0086] In the compound (VII), R⁹ represents, for example, those similar to the aforementioned R⁸.

[0087] An amount of a base to be used is about 1.0 to about 30 moles, preferably about 1.0 to about 10 moles relative to 1 mole of Compound (V).

[0088] As the "base", for example, metal amides such as sodium amide, lithium diisopropylamide, lithium hexamethyldisilazide and the like are used.

[0089] It is advantageous that this reaction is conducted without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, aliphatic hydrocarbons, aromatic hydrocarbons, ethers or a mixture of two or more of them and the like are used.

[0090] A reaction temperature is usually about -78 to about 60°C, preferably about -78 to about 20°C. A reaction time is usually about 5 minutes to about 24 hours, preferably about 0.5 to about 3 hours.

[0091] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0092] Compound (IX) can be obtained by treating Compound (VIII) with halogens. This reaction is performed in the presence of a base or a basic salt if desired.

[0093] An amount of halogens to be used is about 1.0 to about 5.0 moles, preferably about 1.0 to about 2.0 moles relative to 1 mole of Compound (VIII).

[0094] As the "halogens", there are bromine, chlorine, iodine and the like.

[0095] An amount of a base to be used is about 1.0 to about 10.0 moles, preferably about 1.0 to about 3.0 moles relative to 1 mole of Compound (VIII).

[0096] As the "base", for example, there are aromatic amines such as pyridine, lutidine and the like, tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like.

[0097] An amount of a basic salt to be used is about 1.0 to about 10.0 moles, preferably about 1.0 to about 3.0 moles, relative to 1 mole of Compound (VIII).

[0098] As the "basic salt", for example, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, sodium acetate, potassium acetate and the like can be used.

[0099] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, ethers, aromatic hydrocarbons, aliphatic hydrocarbons, amides, halogenated hydrocarbons, nitriles, sulfoxides, organic acids, aromatic amines or a mixture of two or more of them and the like are used.

[0100] A reaction temperature is about -20 to about 150°C, preferably about 0 to about 100°C. A reaction time is usually about 5 minutes to about 24 hours, preferably about 10 minutes to about 5 hours.

[0101] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0102] Compound (Ia) can be obtained by condensing Compound (IX) with Compound (X). This reaction is performed

in the presence of a base if desired.

[0103] In Compound (IX), Hal represents halogens.

[0104] When Compound (X) is commercially available, it can be used as it is, or can be obtained by the method known per se or a method according to the known method or further a method shown in the reaction formula 2.

5 [0105] An amount of Compound (X) to be used is about 0.5 to about 3.0 moles, preferably about 0.8 to about 2.0 moles relative to 1 mole of Compound (IX).

[0106] An amount of a base to be used is about 1.0 to about 30 moles, preferably about 1.0 to about 10 moles relative to 1 mole of Compound (IX).


10 [0107] As the "base", for example, there are basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate and the like, aromatic amines such as pyridine, lutidine and the like, tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like.

15 [0108] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, amides, alcohols, nitriles or a mixture of two or more of them and the like are used.

[0109] A reaction temperature is about -5 to about 200°C, preferably about 5 to about 150°C. A reaction time is usually about 5 minutes to about 72 hours, preferably about 0.5 to about 30 hours.

20 [0110] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[Reaction formula 2]



45 [0111] Compound (XII) is obtained by condensing Compound (XI) and amines represented by the formula R⁴H.

[0112] R⁴ represents "amino group optionally having substituent(s)" represented by the above-mentioned R¹.

[0113] In Compound (XI), R¹⁰ represents an alkoxy group. As the "alkoxy group", for example, there are a C₁₋₆ alkoxy group such as methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like.

[0114] An amount of the "amines" to be used is about 1.0 to about 30 moles, preferably about 1.0 to about 10 moles relative to 1 mole of Compound (XI).

50 [0115] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, amides, alcohols, nitriles, ketones or a mixture of two or more of them and the like are used.

55 [0116] A reaction temperature is about -5 to about 200°C, preferably about 5 to about 120°C. A reaction time is usually about 5 minutes to about 72 hours, preferably about 0.5 to about 30 hours.

[0117] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0118] Compound (X) is obtained by hydrolysing Compound (XII) using an acid or a base.

[0119] An amount of an acid or a base to be used is about 0.1 to about 50 moles, preferably about 1 to about 20 moles relative to 1 mole of Compound (XII), respectively.

[0120] As the "acid", for example, mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and the like, Lewis acids such as boron trichloride, boron tribromide and the like, the use of Lewis acid together with thiols or sulfides, organic acids such as trifluoroacetic acid, p-toluenesulfonic acid and the like are used.

[0121] As the "base", for example, metal hydroxides such as sodium hydroxide, potassium hydroxide, barium hydroxide and the like, basic salts such as sodium carbonate, potassium carbonate and the like, metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like, organic bases such as triethylamine, imidazole, formamidine and the like are used.

[0122] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, alcohols, ethers, aromatic hydrocarbons, aliphatic hydrocarbons, halogenated hydrocarbons, sulfoxides, water or a mixture of two or more of them and the like are used.

[0123] A reaction time is usually about 10 minutes to about 50 hours, preferably about 30 minutes to about 12 hours. A reaction temperature is about 0 to about 200°C, preferably about 20 to about 120°C.

[0124] Compound (X) can be also obtained by treating Compound (XIII) with hydrogen sulfide in the presence of a base.

[0125] An amount of hydrogen sulfide is about 1 mole to about 30 moles relative to 1 mole of Compound (XIII).

[0126] An amount of a base to be used is about 1.0 to about 30 moles, preferably about 1.0 to about 10 moles relative to 1 mole of Compound (XIII).

[0127] As the "base", for example, there are aromatic amines such as pyridine, lutidine and the like, tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like, and the like.

[0128] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, aromatic amines or a mixture of two or more of them and the like are used.

[0129] This reaction is performed under atmospheric pressure or under pressurized condition. A reaction temperature is usually about -20 to about 80°C, preferably about -10 to about 30°C. A reaction time is usually about 5 minutes to about 72 hours, preferably about 0.5 to about 30 hours.

[0130] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0131] Compound (X) can be also obtained by treating compound (XIII) with O,O-diethyl dithiophosphate in the presence of an acid.

[0132] An amount of O,O-diethyl dithiophosphate to be used is about 1 to about 3 moles, preferably about 1 to about 2 moles, relative to 1 mole of Compound (XIII).

[0133] An amount of an acid to be used is about 3 to about 10 moles, relative to 1 mole of Compound (XIII).

[0134] As the "acid", for example, mineral acids such as hydrogen chloride, hydrogen bromide and the like, and the like are used.

[0135] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, ethers, esters, alcohols, water or a mixture of two or more of them and the like are used.

[0136] A reaction temperature is generally about -20 to about 80°C, preferably about -10 to about 30°C. A reaction time is generally about 5 minutes to about 72 hours, preferably about 0.5 to about 30 hours.

[0137] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0138] Compound (X) can also be obtained by treating Compound (XIV) with phosphorus pentasulfide or Lawesson's reagent.

[0139] An amount of phosphorus pentasulfide or Lawesson's reagent to be used is about 0.5 to about 10 moles, preferably about 0.5 to about 3 moles relative to 1 mole of Compound (XIV).

[0140] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, ethers, aromatic hydrocarbons, aliphatic hydrocarbons, halogenated hydrocarbons or a mixture of two or more of them and the like are used.

- [0141] A reaction time is usually 10 minutes to about 50 hours, preferably about 30 minutes to about 12 hours. A reaction temperature is usually about 0 to about 150°C, preferably about 20 to about 120°C.
- [0142] Although a product (X) can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.
- [0143] When Compound (Ia) is acylamino compound, an objective compound can be also obtained by subjecting the corresponding amine compound to an acylating reaction known per se.
- [0144] For example, among Compound (Ia), a compound wherein R¹ is acylamino group optionally having substituent (s) is obtained by reacting the corresponding 2-thiazolamine and an acylating agent optionally in the presence of a base or an acid.
- [0145] An amount of an acylating agent to be used is about 1.0 to about 5.0 moles, preferably about 1.0 to about 2.0 moles relative to 1 mole of the corresponding 2-thiazolamine.
- [0146] As the "acylating agent", for example, there are carboxylic acids corresponding to an objective acyl group or a reactive derivative thereof (for example, acid halide, acid anhydride, ester and the like) and the like.
- [0147] An amount of a base or an acid to be used is about 0.8 to about 5.0 moles, preferable about 1.0 to about 2.0 moles relative to 1 mole of the corresponding 2-thiazolamine.
- [0148] As the "base", for example, there are triethylamine, pyridine, 4-dimethylaminopyridine and the like.
- [0149] As the "acid", for example, there are methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid and the like.
- [0150] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, ethers, aromatic hydrocarbons, aliphatic hydrocarbons, amides, halogenated hydrocarbons, nitriles, sulfoxides, aromatic amines or a mixture of two or more of them and the like are used.
- [0151] A reaction temperature is about -20 to about 150°C, preferably about 0 to about 100°C. A reaction time is usually 5 minutes to about 24 hours, preferably about 10 minutes to about 5 hours.
- [0152] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.
- [0153] When Compound (Ia) is an N-oxide compound, it is obtained by treating the corresponding pyridyl compound with an organic peroxy acid.
- [0154] An amount of an organic peroxy acid to be used is about 0.8 to about 10 moles, preferable about 1.0 to about 3.0 moles relative to 1 mole of the corresponding pyridyl compound.
- [0155] As the "organic peroxy acid", for example, there are peracetic acid, trifluoroperacetic acid, m-chloroperbenzoic acid and the like.
- [0156] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, organic acids, ethers, amides, sulfoxides, alcohols, nitriles, ketones or a mixture of two or more of them and the like are used.
- [0157] A reaction temperature is about -20 to about 130°C, preferably about 0 to about 100°C. A reaction time is usually 5 minutes to about 72 hours, preferably about 0.5 to about 12 hours.
- [0158] Alternatively, the N-oxide compound is also obtained by treating the corresponding pyridyl compound with hydrogen peroxide or alkyl hydroperoxide optionally in the presence of a base, an acid or a metal oxide.
- [0159] An amount of hydrogen peroxide or alkyl hydroperoxide to be used is about 0.8 to about 10 moles, preferably about 1.0 to 3.0 moles relative to 1 mole of the corresponding pyridyl compound.
- [0160] As the "alkyl hydroperoxide", for example, there are tert-butyl hydroperoxide, cumene hydroperoxide and the like.
- [0161] An amount of a base, an acid or a metal oxide to be used is about 0.1 to about 30 moles, preferably 0.8 to about 5 moles relative to 1 mole of the corresponding pyridyl compound.
- [0162] As the "base", for example, there are inorganic bases such as sodium hydroxide, potassium hydroxide and the like, basic salts such as sodium carbonate, potassium carbonate and the like.
- [0163] As the "acid", for example, there are mineral acids such as hydrochloric acid, sulfuric acid, perchloric acid and the like, Lewis acids such as boron trifluoride, aluminum chloride, titanium tetrachloride and the like, organic acids such as formic acid, acetic acid and the like.
- [0164] As the "metal oxide", for example, there are vanadium oxide (V₂O₅), osmium tetroxide (OsO₄), tungsten oxide (WO₃), molybdenum oxide (MoO₃), selenium dioxide (SeO₂), chromium oxide (CrO₃) and the like.
- [0165] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, organic acids, ethers, amides, sulfoxides, alcohols, nitriles,

ketones or a mixture of two or more of them and the like are used.

[0166] A reaction temperature is about -20 to about 130°C, preferably about 0 to about 100°C. A reaction time is usually 5 minutes to about 72 hours, preferably about 0.5 to about 12 hours.

[0167] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0168] When compound (Ia) is an S-oxide compound, it can be obtained by treating the corresponding sulfide compound with peroxide.

[0169] An amount of peroxide to be used is about 0.8 to about 10 moles, preferably about 1.0 to about 3.0 moles, relative to 1 mole of the corresponding sulfide compound.

[0170] As the "peroxide", for example, peracetic acid, trifluoroperacetic acid, m-chloroperbenzoic acid, potassium persulfate, metaperiodic acid and the like can be mentioned.

[0171] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, organic acids, ethers, amides, sulfoxides, alcohols, nitriles, ketones or a mixture of two or more of them and the like are used.

[0172] A reaction temperature is usually about -20 to about 130°C, preferably about 0 to about 100°C. A reaction time is usually about 5 minutes to about 72 hours, preferably about 0.5 to about 12 hours.

[0173] In addition, S-oxide compound can be obtained by treating the corresponding sulfide compound with hydrogen peroxide or alkyl hydroperoxide in the presence of a base, acid or metal oxide, if desired.

[0174] An amount of hydrogen peroxide or alkyl hydroperoxide to be used is about 0.8 to about 10 moles, preferably about 1.0 to about 3.0 moles, relative to 1 mole of the corresponding sulfide compound.

[0175] As the "alkylhydroperoxide", for example, tert-butyl hydroperoxide, cumene hydroperoxide and the like can be mentioned.

[0176] An amount of a "base, acid or metal oxide" to be used is about 0.1 to about 30 moles, preferably about 0.8 to about 5 moles, relative to 1 mole of the corresponding sulfide compound.

[0177] As the "base", for example, there are inorganic bases such as sodium hydroxide, potassium hydroxide and the like, basic salts such as sodium carbonate, potassium carbonate and the like, and the like.

[0178] As the "acid", for example, there are mineral acids such as hydrochloric acid, sulfuric acid, perchloric acid and the like, Lewis acids such as boron trifluoride, aluminum chloride, titanium tetrachloride and the like, organic acids such as formic acid, acetic acid and the like, and the like.

[0179] As the "metal oxide", for example, there are vanadium oxide (V_2O_5), osmium tetroxide (OsO_4), tungsten oxide (WO_3), molybdenum oxide (MoO_3), selenium dioxide (SeO_2), chromium oxide (CrO_3) and the like.

[0180] It is advantageous that this reaction is performed without a solvent or in the presence of an inert solvent for a reaction. The solvent is not particularly limited as long as a reaction proceeds but, for example, halogenated hydrocarbons, aliphatic hydrocarbons, aromatic hydrocarbons, organic acids, ethers, amides, sulfoxides, alcohols, nitriles, ketones or a mixture of two or more of them and the like are used.

[0181] A reaction temperature is usually about -20 to about 130°C, preferably about 0 to about 100°C. A reaction time is usually about 5 minutes to about 72 hours, preferably about 0.5 to about 12 hours.

[0182] Although a product can be used as the reaction solution itself or as a crude product in the next reaction, it can be isolated from the reaction mixture by the conventional method, and can be easily purified by a separating means such as recrystallization, distillation, chromatography and the like.

[0183] In the above respective reactions, when starting compounds have amino, carboxy, hydroxy as substituents, a protecting groups which are generally used in the peptide chemistry or the like may be introduced into these groups and, after reaction, a desired compound can be obtained by removing protecting groups if needed.

[0184] As a protecting group for amino, for example, formyl or C_{1-6} alkyl-carbonyl (for example, acetyl, propionyl and the like), phenylcarbonyl, C_{1-6} alkoxy-carbonyl (for example, methoxycarbonyl, ethoxycarbonyl and the like), phenyloxycarbonyl, C_{7-10} aralkyloxy-carbonyl (for example, benzyloxycarbonyl and the like), trityl, phthaloyl and the like which may have substituent(s), respectively, are used. As these substituent(s), halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like), C_{1-6} alkyl-carbonyl (for example, acetyl, propionyl, valeryl and the like), nitro and the like are used and the number of substituents is 1 to 3.

[0185] As a protecting group for carboxy, for example, C_{1-6} alkyl (for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and the like), phenyl, trityl, silyl and the like which may have substituent(s), respectively, are used. As these substituent(s), halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like), formyl, C_{1-6} alkyl-carbonyl (for example, acetyl, propionyl, butylcarbonyl and the like), nitro, C_{1-6} alkyl (for example, methyl, ethyl, tert-butyl and the like), C_{6-10} aryl (for example, phenyl, naphthyl and the like) and the like are used and the number of substituents is 1 to 3.

[0186] As a protecting group for hydroxy, for example, C_{1-6} alkyl (for example, methyl, ethyl, propyl, isopropyl, butyl,

tert-butyl and the like), phenyl, C₇₋₁₁ aralkyl (for example, benzyl and the like), formyl, C₁₋₆ alkyl-carbonyl (for example, acetyl, propionyl and the like), phenyloxycarbonyl, C₇₋₁₁ aralkyloxy-carbonyl (for example, benzyloxycarbonyl and the like), tetrahydropyranyl, tetrahydrofuranyl, silyl and the like which may have substituent(s), respectively, are used. As these substituent(s), halogen atom(s) (for example, fluorine, chlorine, bromine, iodine and the like), C₁₋₆ alkyl (for example, methyl, ethyl, tert-butyl and the like), C₇₋₁₁ aralkyl (for example, benzyl and the like), C₆₋₁₀ aryl (for example, phenyl, naphthyl and the like), nitro and the like are used and the number of substituents is 1 to 4.

[0187] In addition, as a method of removing a protecting group, the method known per se or a method according to this method is used and, for example, method by treating with an acid, a base, the ultraviolet ray, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate and the like or a method of reduction is used.

[0188] In any cases, Compound (I) can be synthesized by further, optionally, performing the known deprotection, acylation, alkylation, hydrogenation, oxidation, reduction, carbon chain extension and substituent exchange reaction alone or in a combination of two or more of them. As these reactions, the reactions described in Shinjikkengakukozu 14, vol.15, 1977 (Maruzen Press) are adopted.

[0189] As the above "alcohols", for example, there are methanol, ethanol, propanol, isopropanol, tert-butanol and the like.

[0190] As the above "ethers", for example, there are diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane and the like.

[0191] As the above "halogenated hydrocarbons", for example, there are dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride and the like.

[0192] As the above "aliphatic hydrocarbons", for example, there are hexane, pentane, cyclohexane and the like.

[0193] As the above "aromatic hydrocarbons", for example, there are benzene, toluene, xylene, chlorobenzene and the like.

[0194] As the above "aromatic amines", for example, there are pyridine, lutidine, quinoline and the like.

[0195] As the above "amides", for example, there are N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoric triamide and the like.

[0196] As the above "ketones", for example, there are acetone, methyl ethyl ketone and the like.

[0197] As the above "sulfoxides", for example, there are dimethyl sulfoxide and the like.

[0198] As the above "nitriles", for example, there are acetonitrile, propionitrile and the like.

[0199] As the above "organic acids", for example, there are acetic acid, propionic acid, trifluoroacetic acid and the like.

[0200] As the aforementioned "esters", for example, methyl acetate, ethyl acetate, methyl propionate and the like can be mentioned.

[0201] When a desired product is obtained in a free form by the above reaction, it may be converted into a salt according to the conventional method or, when a desired product is obtained as a salt, it can be converted into a free form or another salt according to the conventional method. Compound (I) thus obtained can be isolated and purified from the reaction solution by the known means, for example, trans-solvation, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, chromatography and the like.

[0202] When Compound (I) is present as a configurational isomer, diastereomer, conformer or the like, each can be optionally isolated by the above separation and purification means. In addition, Compound (I) is in the form of its racemate, they can be separated into S- and R-forms by any conventional optical resolution.

[0203] When Compound (I) includes stereoisomers, both the isomers alone and mixtures of each isomers are included in the scope of the present invention.

[0204] In addition, Compound (I) may be hydrated or anhydrated.

[0205] Compound (I) may be labeled with an isotope (for example, ³H, ¹⁴C, ³⁵S) or the like.

[0206] A prodrug of Compound (I) refers to a compound which is converted into Compound (I) by an enzyme, gastric acid or the like under the physiological conditions, that is, a compound which undergoes enzymatic oxidation, reduction, hydrolysis or the like to be converted into Compound (I), and a compound which undergoes hydrolysis or the like by gastric acid or the like to be converted into Compound (I). As a prodrug of Compound (I), there are compounds in which an amino group of Compound (I) is acylated, alkylated or phosphorylated (for example, a compound in which an amino group of Compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbonylated, tetrahydrofuranylated, pyrrolidinylmethylated, pivaloyloxymethylated, tert-butylated); a compound in which a hydroxy group of Compound (I) is acylated, alkylated, phosphorylated or boronylated (for example, a compound in which a hydroxy group of Compound (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated); a compound in which a carboxy group of Compound (I) is esterified or amidated (a compound in which a carboxy group of Compound (I) is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, ethoxycarbonyloxethyl esterified, phthalidyl esterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl esterified, cyclohexyloxycarbonylethyl esterified, methylamidated); and the like. These compounds can be prepared from Compound (I) by the method known

per se.

[0207] Alternatively, a prodrug of Compound (I) may be a compound which is converted to Compound (I) under the physiological conditions described in "Iyakuhin no kaihatsu", published by Hirokawashoten in 1990, vol. 7, Molecular Design, pages 163-198.

5 [0208] The Compound (I) of the present invention, a salt thereof and a prodrug thereof (hereinafter to be briefly referred to as Compound (I)) have a superior p38 MAP kinase inhibitory activity, a TNF- α inhibitory activity (TNF- α production inhibitory activity, TNF- α action inhibitory activity), phosphodiesterase IV (PDE IV) inhibitory activity and the like, show low toxicity, and cause fewer side effects. Therefore, they are useful as a safe pharmaceutical product, a p38 MAP kinase inhibitor, a TNF- α production inhibitor, a PDE IV inhibitor and the like.

10 [0209] A pharmaceutical composition of the present invention containing Compound (I) shows an excellent p38 MAP kinase inhibitory activity and a TNF- α inhibitory activity and is also excellent in (oral) absorption, (metabolism) stability and the like to a mammal (e.g., mouse, rat, hamster, rabbit, cat, dog, cow, sheep, monkey, human and the like) and, therefore, can be used as an agent for prophylaxis or treatment of p38 MAP kinase related diseases and TNF- α production related diseases, such as asthma, chronic obstructive pulmonary disease (COPD), allergic disease (e.g., allergic dermatitis, allergic rhinitis), atopic dermatitis, inflammation, inflammatory eye disease, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, central nervous disease (e.g., cerebrovascular disease such as cerebral hemorrhage and cerebral infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis and the like), neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), AIDS encephalopathy), meningitis, diabetes, arthritis (e.g., chronic rheumatoid arthritis, osteoarthritis, rheumatoid-like spondylitis, urarthritis, synovitis), osteoporosis, toxemia (e.g., sepsis, septic shock, endotoxic shock, Gram negative sepsis, toxic shock syndrome), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), inflammatory pulmonary disease (e.g., chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, pulmonary tuberculosis) or cachexia (e.g., infectious cachexia, cancerous cachexia, cachexia by acquired immunodeficiency syndrome (AIDS)), arteriosclerosis, Creutzfeldt-Jakob disease, virus infection (e.g., infection with cytomegalovirus, influenzavirus, herpesvirus and the like), angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney failure, nephritis, malignant tumor, transplantation, dialysis hypotension, disseminated intravascular coagulation, and the like. Particularly, it can be used for chronic rheumatoid arthritis, osteoarthritis and the like.

15 [0210] The pharmaceutical composition of the present invention containing Compound (I) has a PDE IV inhibitory activity and can be used as a prophylactic or therapeutic agent of diseases caused by inflammation, such as bronchial asthma, chronic obstructive pulmonary disease (COPD), chronic rheumatoid arthritis, autoimmune disease, diabetes, graft versus host disease, multiple sclerosis, sepsis, psoriasis, osteoporosis, depression, central hypergasia after cerebrovascular obstruction, cerebrovascular dementia, Alzheimer's dementia, obesity, cardiac failure and the like.

20 [0211] A pharmaceutical composition of the present invention containing Compound (I) has low toxicity and can be safely administered orally or parenterally (for example, locally, rectally, intravenously or the like) as it is or by mixing Compound (I) with a pharmacologically acceptable carrier into, for example, pharmaceutical preparations such as tablet (including dragee, film coated-tablet and the like), powders, granules, capsules (including soft capsules), solutions, injections, suppositories, sustained releasing preparations and the like according to the method known per se normally used in preparation of pharmaceutical preparations.

25 [0212] A content of Compound (I) or a salt thereof in a pharmaceutical composition of the present invention is about 0.01 to about 100% by weight relative to the whole preparation.

[0213] A content of the component other than Compound (I) or a salt thereof in a pharmaceutical composition of the present invention is about 10 to about 99.9% by weight relative to the whole preparation.

30 [0214] The dose is different depending upon an administration subject, route of administration, diseases, condition and the like and the preparation may be orally administered, as a prophylactic or therapeutic agent for p38 MAP kinase related diseases, for example, to a patient with arthritis (body weight about 60 kg), about 0.01 to about 100 mg active ingredient (Compound (I))/kg body weight per day, preferably about 0.01 to about 30 mg/kg body weight per day, more preferably about 1 to about 20 mg/kg body weight per day, which is given once or divided into several doses a day.

35 [0215] As a pharmacologically acceptable carrier which may be used for preparing a preparation of the present invention, there are the conventional various organic or inorganic carriers as a pharmaceutical material, for example, excipient, lubricant, binder and disintegrating agent in solid preparations, or solvent, solubilizing agent, suspending agent, isotonicizing agent, buffer and soothing agent in liquid preparations. Further, if needed, additives such as the conventional preservative, antioxidant, colorant, sweetening agent, adsorbing agent, wetting agent and the like can be appropriately used at an appropriate amount.

40 [0216] As an excipient, for example, there are lactose, saccharose, D-mannitol, starch, corn starch, crystalline cellulose, light silicic acid anhydride and the like.

[0217] As a lubricant, for example, there are magnesium stearate, calcium stearate, talc, colloidal silica and the like.

45 [0218] As a binder, for example, there are crystalline cellulose, saccharose, D-mannitol, dextrin, hydroxypropylcel-

lulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose and the like.

[0219] As a disintegrating agent, for example, there are starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, L-hydroxypropylcellulose and the like.

5 [0220] As a solvent, for example, there are water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.

[0221] As a solubilizing agent, for example, there are polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, tris-aminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.

10 [0222] As a suspending agent, for example, there are surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like.

[0223] As an isotonicizing agent, for example, there are glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.

15 [0224] As a buffer, for example, there are buffering solutions such as phosphate, acetate, carbonate, citrate and the like.

[0225] As a soothing agent, for example, there are benzyl alcohol and the like.

[0226] As a preservative, for example, there are p-oxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.

20 [0227] As an antioxidant, for example, there are sulfites, ascorbic acid, α -tocopherol and the like.

[0228] The present invention is explained in detail by way of the following Reference Example, Examples, Preparation Examples and Test Examples but these are mere examples and do not limit the present invention and can be varied without departing the scope of the present invention.

25 [0229] "Room temperature" in the following Reference Example and Examples indicates normally about 10°C to about 35°C. "%" indicates percentage by weight unless otherwise indicated, provided that yield represents mol/mol%.

[0230] Abbreviations used elsewhere indicate the following meanings:

30 s: singlet
d: doublet
t: triplet
q: quartet
dd: double doublet
ddd: double double doublet
dt: double triplet
35 br: broad
J: coupling constant
Hz: Hertz
CDCl₃: deuterated chloroform
¹H-NMR: proton nuclear magnetic resonance
40 Me: methyl

[0231] The numbers of the sequence in the Sequence Listing in the present specification show the following sequences.

45 [Sequence No.: 1]

[0232] The base sequence of primer P38-U used in Experimental Example 1.

[Sequence No.: 2]

50 [0233] The base sequence of primer PAG-L used in Experimental Example 1.

[Sequence No.: 3]

55 [0234] The base sequence of primer MKK-U used in Experimental Example 1.

[Sequence No.: 4]

[0235] The base sequence of primer MKK-L used in Experimental Example 1.

5 [Sequence No.: 5]

[0236] The base sequence of primer SER-U used in Experimental Example 1.

10 [Sequence No.: 6]

[0237] The base sequence of primer SER-L used in Experimental Example 1.

Examples

15 Reference Example 1

1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone

20 [0238] A solution of diisopropylamine (33.2 mL) in anhydrous tetrahydrofuran (300 mL) was cooled to -78°C and a 1.6 M n-butyllithium/hexane solution (148 mL) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min at the same temperature, and then β-picoline (20 g) was added dropwise. The temperature was raised to -10-0°C, and after stirring for 20 min, a solution of ethyl p-anisate (19.4 g) in anhydrous tetrahydrofuran (40 mL) was added dropwise. After completion of dropwise addition, the mixture was stirred at room temperature for 1 h, and water (100 mL) was added. The organic solvent was evaporated under reduced pressure and an oily product was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The remaining crude crystals were recrystallized from ethyl acetate-isopropyl ether to give the title compound (20.8 g, yield 85%).
25 melting point: 71-72°C.

30 Reference Example 2:

[0239] In accordance with the above-mentioned Reference Example 1 and respectively using, instead of ethyl p-anisate, ethyl benzoate, ethyl 3,4-dimethoxybenzoate, ethyl 3,4,5-trimethoxybenzoate, ethyl 4-(methoxymethoxy)benzoate, ethyl 4-fluorobenzoate, ethyl 4-ethylbenzoate, ethyl 3,4-methylenedioxybenzoate, methyl 5-indanylcarboxylate, methyl 5,6,7,8-tetrahydro-2-naphthoate, methyl 1,4-benzodioxane-6-carboxylate and methyl 2-naphthoate, the following Reference Example compounds 2-1 to 2-11 were synthesized.

Reference Example compound 2-1: 1-phenyl-2-(3-pyridyl)ethanone melting point: 44.5-45.5°C.
Reference Example compound 2-2: 1-(3,4-dimethoxyphenyl)-2-(3-pyridyl)ethanone melting point: 114-115°C.
40 Reference Example compound 2-3: 2-(3-pyridyl)-1-(3,4,5-trimethoxyphenyl)ethanone melting point: 104-105°C.
Reference Example compound 2-4: 1-(4-methoxymethoxyphenyl)-2-(3-pyridyl)ethanone melting point: 43-44°C.
Reference Example compound 2-5: 1-(4-fluorophenyl)-2-(3-pyridyl)ethanone oil.
Reference Example compound 2-6: 1-(4-ethylphenyl)-2-(3-pyridyl)ethanone melting point: 80-81°C.
Reference Example compound 2-7: 1-(3,4-methylenedioxyphenyl)-2-(3-pyridyl)ethanone melting point: 98-99°C.
45 Reference Example compound 2-8: 1-(5-indanyl)-2-(3-pyridyl)ethanone melting point: 55-56°C.
Reference Example compound 2-9: 2-(3-pyridyl)-1-(5,6,7,8-tetrahydro-2-naphthyl)ethanone melting point: 65-66°C.
Reference Example compound 2-10: 1-(1,4-benzodioxan-6-yl)-2-(3-pyridyl)ethanone melting point: 89-90°C.
Reference Example compound 2-11: 1-(2-naphthyl)-2-(3-pyridyl)ethanone melting point: 69-70°C.

50 Reference Example 3

[0240] In accordance with the above-mentioned Reference Example 2 and respectively using α-picoline, γ-picoline and 3,5-lutidine instead of β-picoline, the following Reference Example compounds 3-1 to 3-3 were synthesized.

55 Reference Example compound 3-1: 1-phenyl-2-(2-pyridyl)ethanone melting point: 59-60°C.
Reference Example compound 3-2: 1-(4-methoxyphenyl)-2-(2-pyridyl)ethanone melting point: 77-78°C.
Reference Example compound 3-3: 1-phenyl-2-(4-pyridyl)ethanone melting point: 109-110°C.

Reference Example 4

1-(4-methoxyphenyl)-2-(4-pyridyl)ethanone

- 5 [0241] A solution of diisopropylamine (33.2 mL) in anhydrous tetrahydrofuran (300 mL) was cooled to -78°C and 1.6 M n-butyllithium-hexane solution (148 mL) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min at the same temperature, then γ -picoline (20 g) was added dropwise. The temperature was raised to -10-0°C, and after stirring for 20 min, a solution of ethyl p-anisate (19.4 g) in anhydrous tetrahydrofuran (40 mL) was added dropwise. After completion of dropwise addition, the mixture was stirred at room temperature for 1 h, and water (100 mL) was added. The organic solvent was evaporated under reduced pressure and an oily product was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The remaining crude crystals were recrystallized from ethyl acetate-isopropyl ether to give the title compound (16.2 g, yield 66 %).
melting point: 103-104°C.

Reference Example 5

2-(5-methyl-3-pyridyl)-1-phenylethanone

- 20 [0242] A solution of diisopropylamine (20.2 mL) in anhydrous tetrahydrofuran (180 mL) was cooled to -78°C, and a 1.6 M n-butyllithium-hexane solution (90 mL) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min at the same temperature, and then 3,5-lutidine (14 g) was added dropwise. The temperature was raised to -10-0°C, and after stirring for 20 min, a solution of ethyl benzoate (9.8 g) in anhydrous tetrahydrofuran (20 mL) was added dropwise. After completion of dropwise addition, the mixture was stirred at room temperature for 1 h, and water (100 mL) was added. The organic solvent was evaporated under reduced pressure and an oily product was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The remaining crude crystals were recrystallized from ethyl acetate-isopropyl ether to give the title compound (10 g, yield 70%).
melting point: 53-54°C.

Reference Example 6

2-bromo-1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide

- 35 [0243] 1-(4-Methoxyphenyl)-2-(3-pyridyl)ethanone (6.9 g) was dissolved in acetic acid (36 mL), bromine (1.7 mL) was added, and the mixture was stirred at 80°C for 3 h. The reaction mixture was cooled with iced water and the precipitated crude crystals were collected by filtration. The crude crystals were recrystallized from ethanol-ethyl ether to give the title compound (10 g, yield 89%).
melting point: 188-195°C.

Reference Example 7

- 45 [0244] In accordance with the above-mentioned Reference Example 6, 1-phenyl-2-(3-pyridyl)ethanone, 1-(3,4-dimethoxyphenyl)-2-(3-pyridyl)ethanone, 2-(3-pyridyl)-1-(3,4,5-trimethoxyphenyl)ethanone, 1-(4-methoxymethoxyphenyl)-2-(3-pyridyl)ethanone, 1-(4-fluorophenyl)-2-(3-pyridyl)ethanone, 1-phenyl-2-(2-pyridyl)ethanone, 1-(4-methoxyphenyl)-2-(2-pyridyl)ethanone, 1-phenyl-2-(4-pyridyl)ethanone, 1-(4-methoxyphenyl)-2-(4-pyridyl)ethanone, 2-(5-methyl-3-pyridyl)-1-phenylethanone, 1-(4-ethylphenyl)-2-(3-pyridyl)ethanone, 1-(3,4-methylenedioxyphenyl)-2-(3-pyridyl)ethanone, 1-(5-indanyl)-2-(3-pyridyl)ethanone, 2-(3-pyridyl)-1-(5,6,7,8-tetrahydro-2-naphthyl)ethanone, 1-(1,4-benzodioxan-6-yl)-2-(3-pyridyl)ethanone, 1-(2-naphthyl)-2-(3-pyridyl)ethanone and 1-(4-methoxyphenyl)-2-(2-pyridyl)ethanone were respectively used instead of 1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone, the following Reference Example compounds 7-1 to 7-17 were synthesized.

Reference Example compound 7-1: 2-bromo-1-phenyl-2-(3-pyridyl)ethanone hydrobromide melting point: 208-215°C.
Reference Example compound 7-2: 2-bromo-1-(3,4-dimethoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide melting point: 191-193°C.

- 55 Reference Example compound 7-3: 2-bromo-2-(3-pyridyl)-1-(3,4,5-trimethoxyphenyl)ethanone hydrobromide melting point: 184-186°C.

Reference Example compound 7-4: 2-bromo-1-(4-hydroxyphenyl)-2-(3-pyridyl)ethanone hydrobromide
Used in the next reaction without purification.

EP 1 205 478 A1

Reference Example compound 7-5: 2-bromo-1-(4-fluorophenyl)-2-(3-pyridyl)ethanone hydrobromide melting point: 189-191°C.

Reference Example compound 7-6: 2-bromo-1-phenyl-2-(2-pyridyl)ethanone hydrobromide melting point: 180-181°C.

5 Reference Example compound 7-7: 2-bromo-1-(4-methoxyphenyl)-2-(2-pyridyl)ethanone hydrobromide melting point: 170-171°C.

Reference Example compound 7-8: 2-bromo-1-phenyl-2-(4-pyridyl)ethanone hydrobromide melting point: 230-232°C.

Reference Example compound 7-9: 2-bromo-1-(4-methoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide melting point: 207-209°C.

10 Reference Example compound 7-10: 2-bromo-2-(5-methyl-3-pyridyl)-1-phenylethanone hydrobromide melting point: 189-193°C.

Reference Example compound 7-11: 2-bromo-1-(4-ethylphenyl)-2-(3-pyridyl)ethanone hydrobromide melting point: 145-146°C.

Reference Example compound 7-12: 2-bromo-1-(3,4-methylenedioxyphenyl)-2-(3-pyridyl)ethanone hydrobromide melting point: 174-175°C.

15 Reference Example compound 7-13: 2-bromo-1-(5-indanyl)-2-(3-pyridyl)ethanone hydrobromide melting point: 177-178°C.

Reference Example compound 7-14: 2-bromo-2-(3-pyridyl)-1-(5,6,7,8-tetrahydro-2-naphthyl)ethanone hydrobromide melting point: 160-162°C.

Reference Example compound 7-15: 1-(1,4-benzodioxan-6-yl)-2-bromo-2-(3-pyridyl)ethanone hydrobromide oil.

20 Reference Example compound 7-16: 2-bromo-1-(2-naphthyl)-2-(3-pyridyl)ethanone hydrobromide melting point: 197-199°C.

Reference Example compound 7-17: 2-bromo-1-(4-methoxyphenyl)-2-(2-pyridyl)ethanone hydrobromide melting point: 170-171°C.

25 Reference Example 8

[4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]amine

30 [0245] To a suspension of thiourea (0.52 g) in acetonitrile (40 mL) was added 2-bromo-1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide (2.5 g) and triethylamine (0.95 mL) was slowly added dropwise with stirring. After completion of dropwise addition, the mixture was stirred at a refluxing temperature for 3 h, and after allowing to cool, the precipitated crystals were collected by filtration. The crystals were washed successively with saturated sodium hydrogencarbonate solution, water, ethanol and ethyl ether and dried. The obtained crude crystals were recrystallized from tetrahydrofuran to give the title compound (1.5 g, yield 90%).

35 melting point: 265-266°C.

Reference Example 9

40 N-methyl [4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]amine

[0246] To a suspension of N-methylthiourea (0.24 g) in acetonitrile (18 mL) was added 2-bromo-1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide (1.0 g) and triethylamine (0.4 mL) was slowly added dropwise with stirring. After completion of dropwise addition, the mixture was stirred at a refluxing temperature for 3 h, and the solvent was evaporated. To the residue was added saturated aqueous sodium hydrogencarbonate and the mixture was extracted with ethyl acetate, and the extract was washed with water and dried, and the solvent was evaporated. The remaining crude crystals were recrystallized from ethyl acetate-isopropyl ether to give the title compound (0.65 g, yield 85%).

45 melting point: 158-159°C.

Reference Example 10

50 N-[4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]acetamide

[0247] Using [4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]amine as a starting compound and according to a method similar to Reference Example 23-128 to be mentioned below, the title compound was obtained (yield 82%).

55 melting point: 208-210°C.

Reference Example 11

2-(4-acetylpiperazin-1-yl)-4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazole


- 5 [0248] In a solution of 1-piperazinecarbothioamide (0.39 g) in acetonitrile (15 mL) was suspended 2-bromo-1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide (1.0 g) and triethylamine (0.4 mL) was slowly added dropwise with stirring. After completion of dropwise addition, the mixture was stirred at a refluxing temperature for 3 h, and the solvent was evaporated. To the residue was added saturated aqueous sodium hydrogencarbonate and the mixture was extracted with ethyl acetate, and the extract was washed with water and dried, and the solvent was evaporated. The residue was dissolved in pyridine (2 mL) and cooled with ice. Acetyl chloride (0.3 mL) was added, and the mixture was left standing at room temperature for 1 h. The reaction mixture was poured into iced water, and the resulting product was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The residue was purified by silica gel column chromatography (ethyl acetate-methanol=9:1) to give the title compound (0.30 g, yield 28%).
- 10
- 15 oil.

Reference Example 12

[4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]amine hydrochloride

- 20 [0249] [4-(4-Methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]amine (200 mg) was dissolved in 1% hydrochloric acid-methanol (3.2 mL) and the solvent was evaporated. The obtained crude crystals were recrystallized from methanol-ethyl acetate to give the title compound (180 mg, yield 80%).
melting point: 145-150°C.
- 25 [0250] The chemical structural formulas of the compounds obtained in Reference Examples 8 to 12 are shown in the following Table 1.

Table 1



Reference Example Compound	R _a	R _b	R _c	additives
40 8	-NH ₂			
9	-NHMe			
45 10	-NHCOMe			
11				
50 12	-NH ₂			HCl

55

Reference Example 13

- [0251] Reference Example compounds 13-1 to 13-102 shown in the following Tables 2-7 were synthesized in ac-

EP 1 205 478 A1

cordance with the methods described in Reference Example 8-12, JP-A-61-10580 and USP 4,612,321.

5

10

15

20

25

30

35


40

45

50

55

Table 2










































Reference Compound	Example	R_a	R_b	R_c	m.p. / °C
13-1	-NHMe				168-169
13-2	-NH ₂				253-254
13-3	-NH ₂				240-241
13-4	-NH ₂				168-169
13-5	-NHMe				157-158
13-6	-NHMe				205-206
13-7	-NH ₂				266-268
13-8	-NHCOCH ₂ COOCH ₂ Me				201-202
13-9	-NHCOCH ₂ COOMe				185-188
13-10	-NH ₂				236-237
13-11	-NHMe				215-216
13-12	-NHMe				214-215
13-13	-NH ₂				217-218
13-14	-NH ₂				282-284
13-15	-NH ₂				248-250
13-16	-NHMe				177-178
13-17	-N 				130-131
13-18	-N 				134-135

Table 3



















































Reference Compound	Example	R _a	R _b	R _c	m.p. / °C
13-19	-CH ₂ Me			84-84.5	
13-20	-CH ₂ Me			59-60	
13-21	-CH ₂ Me			174-175	
13-22	-Me			113-114	
13-23	-CH ₂ Me			83-84	
13-24				135-136	
13-25				104-105	
13-26				96-98	
13-27				195-196	
13-28				211-213	
13-29				280-282	
13-30				100-101	
13-31				92-93	
13-32				111-112	
13-33				264-265	
13-34				245-246	
13-35				247-248	

Table 4




Reference Compound	Example	R_a	R_b	R_c	m.p. / °C
13-36	-Me			HOOC-CH=CH-	208-209
13-37	-CH=CHCOOH				255-256
13-38	-C(=C(Me)H)COOH				225-226
13-39	-(CH ₂) ₃ COOH				143-144
13-40	-(CH ₂) ₃ COOH				163-164
13-41	-(CH ₂) ₃ COOH				134-135
13-42	-(CH ₂) ₈ COOH				112-113
13-43	-(CH ₂) ₄ OH				51-52
13-44	-NHCH ₂ Me				154-155
13-45	-NHMe				187-188
13-46	-NHMe				124-125
13-47	-NHMe				191-192
13-48	-N(CH ₂ Me) ₂				oil
13-49	-NMe ₂				oil
13-50	-CH ₂ Me				oil
13-51	-CH ₂ Me				oil
13-52	-(CH ₂) ₃ Me				oil
13-53	-CH ₂ Me				oil

Table 5




Reference Example Compound	R _a	R _b	R _c	m.p. / °C
13-54				104-105
13-55	-CH ₂ COOH			oil
13-56	-(CH ₂) ₃ COOMe			oil
13-57	-(CH ₂) ₅ COOH			oil
13-58	-(CH ₂) ₅ COOH			oil
13-59	-(CH ₂) ₄ OH			oil
13-60	-(CH ₂) ₆ OH			oil
13-61	-(CH ₂) ₂ Me			oil
13-62	-CHMe ₂			oil
13-63	-NMe ₂			76-77
13-64	-N(CH ₂ Me) ₂			97-98
13-65	-NHMe			234-235
13-66	-NMe ₂			144-145
13-67	-NHMe			146-147
13-68	-NHMe			153-154
13-69	-NHMe			205-206
13-70	-NHMe			224-225
13-71	-NHMe			206-207

Table 6



Reference Compound	Example	R_a	R_b	R_c	additives	m.p./ °C
13-72	-NHMe					191-192
13-73	-NHMe					168-169
13-74	-NHMe					172-173
13-75	-NHCH ₂ CH ₂ -					126-127
13-76						222-223
13-77						132-133
13-78						90-91
13-79						148-149
13-80						180-181
13-81						240-241
13-82						258-259
13-83	-NMe ₂					85-86
13-84	-N(CH ₂ Me) ₂					56-57
13-85	-CH ₂ NH ₂					oil
13-86	-CH ₂ NHMe					oil
13-87	-NHCOMe				HCl	214-217
13-88	-NHCOMe					228-231
13-89	-NHCOMe				HCl	275-278
13-90	-NHCOCH ₂ Me				HCl	248-251

Table 7



Reference Compound	Example R_1	R_2	R_3	m.p. / °C
13-91	-NHCOCH ₂ Me		MeO-	196-199
13-92	-NHCOCHMe ₂		MeO-	213-216
13-93	-NH ₂		Me(CH ₂) ₃ O-	212-215
13-94	-NHCOMe		Me(CH ₂) ₃ O-	230-233
13-95	-NH ₂		-O-	186-189
13-96	-NHCOMe		MeOCO-	230-234
13-97	-NHCO-		MeO-	275-278
13-98	-NHCOMe		HO-	287-292
13-99	-NMeCOMe		MeO-	169-172
13-100	-NHCOMe			222-224
13-101	-NHCOMe		F-	175-178
13-102	-N=CHNMe ₂			118-120

Reference Example 14

N-(4-chlorobenzoyl)propyleneimine

[0252] A solution of propyleneimine (12.3 mL) in tetrahydrofuran (160 mL) was added to 1N aqueous sodium hydroxide solution. To this mixture was added dropwise 4-chlorobenzoyl chloride (25 g) at 0°C. After completion of dropwise addition, the mixture was stirred for further 30 min. The reaction mixture was extracted with ethyl acetate. The extract was dried, and the solvent was evaporated to give the title compound (24.9 g, yield 89%).

oil.
¹H-NMR (CDCl₃) δ: 1.39 (3H, d, J= 5.5 Hz), 2.15 (1H, d, J= 2.9 Hz), 2.51-2.66 (2H, m), 7.39-7.47 (2H, m), 7.93-8.01 (2H, m).

Reference Example 15

5 [0253] In accordance with Reference Example 14, 3-chlorobenzoyl chloride, 2-chlorobenzoyl chloride, 2-methylbenzoyl chloride, 3-methylbenzoyl chloride, 4-methylbenzoyl chloride, 2-methoxybenzoyl chloride, 3-methoxybenzoyl chloride, 4-ethylbenzoyl chloride, 4-(1-methylethyl)benzoyl chloride, 4-(1,1-dimethylethyl)benzoyl chloride, 4-propylbenzoyl chloride, 4-butylbenzoyl chloride, 4-hexylbenzoyl chloride, 4-trifluoromethoxybenzoyl chloride, 4-trifluoromethylbenzoyl chloride, 3,4-dimethoxybenzoyl chloride, 3,4-dimethylbenzoyl chloride, 3,5-dimethylbenzoyl chloride, 3,4-methylenedioxybenzoyl chloride, 2-naphthoyl chloride, 4-fluorobenzoyl chloride and 3-cyclopentyloxy-4-methoxybenzoyl chloride were respectively used instead of 4-chlorobenzoyl chloride, the following Reference Example compounds 15-1 to 15-22 were synthesized.

Reference Example compound 15-1: N-(3-chlorobenzoyl)-propyleneimine oil.

15 [0254] $^1\text{H-NMR}$ (CDCl_3) δ : 1.40 (3H, d, $J = 5.1$ Hz), 2.17 (1H, d, $J = 3.3$ Hz), 2.53-2.68 (2H, m), 7.40 (1H, dd, $J = 8.1$, 7.7 Hz), 7.53 (1H, ddd, $J = 8.1$, 2.2, 1.5 Hz), 7.90 (1H, dt, $J = 7.7$, 1.5 Hz), 8.00 (1H, dd, $J = 2.2$, 1.5 Hz).

Reference Example compound 15-2: N-(2-chlorobenzoyl)-propyleneimine oil.

20 [0255] $^1\text{H-NMR}$ (CDCl_3) δ : 1.30 (3H, d, $J = 5.1$ Hz), 2.12 (1H, d, $J = 3.3$ Hz), 2.53 (1H, d, $J = 5.5$ Hz), 2.56-2.68 (1H, m), 7.28-7.48 (3H, m), 7.75-7.81 (1H, m).

Reference Example compound 15-3: N-(2-methylbenzoyl)-propyleneimine oil.

25 [0256] $^1\text{H-NMR}$ (CDCl_3) δ : 1.30 (3H, d, $J = 5.5$ Hz), 2.08 (1H, d, $J = 3.3$ Hz), 2.43-2.57 (5H, m), 7.20-7.31 (2H, m), 7.33-7.43 (1H, m), 7.89 (1H, d, $J = 7.7$ Hz).

Reference Example compound 15-4: N-(3-methylbenzoyl)-propyleneimine oil.

30 [0257] $^1\text{H-NMR}$ (CDCl_3) δ : 1.39 (3H, d, $J = 5.5$ Hz), 2.14 (1H, d, $J = 3.3$ Hz), 2.41 (3H, s), 2.51-2.66 (2H, m), 7.32-7.39 (2H, m), 7.79-7.87 (2H, m).

Reference Example compound 15-5: N-(4-methylbenzoyl)-propyleneimine oil.

35 [0258] $^1\text{H-NMR}$ (CDCl_3) δ : 1.39 (3H, d, $J = 5.5$ Hz), 2.12 (1H, d, $J = 2.9$ Hz), 2.42 (3H, s), 2.50-2.62 (2H, m), 7.25 (2H, d, $J = 8.1$ Hz), 7.92 (2H, d, $J = 8.1$ Hz).

Reference Example compound 15-6: N-(2-methoxybenzoyl)-propyleneimine oil.

40 [0259] $^1\text{H-NMR}$ (CDCl_3) δ : 1.30 (3H, d, $J = 5.5$ Hz), 2.10 (1H, d, $J = 3.3$ Hz), 2.50 (1H, d, $J = 5.9$ Hz), 2.53-2.65 (1H, m), 3.90 (3H, s), 6.95-7.05 (2H, m), 7.41-7.52 (1H, m), 7.81-7.88 (1H, m).

Reference Example compound 15-7: N-(3-methoxybenzoyl)-propyleneimine oil.

45 [0260] $^1\text{H-NMR}$ (CDCl_3) δ : 1.40 (3H, d, $J = 5.9$ Hz), 2.14 (1H, d, $J = 2.9$ Hz), 2.52-2.65 (2H, m), 3.86 (3H, s), 7.10 (1H, ddd, $J = 8.4$, 2.6, 1.1 Hz), 7.37 (1H, dd, $J = 8.4$, 7.3 Hz), 7.55 (1H, dd, $J = 2.6$, 1.5 Hz), 7.63 (1H, ddd, $J = 7.3$, 1.5, 1.1 Hz).

Reference Example compound 15-8: N-(4-ethylbenzoyl)-propyleneimine oil.

50 [0261] $^1\text{H-NMR}$ (CDCl_3) δ : 1.27 (3H, t, $J = 7.6$ Hz), 1.39 (3H, d, $J = 5.5$ Hz), 2.13 (1H, d, $J = 3.3$ Hz), 2.50-2.61 (2H, m), 2.71 (2H, q, $J = 7.6$ Hz), 7.28 (2H, d, $J = 7.7$ Hz), 7.95 (2H, d, $J = 7.7$ Hz).

Reference Example compound 15-9: N-[4-(1-methylethyl)-benzoyl]propyleneimine oil.

55 [0262] $^1\text{H-NMR}$ (CDCl_3) δ : 1.28 (6H, d, $J = 7.0$ Hz), 1.40 (3H, d, $J = 5.5$ Hz), 2.13 (1H, d, $J = 3.3$ Hz), 2.50-2.64 (2H, m), 2.90-3.05 (1H, m), 7.31 (2H, d, $J = 8.2$ Hz), 7.96 (2H, d, $J = 8.2$ Hz).

EP 1 205 478 A1

Reference Example compound 15-10: N-[4-(1,1-dimethylethyl)-benzoyl]propyleneimine

[0263] A solution of propyleneimine (11 mL, 0.14 mol) in tetrahydrofuran (160 mL) was added to 2N aqueous sodium hydroxide solution (70 mL). To this mixture was added dropwise 4-(1,1-dimethylethyl)benzoyl chloride (25 g, 0.13 mol) at 0°C. After completion of dropwise addition, the mixture was stirred further for 30 min. The reaction mixture was extracted with ethyl acetate. The extract was dried, and the solvent was evaporated to give the title compound (27 g, 0.13 mol, yield 99%).

oil.

¹H-NMR (CDCl₃) δ: 1.35 (9H, s), 1.41 (3H, d, J= 5.5 Hz), 2.12 (1H, d, J= 2.9 Hz), 2.51-2.64 (2H, m), 7.47 (2H, d, J= 8.8 Hz), 7.96 (2H, d, J= 8.8 Hz).

Reference Example compound 15-11: N-(4-propylbenzoyl)-propyleneimine oil.

[0264] ¹H-NMR (CDCl₃) δ: 0.96 (3H, t, J= 7.3 Hz), 1.39 (3H, d, J= 5.5 Hz), 1.57-1.75 (2H, m), 2.12 (1H, d, J= 3.3 Hz), 2.50-2.59 (2H, m), 2.65 (2H, t, J= 7.7 Hz), 7.26 (2H, d, J= 8.1 Hz), 7.94 (2H, d, J= 8.1 Hz).

Reference Example compound 15-12: N-(4-butylbenzoyl)-propyleneimine oil.

[0265] ¹H-NMR (CDCl₃) δ: 0.94 (3H, t, J= 7.1 Hz), 1.26-1.47 (5H, m), 1.54-1.73 (2H, m), 2.12 (1H, d, J= 2.9 Hz), 2.51-2.62 (2H, m), 2.67 (2H, t, J= 7.7 Hz), 7.26 (2H, d, J= 8.1 Hz), 7.94 (2H, d, J= 8.1 Hz).

Reference Example compound 15-13: N-(4-hexylbenzoyl)-propyleneimine oil.

[0266] ¹H-NMR (CDCl₃) δ: 0.89 (3H, t, J= 6.6 Hz), 1.24-1.38 (6H, m), 1.39 (3H, d, J= 5.5 Hz), 1.56-1.68 (2H, m), 2.12 (1H, d, J= 3.3 Hz), 2.51-2.61 (2H, m), 2.66 (2H, t, J= 7.7 Hz), 7.26 (2H, d, J= 8.1 Hz), 7.94 (2H, d, J= 8.1 Hz).

Reference Example compound 15-14: N-(4-trifluoromethoxybenzoyl)propyleneimine oil.

[0267] ¹H-NMR (CDCl₃) δ: 1.40 (3H, d, J= 5.5 Hz), 2.16 (1H, d, J= 3.3 Hz), 2.53-2.68 (2H, m), 7.29 (2H, d, J= 9.0 Hz), 8.08 (2H, d, J= 9.0 Hz).

Reference Example compound 15-15: N-(4-trifluoromethylbenzoyl)propyleneimine oil.

[0268] ¹H-NMR (CDCl₃) δ: 1.40 (3H, d, J= 5.5 Hz), 2.19 (1H, d, J= 3.7 Hz), 2.54-2.70 (2H, m), 7.73 (2H, d, J= 8.0 Hz), 8.13 (2H, d, J= 8.0 Hz).

Reference Example compound 15-16: N-(3,4-dimethoxybenzoyl)-propyleneimine oil.

[0269] ¹H-NMR (CDCl₃) δ: 1.41 (3H, d, J= 5.5 Hz), 2.12 (1H, d, J= 3.3 Hz), 2.51-2.63 (2H, m), 3.94 (3H, s), 3.95 (3H, s), 6.92 (1H, d, J= 8.5 Hz), 7.56 (1H, d, J= 2.2 Hz), 7.69 (1H, dd, J= 8.5, 2.2 Hz).

Reference Example compound 15-17: N-(3,4-dimethylbenzoyl)-propyleneimine oil.

[0270] ¹H-NMR (CDCl₃) δ: 1.39 (3H, d, J= 5.5 Hz), 2.12 (1H, d, J= 3.3 Hz), 2.32 (6H, s), 2.49-2.61 (2H, m), 7.21 (1H, d, J= 7.7 Hz), 7.77 (1H, dd, J= 7.7, 1.8 Hz), 7.80 (1H, d, J= 1.8 Hz).

Reference Example compound 15-18: N-(3,5-dimethylbenzoyl)-propyleneimine

[0271] 3,5-Dimethylbenzoic acid (25 g, 0.17 mol) and dimethylformamide (0.1 mL) were added to thionyl chloride (50 mL) at 0°C. The mixture was refluxed under heating for 2 h. The excess thionyl chloride was evaporated under reduced pressure and to the residue was added toluene (50 mL). Toluene was evaporated under reduced pressure to give oily 3,5-dimethylbenzoyl chloride. A solution of propyleneimine (14 mL, 0.18 mol) in tetrahydrofuran (160 mL) was added to 1N aqueous sodium hydroxide solution (180 mL). 3,5-Dimethylbenzoyl chloride was added dropwise to this mixture at 0°C. After completion of dropwise addition, the mixture was stirred further for 30 min. The reaction mixture was extracted with ethyl acetate. The extract was dried, and the solvent was evaporated to give the title compound (31 g, 0.16 mol, yield 99%).

oil.

¹H-NMR (CDCl₃) δ: 1.39 (3H, d, J= 5.5 Hz), 2.13 (1H, d, J= 3.7 Hz), 2.37 (6H, s), 2.47-2.62 (2H, m), 7.19 (1H, s), 7.64

EP 1 205 478 A1

(2H, s).

Reference Example compound 15-19: N-(3,4-methylenedioxybenzoyl)propyleneimine oil.

5 [0272] ¹H-NMR (CDCl₃) δ: 1.38 (3H, d, J= 4.9 Hz), 2.11 (1H, d, J= 3.1 Hz), 2.48-2.64 (2H, m), 6.05 (2H, s), 6.86 (1H, d, J= 8.2 Hz), 7.48 (1H, d, J= 1.7 Hz), 7.65 (1H, dd, J= 8.2, 1.7 Hz).

Reference Example compound 15-20: N-(2-naphthoyl)-propyleneimine oil.

10 [0273] ¹H-NMR (CDCl₃) δ: 1.44 (3H, d, J= 5.5 Hz), 2.22 (1H, d, J= 3.3 Hz), 2.57-2.84 (2H, m), 7.50-7.65 (2H, m), 7.85-8.00 (3H, m), 8.06 (1H, dd, J= 8.6, 1.5 Hz), 8.59 (1H, s).

Reference Example compound 15-21: N-(4-fluorobenzoyl)-propyleneimine oil.

15 [0274] ¹H-NMR (CDCl₃) δ: 1.39 (3H, d, J= 5.2 Hz), 2.14-2.15 (1H, m), 2.52-2.63 (2H, m), 7.08-7.19 (2H, m), 8.00-8.10 (2H, m).

Reference Example compound 15-22: N-(3-cyclopentyloxy-4-methoxybenzoyl)propyleneimine oil.

20 [0275] ¹H-NMR (CDCl₃) δ: 1.40 (3H, d, J= 5.1 Hz), 1.54-1.68 (2H, m), 1.73-2.06 (6H, m), 2.11 (1H, d, J= 3.3 Hz), 2.51-2.63 (2H, m), 3.91 (3H, s), 4.79-4.90 (1H, m), 6.90 (1H, d, J= 8.4 Hz), 7.55 (1H, d, J= 1.8 Hz), 7.65 (1H, dd, J= 8.4, 1.8 Hz).

Reference Example 16

25

1-(2-chlorophenyl)-2-(4-pyridyl)ethanone

[0276] A solution of diisopropylamine (15 mL) in anhydrous tetrahydrofuran (100 mL) was cooled at -50°C and 1.6 M n-butyllithium/hexane solution (69 mL) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min and a solution of γ-picoline (20 g) in anhydrous tetrahydrofuran (10 mL) was added dropwise at -30°C. The mixture was stirred for 1 h and a solution of N-(2-chlorobenzoyl)propyleneimine (20 g) in anhydrous tetrahydrofuran (10 mL) was added dropwise at -10°C. After completion of dropwise addition, the mixture was stirred for at room temperature for 2 h. To the reaction mixture was added water (100 mL) and the mixture was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate=1:1) to give the title compound (16 g, yield 71%).

35 oil.
¹H-NMR (CDCl₃) δ: 4.28 (2H, s), 7.20 (2H, d, J= 6.2 Hz), 7.28-7.39 (1H, m), 7.41-7.48 (3H, m), 8.56 (2H, d, J= 6.2 Hz).

Reference Example 17

40

[0277] In accordance with Reference Example 16, N-(3-chlorobenzoyl)propyleneimine, N-(4-chlorobenzoyl)-propyleneimine, N-(2-methylbenzoyl)propyleneimine, N-(3-methylbenzoyl)propyleneimine, N-(4-methylbenzoyl)-propyleneimine, N-(2-methoxybenzoyl)propyleneimine, N-(3-methoxybenzoyl)propyleneimine, N-(4-ethylbenzoyl)-propyleneimine, N-[4-(1-methylethyl)benzoyl]propyleneimine, N-[4-(1,1-dimethylethyl)benzoyl]propyleneimine, N-(4-propylbenzoyl)propyleneimine, N-(4-butylbenzoyl)propyleneimine, N-(4-hexylbenzoyl)propyleneimine, N-(4-trifluoromethoxybenzoyl)propyleneimine, N-(4-trifluoromethylbenzoyl)propyleneimine, N-(3,4-dimethoxybenzoyl)propyleneimine, N-(3,4-dimethylbenzoyl)-propyleneimine, N-(3,5-dimethylbenzoyl)propyleneimine, N-(3,4-methylenedioxybenzoyl)propyleneimine, N-(2-naphthoyl)-propyleneimine and N-(3-cyclopentyloxy-4-methoxybenzoyl)-propyleneimine, instead of N-(2-chlorobenzoyl)propyleneimine, the following Reference Example compounds 17-1 to 17-21 were synthesized.

50

Reference Example compound 17-1: 1-(3-chlorophenyl)-2-(4-pyridyl)ethanone

[0278] melting point: 79-80°C.

55

Reference Example compound 17-2: 1-(4-chlorophenyl)-2-(4-pyridyl)ethanone

[0279] melting point: 93-94°C.

EP 1 205 478 A1

Reference Example compound 17-3: 1-(2-methylphenyl)-2-(4-pyridyl)ethanone oil.

[0280] $^1\text{H-NMR}$ (CDCl_3) δ : 2.48 (3H, s), 4.23 (2H, s), 7.19 (2H, d, $J = 6.2$ Hz), 7.24-7.47 (3H, m), 7.73 (1H, d, $J = 7.7$ Hz), 8.56 (2H, d, $J = 6.2$ Hz).

Reference Example compound 17-4: 1-(3-methylphenyl)-2-(4-pyridyl)ethanone

[0281] melting point: 115-116°C.

Reference Example compound 17-5: 1-(4-methylphenyl)-2-(4-pyridyl)ethanone

[0282] melting point: 110-111°C.

Reference Example compound 17-6: 1-(2-methoxyphenyl)-2-(4-pyridyl)ethanone oil.

[0283] $^1\text{H-NMR}$ (CDCl_3) δ : 3.92 (3H, s), 4.30 (2H, s), 6.95-7.07 (2H, m), 7.17 (2H, d, $J = 5.9$ Hz), 7.50 (1H, ddd, $J = 8.4, 7.3, 1.8$ Hz), 7.73 (1H, dd, $J = 7.7, 1.8$ Hz), 8.53 (2H, d, $J = 5.9$ Hz).

Reference Example compound 17-7: 1-(3-methoxyphenyl)-2-(4-pyridyl)ethanone oil.

[0284] $^1\text{H-NMR}$ (CDCl_3) δ : 3.86 (3H, s), 4.28 (2H, s), 7.14 (1H, ddd, $J = 8.1, 2.6, 1.1$ Hz), 7.20 (2H, d, $J = 6.2$ Hz), 7.36 (1H, dd, $J = 8.1, 7.7$ Hz), 7.51 (1H, dd, $J = 2.6, 1.5$ Hz), 7.58 (1H, ddd, $J = 7.7, 1.5, 1.1$ Hz), 8.57 (2H, d, $J = 6.2$ Hz).

Reference Example compound 17-8: 1-(4-ethylphenyl)-2-(4-pyridyl)ethanone

[0285] melting point: 87-89°C.

Reference Example compound 17-9: 1-[4-(1-methylethyl)phenyl]-2-(4-pyridyl)ethanone

[0286] melting point: 86-88°C.

Reference Example compound 17-10: 1-[4-(1,1-dimethylethyl)-phenyl]-2-(4-pyridyl)ethanone

[0287] A solution of diisopropylamine (15 mL, 0.11 mol) in anhydrous tetrahydrofuran (100 mL) was cooled to -50°C, 1.6 M n-butyllithium-hexane solution (69 mL, 0.11 mol) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min, and then a solution of γ -picoline (9.3 g, 0.10 mol) in anhydrous tetrahydrofuran (10 mL) was added dropwise at -30°C. The mixture was stirred for 1 h, a solution of N-[4-(1,1-dimethylethyl)benzoyl]-propyleneimine (22 g, 0.10 mol) in anhydrous tetrahydrofuran (10 mL) was added dropwise at -30°C. After completion of dropwise addition, the temperature of the mixture was increased gradually to room temperature and the mixture was stirred for 2 h. To the reaction mixture was added water (100 mL), the mixture was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate, 1:1) and recrystallized from diisopropyl ether-hexane to give the title compound (11 g, yield 43%).
melting point: 75-76°C.

Reference Example compound 17-11: 1-(4-propylphenyl)-2-(4-pyridyl)ethanone

[0288] melting point: 71-72°C.

Reference Example compound 17-12: 1-(4-butylphenyl)-2-(4-pyridyl)ethanone

[0289] melting point: 41-43°C.

Reference Example compound 17-13: 1-(4-hexylphenyl)-2-(4-pyridyl)ethanone

[0290] melting point: 57-58°C.

EP 1 205 478 A1

Reference Example compound 17-14: 2-(4-pyridyl)-1-(4-trifluoromethoxyphenyl)ethanone

[0291] melting point: 65-66°C.

Reference Example compound 17-15: 2-(4-pyridyl)-1-(4-trifluoromethylphenyl)ethanone

[0292] melting point: 94-95°C.

Reference Example compound 17-16: 1-(3,4-dimethoxyphenyl)-2-(4-pyridyl)ethanone

[0293] melting point: 110-111°C.

Reference Example compound 17-17: 1-(3,4-dimethylphenyl)-2-(4-pyridyl)ethanone

[0294] melting point: 81-83°C.

Reference Example compound 17-18

1-(3,5-dimethylphenyl)-2-(4-pyridyl)ethanone

[0295] A solution of diisopropylamine (15 mL, 0.11 mol) in anhydrous tetrahydrofuran (100 mL) was cooled to -50°C, 1.6 M n-butyllithium-hexane solution (69 mL, 0.11 mol) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min, and a solution of γ -picoline (9.3 g, 0.10 mol) in anhydrous tetrahydrofuran (10 mL) was added dropwise at -30°C. The mixture was stirred for 1 h, a solution of N-(3,5-dimethylbenzoyl)propyleneimine (19 g, 0.10 mol) in anhydrous tetrahydrofuran (10 mL) was added dropwise at -30°C. After completion of dropwise addition, the temperature of the mixture was gradually raised to room temperature and the mixture was stirred for 2 h. To the reaction mixture was added water (100 mL) and the mixture was extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The residue was crystallized from diisopropyl ether-hexane to give the title compound (13 g, yield 58%).
melting point: 90-91°C.

Reference Example compound 17-19: 1-(3,4-methylenedioxypheyl)-2-(4-pyridyl)ethanone

[0296] melting point: 126-127°C.

Reference Example compound 17-20: 1-(2-naphthyl)-2-(4-pyridyl)ethanone

[0297] melting point: 114-115°C.

Reference Example compound 17-21: 1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethanone

[0298] melting point: 87-89°C.

Reference Example 18

[0299] In accordance with Reference Example 17, the following Reference Example compound 18-1-18-9 were synthesized using γ -picoline instead of β -picoline.

Reference Example compound 18-1: 1-(2-chlorophenyl)-2-(3-pyridyl)ethanone oil.

[0300] $^1\text{H-NMR}$ (CDCl_3) δ : 4.28 (2H, s), 7.18-7.49 (5H, m), 7.59-7.67 (1H, m), 8.47-8.56 (2H, m).

Reference Example compound 18-2: 1-(3-chlorophenyl)-2-(3-pyridyl)ethanone oil.

[0301] $^1\text{H-NMR}$ (CDCl_3) δ : 4.29 (2H, s), 7.25-7.34 (1H, m), 7.44 (1H, t, $J = 7.7$ Hz), 7.54-7.63 (2H, m), 7.90 (1H, dt, $J = 7.7, 1.5$ Hz), 8.00 (1H, dd, $J = 1.8, 1.5$ Hz), 8.49-8.57 (2H, m).

EP 1 205 478 A1

Reference Example compound 18-3: 1-(4-chlorophenyl)-2-(3-pyridyl)ethanone

[0302] ¹H-NMR (CDCl₃) δ: 4.27 (2H, s), 7.24-7.31 (1H, m), 7.47 (2H, d, J= 8.8 Hz), 7.55-7.63 (1H, m), 7.96 (2H, d, J= 8.8 Hz), 8.46-8.53 (2H, m).

Reference Example compound 18-4: 1-(2-methylphenyl)-2-(3-pyridyl)ethanone oil.

[0303] ¹H-NMR (CDCl₃) δ: 2.47 (3H, s), 4.23 (2H, s), 7.18-7.47 (5H, m), 7.73 (1H, d, J= 7.7 Hz), 8.47-8.56 (2H, m).

Reference Example compound 18-5: 1-(3-methylphenyl)-2-(3-pyridyl)ethanone oil.

[0304] ¹H-NMR (CDCl₃) δ: 2.43 (3H, s), 4.29 (2H, s), 7.17-7.36 (1H, m), 7.36-7.46 (2H, m), 7.58-7.65 (1H, m), 7.78-7.86 (2H, m), 8.50-8.56 (2H, m).

Reference Example compound 18-6: 1-(4-methylphenyl)-2-(3-pyridyl)ethanone

[0305] melting point: 72-74°C.

Reference Example compound 18-7: 1-(3-methoxyphenyl)-2-(3-pyridyl)ethanone oil.

[0306] ¹H-NMR (CDCl₃) δ: 3.86 (3H, s), 4.29 (2H, s), 7.14 (1H, ddd, J= 8.1, 2.6, 1.8 Hz), 7.28 (1H, dd, J= 7.3, 4.8 Hz), 7.40 (1H, dd, J= 8.1, 7.7 Hz), 7.53 (1H, dd, J= 2.6, 1.8 Hz), 7.58-7.65 (2H, m), 8.50-8.55 (2H, m).

Reference Example compound 18-8: 1-[4-(1,1-dimethylethyl)phenyl]-2-(3-pyridyl)ethanone oil.

[0307] ¹H-NMR (CDCl₃) δ: 1.34 (9H, s), 4.28 (2H, s), 7.22-7.31 (1H, m), 7.50 (2H, d, J= 8.4 Hz), 7.56-7.65 (1H, m), 7.96 (2H, d, J= 8.4 Hz), 8.48-8.55 (2H, m).

Reference Example compound 18-9: 1-(3,5-dimethylphenyl)-2-(3-pyridyl)ethanone oil.

[0308] ¹H-NMR (CDCl₃) δ: 2.38 (6H, s), 4.27 (2H, s), 7.24-7.30 (2H, m), 7.58-7.63 (3H, m), 8.50-8.52 (2H, m).

Reference Example 19

[0309] In accordance with Reference Example 1, the following Reference Example compound 19 was synthesized using ethyl 4-dimethylaminobenzoate instead of ethyl p-anisate.

Reference Example compound 19: 1-(4-dimethylaminophenyl)-2-(4-pyridyl)ethanone

[0310] melting point: 189-192°C.

Reference Example 20

1-(4-fluorophenyl)-2-(4-pyridyl)ethanone

[0311] A solution of diisopropylamine (29 mL) in anhydrous tetrahydrofuran (300 mL) was cooled to -78°C, and 1.6 M n-butyllithium/hexane solution (140 mL) was added dropwise with stirring. After completion of dropwise addition, the mixture was stirred for 10 min, and then a solution of γ-picoline (21 g) in anhydrous tetrahydrofuran (50 mL) was added. The reaction mixture was stirred at -10°C for 30 min. The reaction solution was cooled to -78°C and a solution of N-(4-fluorobenzoyl)propyleneimine (36 g) in anhydrous tetrahydrofuran (50 mL) was added dropwise. After completion of dropwise addition, the mixture was stirred at room temperature for 3 h. To the reaction mixture was added water (100 mL) and extracted with ethyl acetate. The extract was washed with water, and after drying, the solvent was evaporated. The residue was crystallized from diisopropyl ether to give the title compound (28 g, yield 66%).
melting point: 90-91°C.

Reference Example 21

4-(methylthio)thiobenzamide

- 5 [0312] 4-Methylthiobenzonitrile (12 g) was dissolved in a solution (130 mL) of 4N hydrogen chloride in ethyl acetate. To this solution was added O,O-diethyl dithiophosphate (15 mL) and the mixture was stirred at room temperature for 22 h. To the reaction mixture was added water (100 mL), and the mixture was extracted with ethyl acetate. The insoluble material was filtered off and the filtrate was washed with saturated brine, dried and the solvent was evaporated. The residue was recrystallized from ethyl acetate to give the title compound (10 g, yield 67%).
- 10 melting point: 176-178°C.

Reference Example 22

- 15 [0313] In accordance with Reference Example 6 and respectively using 1-(2-chlorophenyl)-2-(3-pyridyl)ethanone, 1-(3-chlorophenyl)-2-(3-pyridyl)ethanone, 1-(4-chlorophenyl)-2-(3-pyridyl)ethanone, 1-(2-methylphenyl)-2-(3-pyridyl)ethanone, 1-(3-methylphenyl)-2-(3-pyridyl)ethanone, 1-(4-methylphenyl)-2-(3-pyridyl)ethanone, 1-(3-methoxyphenyl)-2-(3-pyridyl)ethanone, 1-[4-(1,1-dimethylethyl)phenyl]-2-(3-pyridyl)ethanone, 1-(3,5-dimethylphenyl)-2-(3-pyridyl)ethanone, 1-(2-chlorophenyl)-2-(4-pyridyl)ethanone, 1-(3-chlorophenyl)-2-(4-pyridyl)ethanone, 1-(4-chlorophenyl)-2-(4-pyridyl)ethanone, 1-(2-methylphenyl)-2-(4-pyridyl)ethanone, 1-(3-methylphenyl)-2-(4-pyridyl)ethanone, 20 1-(4-methylphenyl)-2-(4-pyridyl)ethanone, 1-(2-methoxyphenyl)-2-(4-pyridyl)ethanone, 1-(3-methoxyphenyl)-2-(4-pyridyl)ethanone, 1-(4-ethylphenyl)-2-(4-pyridyl)ethanone, 1-[4-(1-methylethyl)phenyl]-2-(4-pyridyl)ethanone, 1-[4-(1,1-dimethylethyl)phenyl]-2-(4-pyridyl)ethanone, 1-(4-propylphenyl)-2-(4-pyridyl)ethanone, 1-(4-butylphenyl)-2-(4-pyridyl)ethanone, 1-(4-hexylphenyl)-2-(4-pyridyl)ethanone, 2-(4-pyridyl)-1-(4-trifluoromethoxyphenyl)ethanone, 2-(4-pyridyl)-1-(4-trifluoromethylphenyl)ethanone, 1-(4-dimethylaminophenyl)-2-(4-pyridyl)ethanone hydrobromide, 25 1-(3,4-dimethoxyphenyl)-2-(4-pyridyl)ethanone, 1-(3,4-dimethylphenyl)-2-(4-pyridyl)ethanone, 1-(3,5-dimethylphenyl)-2-(4-pyridyl)ethanone, 1-(3,4-methylenedioxyphenyl)-2-(4-pyridyl)ethanone, 1-(2-naphthyl)-2-(4-pyridyl)ethanone, 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone and 1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethanone instead of 1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone, the following Reference Example compounds 22-1 to 22-33 were synthesized.

30 Reference Example compound 22-1: 2-bromo-1-(2-chlorophenyl)-2-(3-pyridyl)ethanone hydrobromide

[0314] melting point: 88-90°C.

- 35 Reference Example compound 22-2: 2-bromo-1-(3-chlorophenyl)-2-(3-pyridyl)ethanone hydrobromide

[0315] melting point: 164-166°C

Reference Example compound 22-3: 2-bromo-1-(4-chlorophenyl)-2-(3-pyridyl)ethanone hydrobromide

- 40 [0316] Used in the next reaction without purification.

Reference Example compound 22-4: 2-bromo-1-(2-methylphenyl)-2-(3-pyridyl)ethanone hydrobromide

- 45 [0317] Used in the next reaction without purification.

Reference Example compound 22-5: 2-bromo-1-(3-methylphenyl)-2-(3-pyridyl)ethanone hydrobromide

- 50 [0318] Used in the next reaction without purification.

Reference Example compound 22-6: 2-bromo-1-(4-methylphenyl)-2-(3-pyridyl)ethanone hydrobromide

[0319] melting point: 96-98°C.

- 55 Reference Example compound 22-7: 2-bromo-1-(3-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide

[0320] Used in the next reaction without purification.

EP 1 205 478 A1

Reference Example compound 22-8: 2-bromo-1-[4-(1,1-dimethylethyl)phenyl]-2-(3-pyridyl)ethanone hydrobromide

[0321] melting point: 190-194°C.

5 Reference Example compound 22-9: 2-bromo-1-(3,5-dimethylphenyl)-2-(3-pyridyl)ethanone hydrobromide

[0322] melting point: 195-197°C.

10 Reference Example compound 22-10: 2-bromo-1-(2-chlorophenyl)-2-(4-pyridyl)ethanone hydrobromide

[0323] melting point: 157-159°C.

Reference Example compound 22-11: 2-bromo-1-(3-chlorophenyl)-2-(4-pyridyl)ethanone hydrobromide

15 [0324] melting point: 178-181°C.

Reference Example compound 22-12: 2-bromo-1-(4-chlorophenyl)-2-(4-pyridyl)ethanone hydrobromide

20 [0325] melting point: 189-193°C.

Reference Example compound 22-13: 2-bromo-1-(2-methylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0326] melting point: 183-186°C.

25 Reference Example compound 22-14: 2-bromo-1-(3-methylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0327] Used in the next reaction without purification.

30 Reference Example compound 22-15: 2-bromo-1-(4-methylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0328] melting point: 111-113°C.

Reference Example compound 22-16: 2-bromo-1-(2-methoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide

35 [0329] melting point: 168-171°C.

Reference Example compound 22-17: 2-bromo-1-(3-methoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide

40 [0330] Used in the next reaction without purification.

Reference Example compound 22-18: 2-bromo-1-(4-ethylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0331] melting point: 170-173°C.

45 Reference Example compound 22-19: 2-bromo-1-[4-(1-methylethyl)phenyl]-2-(4-pyridyl)ethanone hydrobromide

[0332] melting point: 185-188°C.

50 Reference Example compound 22-20: 2-bromo-1-[4-(1,1-dimethylethyl)phenyl]-2-(4-pyridyl)ethanone hydrobromide

[0333] 1-[4-(1,1-Dimethylethyl)phenyl]-2-(4-pyridyl)ethanone (10 g, 39 mmol) was dissolved in acetic acid (40 mL) and bromine (2.0 mL, 39 mmol) was added. The mixture was stirred at 80°C for 3 h. The reaction mixture was cooled with iced water and the precipitated crude crystals were collected by filtration. The crude crystals were washed with ethyl acetate to give the title compound (9.6 g, yield 81%).

55 melting point: 209-212°C.

EP 1 205 478 A1

Reference Example compound 22-21: 2-bromo-1-(4-propylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0334] melting point: 167-170°C.

5 Reference Example compound 22-22: 2-bromo-1-(4-butylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0335] melting point: 158-161°C.

Reference Example compound 22-23: 2-bromo-1-(4-hexylphenyl)-2-(4-pyridyl)ethanone hydrobromide

10

[0336] melting point: 153-155°C.

Reference Example compound 22-24: 2-bromo-2-(4-pyridyl)-1-(4-trifluoromethoxyphenyl)ethanone hydrobromide

15

[0337] Used in the next reaction without purification.

Reference Example compound 22-25: 2-bromo-2-(4-pyridyl)-1-(4-trifluoromethylphenyl)ethanone hydrobromide

[0338] melting point: 190-194°C.

20

Reference Example compound 22-26: 2-bromo-1-(4-dimethylaminophenyl)-2-(4-pyridyl)ethanone dihydrobromide

[0339] melting point: 163-167°C.

25

Reference Example compound 22-27: 2-bromo-1-(3,4-dimethoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0340] melting point: 174-175°C.

Reference Example compound 22-28: 2-bromo-1-(3,4-dimethylphenyl)-2-(4-pyridyl)ethanone hydrobromide

30

[0341] melting point: 196-199°C.

Reference Example compound 22-29: 2-bromo-1-(3,5-dimethylphenyl)-2-(4-pyridyl)ethanone hydrobromide

35

[0342] 1-(3,5-Dimethylphenyl)-2-(4-pyridyl)ethanone (7.0 g, 31 mmol) was dissolved in acetic acid (35 mL) and bromine (1.6 mL, 31 mmol) was added. The mixture was stirred at 80°C for 3 h. Ethyl acetate was added to the residue and the precipitated crude crystals were collected by filtration. The crude crystals were washed with ethyl acetate to give the title compound (16 g, yield 96%).
melting point: 216-219°C.

40

Reference Example compound 22-30: 2-bromo-1-(3,4-methylenedioxyphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0343] melting point: 211-214°C.

45

Reference Example compound 22-31: 2-bromo-1-(2-naphthyl)-2-(4-pyridyl)ethanone hydrobromide

[0344] melting point: 149-152°C.

Reference Example compound 22-32: 2-bromo-1-(4-fluorophenyl)-2-(4-pyridyl)ethanone hydrobromide

50

[0345] melting point: 185-189°C.

Reference Example compound 22-33: 2-bromo-1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide

55

[0346] melting point: 168-170°C.

EP 1 205 478 A1

Reference Example 23

[0347] In accordance with the method described in Reference Examples 8-12, JP-A-61-10580 and USP 4,612,321, Reference Example compounds 23-1 to 23-294 and 23-295 to 23-349 shown in the following Tables 8 to 31 were synthesized.

5

10

15

20

25

30

35


40

45

50

55

Table 8


















































Reference Compound	Example	R_a	R_b	R_c	additives	m.p. / °C
23-1	-NHCO-				HCl	260
23-2	-NHCO-				HCl	244-246
23-3	-NHCO-				HCl	255-256
23-4	-NHCO-				HCl	275
23-5	-NHCO-					233
23-6	-NHCOMe					218-220
23-7	-NHCOMe					218-220
23-8	-NHCO-				2HCl	145-148
23-9	-NHCO-					238
23-10	-NHCOCH ₂ -					228-230
23-11	-NHCO(CH ₂) ₂ -					215-217
23-12	-NHCO(CH ₂) ₂ Me					198-200
23-13	-NHCO(CH ₂) ₃ Me					205-206
23-14	-NHCO(CH ₂) ₄ Me					175-177
23-15	-NHCOCMe ₃					219-220
23-16	-NHCO-				HCl	268-270
23-17	-NHCO-				HCl	243-246

Table 9



Reference Example Compound	R _a	R _b	R _c	additives	m.p. / °C
23-18	-NHCO-		MeO-	HCl	237-239
23-19	-NHCO-		MeO-	HCl	220-223
23-20	-NHCOCH ₂ -		MeO-		184-185
23-21	-NHCO(CH ₂) ₂ -		MeO-		214-216
23-22	-NHCO(CH ₂) ₂ Me		MeO-		197-198
23-23	-NHCO(CH ₂) ₃ Me		MeO-		188-190
23-24	-NHCO(CH ₂) ₄ Me		MeO-		167-169
23-25	-NHCOCMe ₃		MeO-		245-246
23-26	-NHCO-				237-238
23-27	-NHCO-				240
23-28	-NHCO-				240
23-29	-NHCOCH ₂ -				233-234
23-30	-NHCO(CH ₂) ₂ -				214-216
23-31	-NHCOCMe ₃				206-208
23-32	-NHCO-				247
23-33	-NHCO(CH ₂) ₂ Me				212-214
23-34	-NHCO(CH ₂) ₃ Me				232-234
23-35	-NHCO(CH ₂) ₄ Me				245-246

Table 10







































Reference Example Compound	R _a	R _b	R _c	m.p. / °C
23-36	-NHCO- 			219-220
23-37	-NHCOCH ₂ Me		MeO- 	254-256
23-38	-NHCO- 		MeO- 	255-257
23-39	-NH ₂		Cl- 	278-280
23-40	-NHCOMe		Cl- 	266-268
23-41	-NHCOCH ₂ Me		Cl- 	241-242
23-42	-NH ₂		Me- 	286-288
23-43	-NHCOMe		Me- 	260-261
23-44	-NHCOCH ₂ Me		Me- 	226-227
23-45	-NHCOMe		Cl- 	217-219
23-46	-NHCOCH ₂ Me		Cl- 	228-229
23-47	-NHCOMe		Me- 	235-236
23-48	-NHCOCH ₂ Me		Me- 	239-241
23-49	-NHCOMe		Cl- 	290-293
23-50	-NHCOCH ₂ Me		Cl- 	289-290
23-51	-NHCOMe		Me- 	287-289

Table 11




Reference Example Compound	R _a	R _b	R _c	m.p. / °C
23-52	-NHCOCH ₂ Me			258-260
23-53	-NHCOMe			317-320
23-54	-NHCOCH ₂ Me			257-259
23-55	-NHCOMe			308-309
23-56	-NHCOCH ₂ Me			249-250
23-57	-NH ₂			228-230
23-58	-NH ₂			231-232
23-59	-NH ₂			258-258
23-60	-NH ₂			255-258
23-61	-NH ₂			>300
23-62	-NH ₂			296-298
23-63	-N=C(Me)NMe ₂			129-131
23-64	-NHCOMe			282-284
23-65	-NHCOMe			236-239
23-66	-NHCOCH ₂ Me			222-224
23-67	-NHCO-			236-239

Table 12




Reference Example Compound	R _a	R _b	R _c	m.p. / °C
23-68	-NHCOMe			234-236
23-69	-NHCOCH ₂ Me			237-239
23-70	-NHCO-			220-222
23-71	-NHCOMe			294-297
23-72	-NHCOCH ₂ Me			267-269
23-73	-N(CH ₂ Me)COMe			143-144
23-74	-N((CH ₂) ₄ Me)COMe			111-113
23-75	-N-CH ₂ - COMe			162-164
23-76	-NH ₂			206-209
23-77	-NH ₂			232-234
23-78	-NH ₂			236-239
23-79	-NH ₂			232-235
23-80	-NH-			287-289
23-81	-NHCO-			330-333
23-82	-NHCO-			292-294

Table 13



Reference Compound	Example	R _a	R _b	R _c	m.p. / °C
23-83		-NHCO-		MeO-	346-348
23-84		-NHCO-		MeO-	308-310
23-85		-NH ₂		HO-	323-326
23-86		-NHCOMe			259-261
23-87		-NHCOMe			292-293
23-88				MeO-	161-163
23-89		-NH ₂			235-237
23-90		-NHCOMe		MeCOO-	254-257
23-91		-NHCOCH ₂ -		MeO-	274-277
23-92		-NHCOMe			237-239
23-93		-NHCOMe		HO-	285-287
23-94		-NH ₂			235-238
23-95		-NHCOMe			272-274
23-96		-NH ₂			213-215
23-97		-NHCOMe			259-261
23-98		-NHCO(CH ₂) ₄ Cl		MeO-	228-229

Table 14









































Reference Example Compound	R_a	R_b	R_c	m.p. / °C
23-99	-NHCOMe			254-257
23-100				159-160
23-101	-NHCO- 			278-281
23-102	-NHCO- 			295-297
23-103	-NHCO- 			262-264
23-104	-NHCO- 			268-269
23-105	-NHCOCHMe ₂			227-230
23-106	-NHCOCHMe ₃			254-256
23-107	-NHCOCH ₂ CHMe ₂			261-262
23-108	-NHCONH(CH ₂) ₂ Me			215-219
23-109	-NH ₂			285-288
23-110	-NHCOMe			294-295
23-111	-NHCOMe			206-209
23-112	-NHCOMe			201-203
23-113	-NHCOMe			210-212
23-114	-NHCO(CH ₂) ₃ Cl			191-194

Table 15




































Reference Example Compound	R_a	R_b	R_c	m.p. / °C
23-115				133-135
23-116	$-\text{NHCO}(\text{CH}_2)_5\text{Cl}$			223-225
23-117				351-352
23-118	$-\text{NHCOMe}$			265-267
23-119	$-\text{NHCOMe}$			248-250
23-120	$-\text{NHCOMe}$			295-297
23-121	$-\text{NHCO}(\text{CH}_2)_2\text{COOCH}_2\text{Me}$			261-264
23-122	$-\text{NHCO}(\text{CH}_2)_2\text{COOH}$			334-336
23-123	$-\text{NH}_2$			267-269
23-124	$-\text{NH}_2$			218-219
23-125	$-\text{NH}_2$			248-250
23-126	$-\text{NH}_2$			273-275
23-127	$-\text{NHCOMe}$			295-296
23-128	$-\text{NHCOMe}$			284-286
23-129	$-\text{NHCOMe}$			289-291

Table 16








































Reference Compound	Example	R_a	R_b	R_c	additives	m.p./°C
23-130	-NHCOCHMe ₂					284-285
23-131	-NHCOCMe ₃					293-295
23-132	-NHCONH(CH ₂) ₂ Me					287-288
23-133	-NH ₂					242-244
23-134	-NH ₂					309-311
23-135	-CH ₂ COOCH ₂ Me				HCl	150-152
23-136	-CH ₂ NHCO- 					150-151
23-137	-NHCOMe					280-281
23-138	-NHCOCHMe ₂					303-304
23-139	-NHCOCMe ₃					317-319
23-140	-NHCOMe					342-345
23-141	-NHCOCHMe ₂					297-298
23-142	-NHCOCMe ₃					313-315
23-143	-NH ₂					254-257
23-144	-NH ₂					261-264
23-145	-CH ₂ COOH					135-137
23-146	-CH ₂ CONHMe					129-130

Table 17



Reference Compound	Example R_a	R_b	R_c	m.p. / °C
23-147	-Me			132-133
23-148	-NHCOMe			256-258
23-149	-NHCOCHMe ₂			269-272
23-150	-NHCO-			240-242
23-151	-NHCOMe			259-261
23-152	-NHCOMe			237-239
23-153	-NHCOMe			298-298
23-154	-NHCOCHMe ₂			285-286
23-155	-NHCOCF ₃			260-262
23-156	-NHCONHCH ₂ Me			224-226
23-157	-NHCONHCH ₂ Me			181-183
23-158	-NH ₂			240-242
23-159	-NH ₂			204-206
23-160	-NH ₂			178-179
23-161	-NH ₂			262-264
23-162	-COOH			141-143
23-163	-NHCOCH ₂ Me			295-297
23-164	-NHCO-			292-294
23-165	-NHCO-			326-328

Table 18

















































Reference Compound	Example	R_a	R_b	R_c	m.p. / °C
23-166	-NHCO-				328-329
23-167	-NHCOCH ₂ -				277-279
23-168	-NHCO-				309-311
23-169	-NHCONHCH ₂ Me				289-292
23-170	-NHCONH(CH ₂) ₂ Me				212-214
23-171	-NHCOCH ₂ OMe				248-249
23-172	-NHCOMe				228-230
23-173	-NHCOCH ₂ Me				244-246
23-174	-NHCOCHMe ₂				228-229
23-175	-NHCOCH ₂ -				204-206
23-176	-NHCO-				218-218
23-177	-NHCO-				218-220
23-178	-NHCO-				251-253
23-179	-NHCO-				271-273
23-180	-NHCONHCH ₂ Me				302-305
23-181	-NHCONH(CH ₂) ₂ Me				190-192
23-182	-NH ₂				239-241
23-183	-NH ₂				304-306

Table 19



Reference Compound	Example	R _a	R _b	R _c	m.p. / °C
23-184	-NHCOMe				328-330
23-185	-NHCOCH ₂ Me				284-286
23-186	-NHCOCHMe ₂				274-275
23-187	-NHCOCH ₂ -				295-296
23-188	-NHCO-				254-255
23-189	-NHCO-				272-273
23-190	-NHCO-				262-264
23-191	-NHCO-				263-264
23-192	-NHCONHCH ₂ Me				206-207
23-193	-NHCONH(CH ₂) ₂ Me				208-210
23-194	-NHCOCH ₂ Me				291-293
23-195	-NHCOCHMe ₂				270-272
23-196	-NHCOCH ₂ -				226-229
23-197	-NHCO-				285-286
23-198	-NHCO-				275-278

Table 20




























Reference Compound	Example	R_a	R_b	R_c	m.p./°C
23-199	-NHCO-				267-270
23-200	-NHCO-				302-304
23-201	-NHCONHCH ₂ Me				202-203
23-202	-NHCONH(CH ₂) ₂ Me				128-130
23-203	-NHCOCH ₂ OMe				220-222
23-204	-NH ₂				237-240
23-205	-NHCOMe				288-289
23-206	-NHCOCH ₂ Me				292-293
23-207	-NHCOCHMe ₂				253-254
23-208	-NHCOCH ₂ -				235-238

Table 21



Reference Compound	Example R_a	R_b	R_c	additives	m.p./ $^{\circ}\text{C}$
23-209					300-301
23-210					277-278
23-211					278-280
23-212	$-\text{NHCONHCH}_2\text{Me}$				220-224
23-213	$-\text{NHCONH}(\text{CH}_2)_2\text{Me}$				204-206
23-214	$-\text{COOCH}_2\text{Me}$				149-150
23-215	$-\text{NHCOCH}_2\text{NMe}_2$				230-231
23-216	$-\text{NH}_2$				167-169
23-217	$-\text{NHCOMe}$				195-197
23-218	$-\text{NHCOMe}$				266-270
23-219	$-\text{NH}_2$				181-185
23-220	$-\text{NHCOMe}$				239-244
23-221	$-\text{NHCOMe}$			HCl	237-242
23-222					248-250

Table 22
































Reference Compound	Example R_a	R_b	R_c	additives	m.p. / °C
23-223	-NHCOCH ₂ OH				243-245
23-224	-NHCOMe				371-373
23-225	-NHCOMe				350-351
23-226	-NOCH ₂ -C(=O)Me 				156-157
23-227	-NHOCH ₂ - 				171-172
23-228	-NHCO- 				276-278
23-229	-NHCO- 				276-277
23-230	-NHCO- 				250-251
23-231	-NHCO- 				241-242
23-232	-NMeCOMe			HCl	219-222
23-233	-NHMe				226-227

Table 23



































Reference Example Compound	R _a	R _b	R _c	additives	m.p./ °C
23-234	-NMeCOMe				171-174
23-235	-NMeCOMe			HCl	189-193
23-236	-NMeCO- 				210-214
23-237	-NMeCO- 			HCl	210-214
23-238	-NMeCO- 				212-214
23-239	-NMeCO- 			2HCl	206-210
23-240	-NHCO- 			HCl	285-287
23-241	-NHCO- 			2HCl	264-269
23-242	-NHCH ₂ Me				179-182
23-243	-NHCO- 			2HCl	327-329
23-244	-NHCO- 				293-295

Table 24



Reference Example Compound	R _a	R _b	R _c	additives	m.p. / °C
23-245	-NHCO-		Me ₃ C-		245-247
23-246	-NHCO-		Me-		269-270
23-247	-NHCO-		Me ₃ C-		171-173
23-248	-NMeCO-		MeO-		141-142
23-249	-NMeCO-		MeO-	HCl	194-196
23-250	-NMeCO-		MeO-		144-145
23-251	-NMeCO-		MeO-	2HCl	175-178
23-252	-NCOMe CH ₂ Me		MeO-	HCl	184-187
23-253	-NCO- CH ₂ Me		MeO-		128-130
23-254	-NCO- CH ₂ Me		MeO-	HCl	149-151
23-255	-NCO- CH ₂ Me		MeO-		144-145
23-256	-NCO- CH ₂ Me		MeO-	2HCl	151-154
23-257	-NMeCOMe		Me ₃ C-		186-188

Table 25



5

10

15

20

25

30

35

40


45

50

55

Reference Example Compound	R _a	R _b	R _c	additives	m.p./°C
23-258	-NMeCOMe			HCl	189-191
23-259	-NMeCO-				204-206
23-260	-NMeCO-			HCl	202-203
23-261	-NMeCO-				136-138
23-262	-NMeCO-			2HCl	169-171
23-263	-NCOMe CH ₂ Me				182-183
23-264	-NCOMe CH ₂ Me			HCl	184-185
23-265	-NCO- CH ₂ Me				222-224
23-266	-NCO- CH ₂ Me			HCl	219-222
23-267	-NCO- CH ₂ Me				159-160
23-268	-NCO- CH ₂ Me			2HCl	159-191
23-269	-NHCH ₂ Me				175-178
23-270	-NHMe				286-289
23-271	-NHCH ₂ Me				223-225

Table 26




































Reference Example Compound	R _a	R _b	R _c	additives	m.p. / °C
23-272	-NCOMe CH ₂ Me				159-161
23-273	-NCOMe CH ₂ Me			HCl	179-184
23-274	-NCO-  CH ₂ Me				178-182
23-275	-NCO-  CH ₂ Me				174-178
23-276	-NH(CH ₂) ₂ Me				177-180
23-277	-NCOMe (CH ₂) ₂ Me				130-132
23-278	-NCO-  (CH ₂) ₂ Me				138-140
23-279	-NCO-  (CH ₂) ₂ Me				130-131
23-280	-NH(CH ₂) ₃ Me				165-168
23-281	-NHCH ₂ - 				186-188
23-282	-NCH ₂ -  COMe				193-195
23-283	-NH- 				230-234

Table 27




Reference Compound	Example R _a	R _b	R _c	m.p. / °C
23-284				183-187
23-285				137-138
23-286				144-146
23-287				131-132
23-288				122-124
23-289				142-144
23-290				141-142
23-291				161-163
23-292				188-191
23-293				131-132
23-294				332-334

Table 28



Reference Example Compound	R _a	R _b	R _c	m.p. / °C
23-295	-NCOCH=CH ₂		MeO-	236-238
23-296	-NHCONH-		MeO-	217-219
23-297	-NHCONH-		Me ₃ C-	296-298
23-298	-NHCO--CO ₂ Me		MeO-	304-308
23-299	-NHCO--CO ₂ H		MeO-	332-335
23-300	--SMe		MeO-	127-128
23-301	--SMe		Me ₃ C-	125-126
23-302	--SMe			142-144
23-303	--SOMe		MeO-	169-170
23-304	--SOMe		Me ₃ C-	184-185
23-305	--SOMe			199-201
23-306	--SO ₂ Me		MeO-	211-212
23-307	--SO ₂ Me		Me ₃ C-	215-217
23-308	--SO ₂ Me			205-207
23-309	--SMe		F-	115-118
23-310	--SMe		Cl-	147-149
23-311	--SOMe		F-	186-188
23-312	--SOMe		Cl-	187-189

Table 29



5

10

15

20

25

30

35

40


45

50

55

Reference Example Compound	R _a	R _b	R _c	additives	m.p. / °C
23-313					191-194
23-314					202-204
23-315					167-169
23-316				HCl	267-269
23-317					227-229
23-318					185-187
23-319					247-250
23-320					179-183
23-321				HCl	232-236
23-322					234-235
23-323					233-234
23-324					175-176
23-325					221-222

Table 30.
























































Reference Compound	Example	R_a	R_b	R_c	m.p. / °C
23-326					159-161
23-327					161-164
23-328					194-196
23-329					228-230
23-330					261-263
23-331					386-389
23-332					300-303
23-333					393-395
23-334					123-125
23-335					161-163
23-336					161-162
23-337					347-349
23-338					166-167

Table 31



5

10

15

20

25

30

35

40

45

50

55

Reference Example Compound	R _a	R _b	R _c	m.p. / °C
23-339				146-147
23-340				142-143
23-341				253-256
23-342				350-353
23-343				257-261
23-344				276-279
23-345				303-304
23-346				149-150
23-347				175-177
23-348				272-274
23-349				341-343

EP 1 205 478 A1

Reference Example 23-128

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide

- 5 [0348] To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.50 g, 1.78 mmol) and 4-dimethylaminopyridine (0.06 g, 0.51 mmol) in N,N-dimethylacetamide (5 mL) was added acetyl chloride (0.21 g, 2.67 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate. The precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.17 g, yield 29%).
10 melting point: 284-286°C.

Reference Example 23-133

[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine

- 15 [0349] To a solution of 2-bromo-1-(3,5-dimethylphenyl)-2-(4-pyridyl)ethanone hydrobromide (5.0 g, 13 mmol) and thiourea (1.0 g, 14 mmol) in acetonitrile (60 mL) was added dropwise triethylamine (1.9 mL, 14 mmol) and the mixture was stirred at room temperature for 3 h. The solvent was concentrated under reduced pressure and a saturated aqueous sodium hydrogencarbonate solution was added to the residue. The mixture was extracted with ethyl acetate. The
20 organic layer was washed with water and the solvent was evaporated. The obtained crude crystals were recrystallized from ethyl acetate to give the title compound (2.0 g, 7.2 mmol, yield 55%).
melting point: 242-244°C.

Reference Example 23-137

- 25 N-[4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide

- [0350] To a solution of [4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.40 g, 1.29 mmol) and 4-dimethylaminopyridine (0.05 g, 0.39 mmol) in N,N-dimethylacetamide (4 mL) was added acetyl chloride (0.15 g, 1.94
30 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. Crude crystals were recrystallized from ethanol to give the title compound (0.23 g, yield 50%).
melting point: 280-281°C.

Reference Example 23-143

[4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]amine

- [0351] To a solution of 2-bromo-1-[4-(1,1-dimethylethyl)phenyl]-2-(4-pyridyl)ethanone hydrobromide (5.0 g, 12
40 mmol) and thiourea (0.95 g, 13 mmol) in acetonitrile (60 mL) was added dropwise triethylamine (1.8 mL, 13 mmol) and the mixture was refluxed for 3 h. The solvent was evaporated under reduced pressure and saturated aqueous sodium hydrogencarbonate solution was added to the residue. The precipitated solid was collected by filtration. The obtained crude crystal was recrystallized from ethanol to give the title compound (2.6 g, 8.4 mmol, yield 69%).
melting point: 254-257°C.

45

Reference Example 23-164

N-[4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]benzamide

- 50 [0352] To a solution of [4-[4-(1,1-Dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.50 g, 1.62 mmol) and 4-dimethylaminopyridine (0.05 g, 0.39 mmol) in N,N-dimethylacetamide (5 mL) was added benzoyl chloride (0.15 g, 1.94 mmol), and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured an aqueous sodium hydrogencarbonate and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.44 g, yield 66%).
55 melting point: 292-294°C.

EP 1 205 478 A1

Reference Example 23-165

N-[4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]nicotinamide

- 5 **[0353]** To a solution of [4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.50 g, 1.62 mmol) and 4-dimethylaminopyridine (0.06 g, 0.49 mmol) in N,N-dimethylacetamide (5 mL) was added nicotinoyl chloride hydrochloride (0.43 g, 2.42 mmol) and the mixture was stirred at 70°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.49 g, yield 73%).
10 melting point: 326-328°C.

Reference Example 23-168

- 15 N-[4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]cyclopentanecarboxamide

- [0354]** To a solution of [4-[4-(1,1-dimethylethyl)phenyl]-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.50 g, 1.62 mmol) and 4-dimethylaminopyridine (0.06 g, 0.49 mmol) in N,N-dimethylacetamide (5 mL) was added cyclopentanecarbonyl chloride (0.32 g, 2.42 mmol) and the mixture was stirred at 70°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.43 g, yield 66%).
20 melting point: 309-311°C.

- 25 Reference Example 23-194

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide

- 30 **[0355]** To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) and 4-dimethylaminopyridine (0.06 g, 0.52 mmol) in N,N-dimethylacetamide (20 mL) was added propionyl chloride (0.18 g, 1.96 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.41 g, yield 67%).
35 melting point: 291-293°C.

Reference Example 23-195

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-2-methylpropionamide

- 40 **[0356]** To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.50 g, 1.8 mmol) and 4-dimethylaminopyridine (0.06 g, 0.53 mmol) in N,N-dimethylacetamide (20 mL) was added 2-methylpropionyl chloride (0.20 g, 1.91 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.52 g, yield 83%).
45 melting point: 270-272°C.

Reference Example 23-196

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-2-phenylacetamide

- 50 **[0357]** To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) and 4-dimethylaminopyridine (0.06 g, 0.52 mmol) in N,N-dimethylacetamide (15 mL) was added 2-phenylacetyl chloride (0.32 g, 2.0 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.33 g, yield 46%).
55 melting point: 226-229°C.

EP 1 205 478 A1

Reference Example 23-197

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]benzamide

- 5 [0358] To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) and 4-dimethylaminopyridine (0.06 g, 0.52 mmol) in N,N-dimethylacetamide (20 mL) was added benzoyl chloride (0.30 g, 2.15 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.18 g, yield 26%).
10 melting point: 285-286°C.

Reference Example 23-198

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]cyclopentanecarboxamide

- 15 [0359] To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) and 4-dimethylaminopyridine (0.07 g, 0.56 mmol) in N,N-dimethylacetamide (10 mL) was added cyclopentanecarbonyl chloride (0.33 g, 2.47 mmol) and the mixture was stirred at 70°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with
20 water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.41 g, yield 59%).
melting point: 275-278°C.

Reference Example 23-199

- 25 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]nicotinamide

- [0360] To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.52 g, 1.9 mmol) and 4-dimethylaminopyridine (0.07 g, 0.56 mmol) in N,N-dimethylacetamide (10 mL) was added nicotinoyl chloride hydrochloride (0.51 g, 2.86 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium
30 hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.44 g, yield 61%).
melting point: 267-270°C.

Reference Example 23-200

- 35 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]isonicotinamide

- [0361] To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) and 4-dimethylaminopyridine (0.07 g, 0.56 mmol) in N,N-dimethylacetamide (10 mL) was added isonicotinoyl chloride hydrochloride
40 (0.48 g, 2.72 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.22 g, yield 32%).
melting point: 302-304°C.

- 45 Reference Example 23-201

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-ethylurea

- [0362] To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) in N,N-dimethylacetamide (10 mL) was added ethyl isocyanate (0.20 g, 2.8 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected
50 by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.27 g, yield 42%).
melting point: 202-203°C.

55

EP 1 205 478 A1

Reference Example 23-202

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-propylurea

- 5 **[0363]** To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.51 g, 1.8 mmol) in N,N-dimethylacetamide (15 mL) was added propyl isocyanate (0.23 g, 2.67 mmol) and the mixture was stirred at 80°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.23 g, yield 33%).
10 melting point: 128-130°C.

Reference Example 23-246

N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]pyrazinecarboxamide

- 15 **[0364]** To a solution of [4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (0.50 g, 1.8 mmol) and 4-dimethylaminopyridine (0.06 g, 0.53 mmol) in N,N-dimethylacetamide (5 mL) was added pyrazinecarbonyl chloride (0.44 g, 2.7 mmol) and the mixture was stirred at 70°C for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water
20 and dried. The crude crystals were recrystallized from ethanol to give the title compound (0.41 g, yield 59%).
melting point: 269-270°C.

Reference Example 24

- 25 1-bromo-3-ethylbenzene

- [0365]** To a 50% aqueous sulfuric acid solution (43.6 g) of 3-ethylaniline (10.0 g, 82.5 mmol) was added dropwise at 0°C an aqueous solution (16.5 mL) of sodium nitrite (6.83 g, 99.0 mmol) over 30 min. The obtained reaction mixture was stirred at 0°C for 45 min. This diazonium salt solution was added by small portions to a 48% hydrobromic acid solution (82.5 mL) of copper(I) bromide (12.4 g, 86.6 mmol) being gently refluxed under heating. After the addition, the
30 reaction mixture was refluxed under heating for 30 min. The reaction mixture was cooled to room temperature and extracted with ether. The extract was washed successively with 1N aqueous sodium hydroxide solution and saturated brine, filtrated, dried and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate = 20:1) to give the title compound (6.13 g, yield 40%).
35 oil.
¹H-NMR (CDCl₃) δ: 1.23 (3H, t, J = 7.5 Hz), 2.63 (2H, q, J = 7.5 Hz), 7.11-7.20 (2H, m), 7.28-7.38 (2H, m).

Reference Example 25

- 40 **[0366]** In accordance with Reference Example 24, the following Reference Example compound 25 was synthesized using 3-(1-methylethyl)aniline instead of 3-ethylaniline.

Reference Example compound 25: 1-bromo-3-(1-methylethyl)benzene oil.

- 45 **[0367]** ¹H-NMR (CDCl₃) δ: 1.24 (6H, d, J = 7.0 Hz), 2.77-2.99 (1H, m), 7.03-7.16 (2H, m), 7.27-7.34 (1H, m), 7.37 (1H, s).

Reference Example 26

- 50 3-ethylbenzoic acid

- [0368]** A solution (45 mL) of 1-bromo-3-ethylbenzene (5.1 g, 28 mmol) in tetrahydrofuran was added dropwise to a mixture (5.0 mL) of magnesium turnings (0.74 g, 31 mmol) and tetrahydrofuran under an argon atmosphere, and the mixture was stirred as it was for 30 min. The reaction mixture was added to the crushed dry ice and the mixture was
55 stirred as it was for 1 h. 1N Hydrochloric acid was added to the reaction mixture and the mixture was extracted with ethyl acetate. The extract was dried, filtrated and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate = 5:1) to give the title compound (3.87 g, yield 93%). oil.
¹H-NMR (CDCl₃) δ: 1.28 (3H, t, J = 7.5 Hz), 2.73 (2H, q, J = 7.5 Hz), 7.34-7.50 (2H, m), 7.92-7.98 (2H, m).

EP 1 205 478 A1

Reference Example 27

[0369] In accordance with Reference Example 26, the following Reference Example compounds 27-1 and 27-2 were synthesized using 1-bromo-3-(1-methylethyl)benzene or 1-bromo-4-fluoro-3-methylbenzene instead of 1-bromo-3-ethylbenzene.

Reference Example compound 27-1: 3-(1-methylethyl)benzoic acid oil.

[0370] $^1\text{H-NMR}$ (CDCl_3) δ : 1.29 (6H, d, $J=7.0$ Hz), 2.98-3.06 (1H, m), 7.38-7.54 (2H, m), 7.90-8.02 (2H, m).

Reference Example compound 27-2: 4-fluoro-3-methylbenzoic acid

[0371] melting point: 165-167°C.

Reference Example 28

3-ethylbenzoyl chloride

[0372] 3-Ethylbenzoic acid (9.40 g, 62.6 mmol) was added slowly to thionyl chloride (45 mL) at 0°C, and N,N-dimethylformamide (3 drops) was added dropwise. The obtained reaction mixture was refluxed under heating as it was for 2 h. The reaction mixture was concentrated and used without purification in the next reaction.

Reference Example 29

[0373] In accordance with Reference Example 28, the following Reference Example compounds 29-1 to 29-3 were synthesized using 3-(1-methylethyl)benzoic acid, 4-fluoro-3-methylbenzoic acid or 4-cyclohexylbenzoic acid instead of 3-ethylbenzoic acid.

Reference Example compound 29-1: 3-(1-methylethyl)benzoyl chloride

[0374] Used in the next reaction without purification.

Reference Example compound 29-2: 4-fluoro-3-methylbenzoyl chloride

[0375] Used in the next reaction without purification.

Reference Example compound 29-3: 4-cyclohexylbenzoyl chloride

[0376] Used in the next reaction without purification.

Reference Example 30

[0377] In accordance with Reference Example 14, the following Reference Example compounds 30-1 to 30-7 were synthesized respectively using 3-trifluoromethylbenzoyl chloride, 3,5-dichlorobenzoyl chloride, 3-ethylbenzoyl chloride, 3-(1-methylethyl)benzoyl chloride, 4-fluoro-3-methylbenzoyl chloride, 4-cyclohexylbenzoyl chloride and 3-fluorobenzoyl chloride instead of 4-chlorobenzoyl chloride.

Reference Example compound 30-1: N-(3-trifluoromethylbenzoyl)-propyleneimine oil.

[0378] $^1\text{H-NMR}$ (CDCl_3) δ : 1.42 (3H, d, $J=5.5$ Hz), 2.20 (1H, d, $J=3.3$ Hz), 2.56-2.67 (2H, m), 7.61 (1H, t, $J=7.7$ Hz), 7.81 (1H, d, $J=7.7$ Hz), 8.21 (1H, d, $J=7.7$ Hz), 8.30 (1H, s).

Reference Example compound 30-2: N-(3,5-dichlorobenzoyl)-propyleneimine oil.

[0379] $^1\text{H-NMR}$ (CDCl_3) δ : 1.40 (3H, d, $J=5.1$ Hz), 2.19 (1H, d, $J=3.3$ Hz), 2.57 (1H, t, $J=5.5$ Hz), 2.57-2.70 (1H, m), 7.54 (1H, t, $J=1.8$ Hz), 7.88 (2H, d, $J=1.8$ Hz).

EP 1 205 478 A1

Reference Example compound 30-3: N-(3-ethylbenzoyl)-propyleneimine oil.

[0380] ¹H-NMR (CDCl₃) δ: 1.27 (3H, t, J= 7.5 Hz), 1.40 (3H, d, J= 5.5 Hz), 2.14 (1H, d, J= 2.9 Hz), 2.52-2.61 (2H, m), 2.71 (2H, q, J= 7.5 Hz), 7.32-7.41 (2H, m), 7.81-7.89 (2H, m).

Reference Example compound 30-4: N-[3-(1-methylethyl)benzoyl]-propyleneimine oil.

[0381] ¹H-NMR (CDCl₃) δ: 1.29 (6H, d, J= 7.0 Hz), 1.40 (3H, d, J= 5.9 Hz), 2.14 (1H, d, J= 3.7 Hz), 2.51-2.64 (2H, m), 2.87-3.10 (1H, m), 7.33-7.46 (2H, m), 7.84 (1H, dt, J= 7.0, 1.8 Hz), 7.91 (1H, s).

Reference Example compound 30-5: N-(4-fluoro-3-methylbenzoyl)-propyleneimine oil.

[0382] ¹H-NMR (CDCl₃) δ: 1.39 (3H, d, J= 5.4 Hz), 2.14 (1H, d, J= 3.4 Hz), 2.33 (s, 3H), 2.51-2.61 (2H, m), 7.06 (1H, t, J= 8.8 Hz), 7.81-7.90 (2H, m).

Reference Example compound 30-6: N-(4-cyclohexylbenzoyl)-propyleneimine oil.

[0383] ¹H-NMR (CDCl₃) δ: 1.22-1.54 (7H, m), 1.67-1.89 (6H, m), 2.12 (1H, d, J= 3.2 Hz), 2.52-2.60 (3H, m), 7.28 (2H, d, J= 8.3 Hz), 7.95 (2H, d, J= 8.3 Hz).

Reference Example compound 30-7: N-(3-fluorobenzoyl)-propyleneimine oil.

[0384] ¹H-NMR (CDCl₃) δ: 1.40 (3H, d, J= 5.5 Hz), 2.16 (1H, d, J= 3.3 Hz), 2.52-2.68 (2H, m), 7.25 (1H, ddd, J= 8.4, 2.6, 1.1 Hz), 7.43 (1H, ddd, J= 8.1, 7.7, 5.5 Hz), 7.69 (1H, ddd, J= 8.1, 2.6, 1.5 Hz), 7.81 (1H, ddd, J= 7.7, 1.5, 1.1 Hz).

Reference Example 31

[0385] In accordance with Reference Example 16, the following Reference Example compounds 31-1 to 31-7 were synthesized respectively using N-(3-trifluoromethylbenzoyl)propyleneimine, N-(3,5-dichlorobenzoyl)propyleneimine, N-(3-ethylbenzoyl)-propyleneimine, N-[3-(1-methylethyl)benzoyl]propyleneimine, N-(4-fluoro-3-methylbenzoyl)propyleneimine, N-(4-cyclohexylbenzoyl)propyleneimine and N-(3-fluorobenzoyl)-propyleneimine instead of N-(2-chlorobenzoyl)propyleneimine.

Reference Example compound 31-1: 2-(4-pyridyl)-1-(3-trifluoromethylphenyl)ethanone oil.

[0386] ¹H-NMR (CDCl₃) δ: 4.33 (2H, s), 7.21 (2H, d, J= 6.0 Hz), 7.65 (1H, dd, J= 8.4, 7.7 Hz), 7.87 (1H, d, J= 7.7 Hz), 8.18 (1H, d, J= 8.4 Hz), 8.26 (1H, s), 8.59 (2H, d, J= 6.0 Hz).

Reference Example compound 31-2: 1-(3,5-dichlorophenyl)-2-(4-pyridyl)ethanone

[0387] melting point: 163-164°C.

Reference Example compound 31-3: 1-(3-ethylphenyl)-2-(4-pyridyl)ethanone

[0388] melting point: 102-103°C.

Reference Example compound 31-4: 1-[3-(1-methylethyl)phenyl]-2-(4-pyridyl)ethanone

[0389] melting point: 50-52°C.

Reference Example compound 31-5: 1-(4-fluoro-3-methylphenyl)-2-(4-pyridyl)ethanone

[0390] melting point: 86-88°C.

Reference Example compound 31-6: 1-(4-cyclohexylphenyl)-2-(4-pyridyl)ethanone oil.

[0391] ¹H-NMR (CDCl₃) δ: 1.32-1.52 (5H, m), 1.77-1.89 (5H, m), 2.58 (1H, m), 4.26 (2H, s), 7.20 (2H, d, J= 6.3 Hz), 7.32 (2H, d, J= 8.4 Hz), 7.93 (2H, d, J= 8.4 Hz), 8.56 (2H, d, J= 6.3 Hz).

EP 1 205 478 A1

Reference Example compound 31-7: 1-(3-fluorophenyl)-2-(4-pyridyl)ethanone Amorphous powder.

[0392] ¹H-NMR (CDCl₃) δ: 4.28 (2H, s), 7.20 (2H, d, J= 6.2 Hz), 7.33 (1H, ddd, J= 8.1, 2.6, 1.1 Hz), 7.49 (1H, ddd, J= 8.1, 7.7, 5.5 Hz), 7.68 (1H, ddd, J= 9.5, 2.6, 1.5 Hz), 7.79 (1H, ddd, J= 7.7, 1.5, 1.1 Hz), 8.58 (2H, d, J= 6.2 Hz).

Reference Example 32

[0393] In accordance with Reference Example 17, the following Reference Example compounds 32-1 to 32-4 were synthesized using 2,4-lutidine or γ-collidine instead of γ-picoline.

Reference Example compound 32-1: 1-(3-methylphenyl)-2-(2-methyl-4-pyridyl)ethanone

[0394] melting point: 56-57°C.

Reference Example compound 32-2: 1-(3,5-dimethylphenyl)-2-(2-methyl-4-pyridyl)ethanone oil.

[0395] ¹H-NMR (CDCl₃) δ: 2.38 (6H, s), 2.54 (3H, s), 4.21 (2H, s), 6.98-7.10 (1H, m), 7.01 (1H, m), 7.06 (1H, s), 7.23 (1H, s), 7.60 (2H, s), 8.42-8.45 (1H, m).

Reference Example compound 32-3: 2-(2,6-dimethyl-4-pyridyl)-1-(3-methylphenyl)ethanone

[0396] melting point: 46-48°C.

Reference Example compound 32-4: 1-(3,5-dimethylphenyl)-2-(2,6-dimethyl-4-pyridyl)ethanone

[0397] melting point: 135-136°C.

Reference Example 33

2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone

[0398] A solution of 2-tert-butoxycarbonylamino-4-methylpyridine (20 g, 97 mmol) in anhydrous tetrahydrofuran (300 mL) was cooled to -78°C and 1.6 M n-butyllithium/hexane solution (140 mL, 0.23 mol) was added dropwise with stirring. After completion of the dropwise addition, the mixture was stirred at room temperature for 30 min and cooled to -78°C. A solution of N-(4-methoxybenzoyl)propyleneimine (25 g, 0.13 mol) in anhydrous tetrahydrofuran (50 mL) was added dropwise. After completion of the dropwise addition, the mixture was stirred at room temperature for 2 h. To the reaction mixture were added water (100 mL) and isopropyl ether (300 mL), and the obtained crude crystals were collected by filtration. The crude crystals were recrystallized from tetrahydrofuran-hexane to give the title compound (23 g, yield 69%).

melting point: 187-190°C.

Reference Example 34

[0399] In accordance with Reference Example 33, the following Reference Example compound 34-1 and 34-2 were synthesized respectively using N-(3-methylbenzoyl)propyleneimine and N-(3,5-dimethylbenzoyl)propyleneimine instead of N-(4-methoxybenzoyl)propyleneimine.

Reference Example compound 34-1: 2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(3-methylphenyl)ethanone

[0400] melting point: 144-146°C.

Reference Example compound 34-2: 2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(3,5-dimethylphenyl)ethanone

[0401] melting point: 133-136°C.

Reference Example 35

2-fluoro-4-methylpyridine

- 5 [0402] Synthesized in accordance with the method described in Journal of Medicinal Chemistry, vol. 33, pp. 1667-1675 (1990). boiling point: 82-86°C (10 kPa).

Reference Example 36

- 10 2-(2-fluoro-4-pyridyl)-1-(3-methylphenyl)ethanone

- [0403] A solution of diisopropylamine (44 mL, 0.31 mol) in anhydrous tetrahydrofuran (300 mL) was cooled to -78°C under an argon atmosphere, and 1.6 M n-butyllithium/hexane solution (190 mL, 0.31 mol) was added dropwise with stirring. After completion of the dropwise addition, the mixture was stirred for 10 min, and a solution of 2-fluoro-4-methylpyridine (34.5 g, 0.31 mol) in anhydrous tetrahydrofuran (30 mL) was added. The reaction mixture was stirred at -10°C for 30 min. The reaction solution was cooled to -78°C and a solution of N-(3-methylbenzoyl)propyleneimine (52 g, 0.30 mol) in anhydrous tetrahydrofuran (30 mL) was added dropwise. After completion of dropwise addition, the mixture was stirred at room temperature for 2 h. To the reaction mixture was added water (100 mL), and the mixture was extracted with ethyl acetate. The extract was washed with water, dried and the solvent was evaporated. The residue was recrystallized from isopropyl ether to give the title compound (35 g, yield 52%).
melting point: 66-67°C.

Reference Example 37

- 25 [0404] In accordance with Reference Example 36, the following Reference Example compound 37 was synthesized using N-(3-methoxybenzoyl)propyleneimine instead of N-(3-methylbenzoyl)propyleneimine.

Reference Example compound 37: 2-(2-fluoro-4-pyridyl)-1-(3-methoxyphenyl)ethanone oil

- 30 [0405] ¹H-NMR (CDCl₃) δ: 3.86 (3H, s), 4.31 (2H, s), 6.86 (1H, s), 7.03-7.19 (2H, m), 7.31-7.59 (3H, m), 8.18 (1H, d, J= 5.6 Hz). Reference Example 38
[0406] In accordance with Reference Example 21, the following Reference Example compounds 38-1 to 38-21 were synthesized respectively using 2-methylbenzonitrile, 3-methylbenzonitrile, 4-methylbenzonitrile, 2-chlorobenzonitrile, 3-chlorobenzonitrile, 4-chlorobenzonitrile, 3-methoxybenzonitrile, 4-methoxybenzonitrile, 2-fluorobenzonitrile, 3-fluorobenzonitrile, 4-fluorobenzonitrile, 4-nitrobenzonitrile, piperonylnitrile, 3-methoxycarbonylbenzonitrile, 4-methoxycarbonylbenzonitrile, butyronitrile, isobutyronitrile, valeronitrile, hexanenitrile, 3-phenylpropionitrile and 4-phenylbutyronitrile instead of 4-methylthiobenzonitrile.

Reference Example compound 38-1: 2-methyl(thiobenzamide) oil

- 40 [0407] ¹H-NMR (CDCl₃) δ: 2.37 (3H, s), 6.88 (1H, br s), 7.06-7.23 (3H, m), 7.24-7.31 (1H, m), 7.88 (1H, br s).

Reference Example compound 38-2: 3-methyl(thiobenzamide)

- 45 [0408] melting point: 88-89°C.

Reference Example compound 38-3: 4-methyl(thiobenzamide)

- [0409] melting point: 172-174°C.

50

Reference Example compound 38-4: 2-chlorothiobenzamide

- [0410] melting point: 58-59°C.

- 55 Reference Example compound 38-5: 3-chlorothiobenzamide

- [0411] melting point: 114-115°C.

EP 1 205 478 A1

Reference Example compound 38-6: 4-chlorothiobenzamide

[0412] melting point: 130-131°C.

5 Reference Example compound 38-7: 3-methoxythiobenzamide oil

[0413] ¹H-NMR (CDCl₃) δ: 3.86 (3H, s), 7.02-7.08 (1H, m), 7.31-7.36 (3H, m), 7.46-7.49 (1H, m), 7.76 (1H, br s).

Reference Example compound 38-8: 4-methoxythiobenzamide

10

[0414] melting point: 148-149°C.

Reference Example compound 38-9: 2-fluorothiobenzamide

15

[0415] melting point: 113-114°C.

Reference Example compound 38-10: 3-fluorothiobenzamide

[0416] melting point: 151-152°C.

20

Reference Example compound 38-11: 4-fluorothiobenzamide

[0417] melting point: 156-157°C.

25

Reference Example compound 38-12: 4-nitrothiobenzamide

[0418] melting point: 159-160°C.

Reference Example compound 38-13: thiopiperonylamide

30

[0419] melting point: 188-189°C.

Reference Example compound 38-14: 3-methoxycarbonyl-thiobenzamide

35

[0420] melting point: 140-141°C.

Reference Example compound 38-15: 4-methoxycarbonylthiobenzamide

[0421] melting point: 191-192°C.

40

Reference Example compound 38-16: thiobutylamide oil

[0422] ¹H-NMR (CDCl₃) δ: 0.99 (3H, t, J= 7.6 Hz), 1.72-1.93 (2H, m), 2.64 (2H, t, J= 7.6 Hz), 7.02 (1H, br s), 7.77 (1H, br s).

45

Reference Example compound 38-17: thioisobutylamide oil

[0423] ¹H-NMR (CDCl₃) δ: 1.28 (6H, d, J= 5.8 Hz), 2.79-2.96 (1H, m), 6.99 (1H, br s), 7.71 (1H, br s).

50

Reference Example compound 38-18: thiovaleramide oil

[0424] ¹H-NMR (CDCl₃) δ: 0.94 (3H, t, J= 7.3 Hz), 1.31-1.49 (2H, m), 1.68-1.83 (2H, m), 2.67 (2H, t, J= 7.7 Hz), 6.92 (1H, br s), 7.73 (1H, br s).

55

Reference Example compound 38-19: hexanethioamide oil

[0425] ¹H-NMR (CDCl₃) δ: 0.90 (3H, t, J= 6.9 Hz), 1.22-1.45 (4H, m), 1.70-1.84 (2H, m), 2.66 (2H, t, J= 7.5 Hz), 7.05 (1H, br s), 7.91 (1H, br s).

EP 1 205 478 A1

Reference Example compound 38-20: 3-phenyl(thiopropionamide)

[0426] melting point: 83-84°C.

5 Reference Example compound 38-21: 4-phenyl(thiobutylamide)

[0427] melting point: 60-61°C.

Reference Example 39

10

[0428] In accordance with Reference Example 6, the following Reference Example compounds 39-1 to 39-13 were synthesized respectively using 2-(4-pyridyl)-1-(3-trifluoromethylphenyl)-ethanone, 1-(3,5-dichlorophenyl)-2-(4-pyridyl) ethanone, 1-(3-ethylphenyl)-2-(4-pyridyl)ethanone, 1-[3-(1-methylethyl)-phenyl]-2-(4-pyridyl)ethanone, 1-(4-fluoro-3-methylphenyl)-2-(4-pyridyl)ethanone, 1-(4-cyclohexylphenyl)-2-(4-pyridyl)-ethanone, 1-(3-fluorophenyl)-2-(4-pyridyl)ethanone, 2-(2-fluoro-4-pyridyl)-1-(3-methylphenyl)ethanone, 2-(2-fluoro-4-pyridyl)-1-(3-methoxyphenyl)ethanone, 1-(3-methylphenyl)-2-(2-methyl-4-pyridyl)ethanone, 1-(3,5-dimethylphenyl)-2-(2-methyl-4-pyridyl)ethanone, 2-(2,6-dimethyl-4-pyridyl)-1-(3-methylphenyl)ethanone and 1-(3,5-dimethylphenyl)-2-(2,6-dimethyl-4-pyridyl)ethanone instead of 1-(4-methoxyphenyl)-2-(3-pyridyl)ethanone.

20 Reference Example compound 39-1: 2-bromo-2-(4-pyridyl)-1-(3-trifluoromethylphenyl)ethanone hydrobromide

[0429] Used in the next reaction without purification.

Reference Example compound 39-2: 2-bromo-1-(3,5-dichlorophenyl)-2-(4-pyridyl)ethanone hydrobromide

25

[0430] melting point: 253-254°C

Reference Example compound 39-3: 2-bromo-1-(3-ethylphenyl)-2-(4-pyridyl)ethanone hydrobromide

30

[0431] melting point: 146-148°C.

Reference Example compound 39-4: 2-bromo-1-[3-(1-methylethyl)phenyl]-2-(4-pyridyl)ethanone hydrobromide

35

[0432] melting point: 143-144°C.

Reference Example compound 39-5: 2-bromo-1-(4-fluoro-3-methylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0433] melting point: 211-214°C.

40

Reference Example compound 39-6: 2-bromo-1-(4-cyclohexylphenyl)-2-(4-pyridyl)ethanone hydrobromide

[0434] melting point: 189-191°C.

Reference Example compound 39-7: 2-bromo-1-(3-fluorophenyl)-2-(4-pyridyl)ethanone hydrobromide

45

[0435] melting point: 191-194°C.

Reference Example compound 39-8: 2-bromo-2-(2-fluoro-4-pyridyl)-1-(3-methylphenyl)ethanone hydrobromide

50

[0436] Used in the next reaction without purification.

Reference Example compound 39-9: 2-bromo-2-(2-fluoro-4-pyridyl)-1-(3-methoxyphenyl)ethanone hydrobromide

[0437] Used in the next reaction without purification.

55

Reference Example compound 39-10: 2-bromo-1-(3-methylphenyl)-2-(2-methyl-4-pyridyl)ethanone hydrobromide

[0438] melting point: 144-146°C.

EP 1 205 478 A1

Reference Example compound 39-11: 2-bromo-1-(3,5-dimethylphenyl)-2-(2-methyl-4-pyridyl)ethanone hydrobromide

[0439] Used in the next reaction without purification.

Reference Example compound 39-12: 2-bromo-2-(2,6-dimethyl-4-pyridyl)-1-(3-methylphenyl)ethanone hydrobromide

[0440] Used in the next reaction without purification.

Reference Example compound 39-13: 2-bromo-1-(3,5-dimethylphenyl)-2-(2,6-dimethyl-4-pyridyl)ethanone hydrobromide

[0441] melting point: 208-212°C.

Reference Example 40

2-bromo-2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone hydrobromide

[0442] To a solution of 2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone (0.36 g, 1.1 mmol) in acetic acid (5 mL) was added bromine (0.058 mL, 1.1 mmol) and the mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated and the residue was washed with isopropyl ether to give the title compound (0.44 g, yield 82%).

Amorphous powder

[0443] ¹H-NMR (CDCl₃) δ: 1.55 (6H, s), 3.92 (3H, s), 6.35 (1H, s), 6.99-7.03 (2H, m), 7.66 (1H, dd, J= 6.6, 1.8 Hz), 8.02-8.07 (2H, m), 8.20 (1H, d, J= 6.6 Hz), 8.70 (2H, d, J= 1.8 Hz), 11.02 (1H, br s).

Reference Example 41

[0444] In accordance with Reference Example 40, the following Reference Example compounds 41-1 and 41-2 were synthesized respectively using 2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(3-methylphenyl)ethanone and 2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(3,5-dimethylphenyl)ethanone instead of 2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone. Reference Example compound 41-1: 2-bromo-2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(3-methylphenyl)ethanone hydrobromide

Used in the next reaction without purification.

Reference Example compound 41-2: 2-bromo-2-(2-tert-butoxycarbonylamino-4-pyridyl)-1-(3,5-dimethylphenyl)ethanone hydrobromide

[0445] Used in the next reaction without purification.

Reference Example 42

ethyl (4-phenyl-1-piperazinyl)carbothioylcarbamate

[0446] 1-Phenylpiperazine (10 g, 62 mmol) was added to a solution of ethyl isothiocyanatoformate (8.1 g, 62 mmol) in acetone (30 mL) and the mixture was refluxed under heating for 1 h. The reaction mixture was concentrated and the crude crystals were recrystallized from ethyl acetate to give the title compound (13 g, yield 73%). melting point: 134-135°C.

Reference Example 43

4-phenyl-1-piperazinecarbothioamide

[0447] Ethyl (4-phenyl-1-piperazinyl)carbothioylcarbamate (13 g, 44 mmol) was added to conc. hydrochloric acid (44 mL) and the mixture was stirred at 80°C for 2 h. The reaction mixture was made basic with 8N aqueous sodium hydroxide solution and the crystals were collected by filtration. The crystals were washed with water and dried to give the title compound (6.1 g, yield 63%).

EP 1 205 478 A1

melting point: 178-179°C.

Reference Example 44

- 5 **[0448]** In accordance with the methods described in Reference Examples 8 to 12, Reference Example 44-1, JP-A-61-10580 and USP 4,612,321, Reference Example compounds 44-1 to 44-129 shown in the following Tables 32-42 were synthesized.

10

15

20

25

30

35


40

45

50

55

Table 32



5

10

15

20

25

30

35

40


45

50

55


Reference Compound	Example	R _a	R _b	R _c	m.p. / °C
44-1					135-137
44-2	-NH ₂				267-269
44-3					246-248
44-4	-Me				74-75
44-5					110-111
44-6					107-108
44-7					101-102
44-8					188-189
44-9	-NH ₂				229-230
44-10	-NHCOMe				247-249
44-11					208-210
44-12					279-281
44-13					351-353
44-14					92-93

Table 33




Reference Example Compound	R _a	R _b	R _c	m.p. / °C
44-15				153-154
44-16				172-173
44-17				221-222
44-18				259-282
44-19	-NHMe			199-202
44-20	-NHCH ₂ Me			190-191
44-21	-NMeCOMe			189-170
44-22	-NMeCONH-			190-191
44-23	-NMeCO-			134-135
44-24	-CH ₂ Me			56-58
44-25				152-153
44-26				171-174
44-27	-NHCOMe			307-308
44-28	-NH ₂			263-264

Table 34




Reference Example Compound	R _a	R _b	R _c	m.p. / °C
44-29	-NHCOMe			326-328
44-30	-NHCONH-			227-228
44-31	-			117-119
44-32	-			144-145
44-33	-NH ₂			232-234
44-34	-			188-189
44-35	-			316-318
44-36	-			165-166
44-37	-NHCOMe			304-306
44-38	-NHCONH-			210-213
44-39	-NHCONH-			223-224
44-40	-NHCONH-			206-207
44-41	-NHCONH-			205-206
44-42	-NHCONH-			227-229

Table 35



Reference Example Compound	R_a	R_b	R_c	m.p. / °C
44-43				190-193
44-44				220-221
44-45				208-210
44-46				335-336
44-47				103-104
44-48				143-145
44-49				oil
44-50				86-87
44-51				137-138
44-52				332-333
44-53				193-194
44-54				164-166
44-55				197-199

Table 36









































Reference Compound	Example	R _a	R _b	R _c	m.p. / °C
44-58	-NHCONH-				190-192
44-57	-NHCONH-				192-194
44-58	-				133-134
44-59	-				153-154
44-60	-NHCONH-				158-163
44-61	-NHCONH-				168-170
44-62	-NHCONH-				212-215
44-63	-NHCONH-				203-205
44-64	-				131-132
44-65	-				152-153
44-66	-				123-124
44-67	-				142-144

Table 37



Reference Example Compound	R _a	R _b	R _c	m.p. / °C
44-68				137-139
44-69				209-210
44-70				111-112
44-71	$-(CH_2)_2Me$			74-75
44-72	$-CHMe_2$			104-105
44-73				120-121
44-74	$-(CH_2)_3$			oil
44-75	$-(CH_2)_2$			oil
44-76	$-(CH_2)_3Me$			oil
44-77	$-(CH_2)_4Me$			oil

Table 38






































Reference Example Compound	R_a	R_b	R_c	m.p. / °C
44-78				147-148
44-79				101-102
44-80				153-154
44-81	-NHCOMe			253-254
44-82				98-99
44-83	-NH ₂			201-202
44-84				189-192
44-85				217-220
44-86				107-109
44-87				162-164
44-88				332-334
44-89				288-290

Table 39









































Reference Example Compound	R _a	R _b	R _c	m.p. / °C
44-90				130-131
44-91				296-297
44-92				251-252
44-93				165-166
44-94				129-130
44-95				349-350
44-96				269-270
44-97				126-127
44-98				290-291
44-99				324-326
44-100				197-198
44-101				269-270

Table 40



Reference Example Compound	R_a	R_b	R_c	m.p. / °C
44-102				315-318
44-103				189-190
44-104				325-328
44-105				249-251
44-106				187-189
44-107				169-171
44-108				122-124
44-109				250-252
44-110				295-298
44-111				137-139
44-112				272-274
44-113				170-173
44-114				299-300

Table 42



Reference Example Compound	R_a	R_b	R_c	m.p. / °C
44-126				267-270
44-127				248-249
44-128				127-129
44-129				154-155

Reference Example 44-1

4-(4-fluorophenyl)-2-phenyl-5-(4-pyridyl)-1,3-thiazole

[0449] A solution of 2-bromo-1-(4-fluorophenyl)-2-(4-pyridyl)ethanone hydrobromide (1.6 g, 4.1 mmol) and thiobenzamide (0.57 g, 4.2 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 14 h. To the reaction mixture was poured aqueous sodium hydrogencarbonate solution and the precipitated solid was collected by filtration. The obtained solid was washed with water and dried. The crude crystals were recrystallized from ethyl acetate to give the title compound (0.27 g, yield 19%).
melting point: 135-137°C.

[0450] The proton nuclear magnetic resonance spectrum of the aforementioned Reference Example 44 is shown in the following Table 43.

Table 43

Reference Example Compound No.	Proton Nuclear Magnetic Resonance Spectrum
44-49	$^1\text{H-NMR}$ (CDCl_3) δ : 2.34 (3H, s), 2.70 (3H, s), 7.14-7.38 (8H, m), 7.46 (1H, s), 7.81 (1H, ddd, J = 6.6, 1.8, 1.1 Hz), 8.56 (2H, d, J = 6.0 Hz).
44-74	$^1\text{H-NMR}$ (CDCl_3) δ : 2.04-2.26 (8H, m), 2.79 (2H, t, J = 7.5 Hz), 3.08 (2H, t, J = 7.6 Hz), 6.97 (1H, s), 7.08 (2H, s), 7.17-7.35 (7H, m), 8.50 (2H, dd, J = 4.6, 1.8 Hz).
44-75	$^1\text{H-NMR}$ (CDCl_3) δ : 2.27 (6H, s), 3.13-3.23 (2H, m), 3.31-3.41 (2H, m), 6.98 (1H, s), 7.08 (2H, s), 7.19 (2H, dd, J = 4.5, 1.7 Hz), 7.24-7.37 (5H, m), 8.50 (2H, dd, J = 4.5, 1.7 Hz).
44-76	$^1\text{H-NMR}$ (CDCl_3) δ : 0.98 (3H, t, J = 7.3 Hz), 1.43-1.55 (2H, m), 1.76-1.88 (2H, m), 2.26 (6H, m), 3.05 (2H, t, J = 7.7 Hz), 6.97 (1H, s), 7.08 (2H, s), 7.21 (2H, dd, J = 4.6, 1.8 Hz), 8.50 (2H, dd, J = 4.6, 1.8 Hz).

EP 1 205 478 A1

Table 43 (continued)

Reference Example Compound No.	Proton Nuclear Magnetic Resonance Spectrum
44-77	¹ H-NMR (CDCl ₃) δ : 0.90-0.97 (3H, m), 1.38-1.49 (4H, m), 1.78-1.89 (2H, m), 2.26 (6H, s), 3.04 (2H, t, J= 7.9 Hz), 6.97 (1H, s), 7.08 (2H, s), 7.21 (2H, dd, J= 4.5, 1.8 Hz), 8.50 (2H, dd, J= 4.5, 1.8 Hz).
44-124	¹ H-NMR (CDCl ₃) δ : 2.27 (6H, s), 4.38 (2H, s), 6.99 (1H, s), 7.10 (2H, s), 7.16 (2H, dd, J= 4.9, 1.6 Hz), 7.34-7.41 (5H, m), 8.47 (2H, dd, J=4.9, 1.6 Hz).

Reference Example 45

[0451] In accordance with Reference Example 21, the following Reference Example compound 45 was synthesized using pivalonitrile instead of 4-methylthiobenzonitrile.


Reference Example compound 45: thiopivaloamide


















[0452] melting point: 117-119°C.

Reference Example 46

[0453] In accordance with the methods described in Reference Examples 8 to 12, Reference Example 44-1, JP-A-61-10580 and USP 4,612,321, Reference Example compounds 46-1 to 46-5 shown in the following Table 44 were synthesized.

Table 44



Reference Compound	Example	R_a	R_b	R_c	m.p. / °C
46-1	-CH ₂ Me				100-101
46-2	-CMe ₃				140-142
46-3					198-197
46-4	-NHCONHOMe				235-236
46-5	-NHCONHO- 				168-169
46-6	-NH ₂				380-381
46-7	-NHCO- 				220-222

Example 1

(1) Reference Example compound 23-313	10.0 mg
(2) lactose	60.0 mg
(3) cornstarch	35.0 mg
(4) gelatin	3.0 mg
(5) magnesium stearate	2.0 mg

[0454] A mixture of Reference Example compound 23-313 (10.0 mg), lactose (60.0 mg) and cornstarch (35.0 mg) is granulated using 10% aqueous gelatin solution (0.03 ml, 3.0 mg as gelatin) and passing through a 1 mm mesh sieve. The granules are dried at 40°C and passed through the sieve again. The granules thus obtained are mixed with magnesium stearate (2.0 mg) and compressed. The obtained core tablet is coated with sugar coating made of an aqueous suspension of sucrose, titanium dioxide, talc and gum arabic. The coated tablet is polished with bee wax to give a coated tablet.

Example 2

(1) Reference Example compound 23-313	10.0 mg
---------------------------------------	---------

EP 1 205 478 A1

(continued)

Example 2	
(2) lactose	70.0 mg
(3) cornstarch	50.0 mg
(4) soluble starch	7.0 mg
(5) magnesium stearate	3.0 mg

[0455] Reference Example compound 23-313 (10.0 mg) and magnesium stearate (3.0 mg) are granulated using an aqueous solution (0.07 ml) of soluble starch (7.0 mg as soluble starch), dried and mixed with lactose (70.0 mg) and cornstarch (50.0 mg). The mixture is compressed to give tablets.

Example 3	
(1) Reference Example compound 23-313	5.0 mg
(2) sodium chloride	20.0 mg
(3) distilled water to total	2 ml

[0456] Reference Example compound 23-313 (5.0 mg) and sodium chloride (20.0 mg) are dissolved in distilled water and water is added to make the total amount 2.0 ml. The solution is filtrated and aseptically filled in a 2 ml ampoule. The ampoule is sterilized and sealed to give a solution for injection.

Example 4	
(1) Reference Example compound 23-331	10.0 mg
(2) lactose	60.0 mg
(3) cornstarch	35.0 mg
(4) gelatin	3.0 mg
(5) magnesium stearate	2.0 mg

[0457] A mixture of Reference Example compound 23-331 (10.0 mg), lactose (60.0 mg) and cornstarch (35.0 mg) is granulated using 10% aqueous gelatin solution (0.03 ml, 3.0 mg as gelatin) and passing through a 1 mm mesh sieve. The granules are dried at 40°C and passed through the sieve again. The granules thus obtained are mixed with magnesium stearate (2.0 mg) and compressed. The obtained core tablet is coated with sugar coating made of an aqueous suspension of sucrose, titanium dioxide, talc and gum arabic. The coated tablet is polished with bee wax to give a coated tablet.

Example 5	
(1) Reference Example compound 23-331	10.0 mg
(2) lactose	70.0 mg
(3) cornstarch	50.0 mg
(4) soluble starch	7.0 mg
(5) magnesium stearate	3.0 mg

[0458] Reference Example compound 23-331 (10.0 mg) and magnesium stearate (3.0 mg) are granulated using an aqueous solution (0.07 ml) of soluble starch (7.0 mg as soluble starch), dried and mixed with lactose (70.0 mg) and cornstarch (50.0 mg). The mixture is compressed to give tablets.

Example 6	
(1) Reference Example compound 23-331	5.0 mg
(2) sodium chloride	20.0 mg
(3) distilled water to total	2 ml

[0459] Reference Example compound 23-331 (5.0 mg) and sodium chloride (20.0 mg) are dissolved in distilled water and water is added to make the total 2.0 ml. The solution is aseptically filtered and filled into a 2 ml ampoule. The

ampoule is sterilized and sealed to give a solution for injection.

Experimental Example 1:

[0460] The genetic manipulations described below were according to a method described in the book (Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, 1989) or methods described in the protocols attached to the reagents.

(1) Cloning of human p38 MAP kinase gene and preparation of recombinant baculovirus

[0461] Cloning of human p38 MAP kinase gene was performed by a PCR method using a primer set P38-U: 5'-ACCACTCGAGATGGACTACAAGGACGACGATGACAAGTCTCAGGAGAGGCCACGTTCTACC-3' [SEQ ID NO: 1] and PAG-L: 5'-ACCCGGTACCACCAGGTGCTCAGGACTCCATCTCT-3' [SEQ ID NO:2] made by the use of kidney cDNA (Toyobo, QUICK-Clone cDNA) as a template and referring to the base sequence of p38 MAP kinase gene reported by Han et al. (Science 265 (5173), 808-811 (1994)).

[0462] A PCR reaction was performed by a Hot Start method using AmpliWax PCR Gem 100 (Takara Shuzo). As the lower mixed solution, 2 μ L 10 \times LA PCR Buffer, 3 μ L 2.5 mM dNTP solution, each 2.5 μ L of 12.5 μ M primer solutions, and 10 μ L sterile distilled water were mixed. As the upper mixed solution, 1 μ L human cardiac cDNA (1 ng/mL) as a template, 3 μ L 10 \times LA PCR Buffer, 1 μ L 2.5 mM dNTP solution, 0.5 μ L TaKaRa LA Taq DNA polymerase (Takara Shuzo), and 24.5 μ L sterile distilled water were mixed. One AmpliWax PCR Gem 100 (Takara Shuzo) was added to the prepared lower mixed solution and the mixture was treated at 70°C for 5 min and for 5 min in an ice and, thereafter, the upper mixed solution was added to prepare a reaction solution for PCR. A tube containing the reaction solution was set at a thermal cycler (Perkin Elmer), which was treated at 95°C for 2 min. Further, after repeating 35 times a cycle of 15 seconds at 95°C and 2 minutes at 68°C, treatment was performed at 72°C for 8 minutes. The resulting PCR product was subjected to agarose gel (1%) electrophoresis, 1.1 kb DNA fragment containing p38 MAP kinase gene was recovered from the gel and, thereafter, which was inserted into pT7Blue-T vector (Takara Shuzo) to make the plasmid pHP38.

[0463] The 4.8 kb XhoI-KpnI fragment of the plasmid pFASTBAC1 (GIBCOBRL) and the 1.1 kb XhoI-Kpn fragment of the above plasmid pHP38 were ligated to make the plasmid pFBHP38.

[0464] The plasmid pFBHP38 and BAC-TO-BAC Baculovirus Expression System (GIBCOBRL) were used to prepare the recombinant baculovirus virusstock BAC-HP38.

(2) Cloning of human MKK3 gene and preparation of recombinant baculovirus

[0465] Cloning of human MKK3 gene was performed by a PCR method using a primer set MKK-U: 5'-ACAAGAATTCATAACATATGGCTCATCATCATCATCATTCCTCAAGCCACCCGCACCCAA-3' [SEQ ID NO:3] and ILK-L: 5'-TCCCGTCTAGACTATGAGTCTTCTCCCAGGAT-3' [SEQ ID NO:4] made by the use of kidney cDNA (Toyobo, QUICK-Clone cDNA) as a template and referring to the base sequence of MKK3 gene reported by Derijard, B. et al., Science 267 (5198), 682-685 (1995).

[0466] A PCR reaction was performed by a Hot Start method using AmpliWax PCR Gem 100 (Takara Shuzo). As the lower mixed solution, 2 μ L 10 \times LA PCR Buffer, 3 μ L 2.5 mM dNTP solution, each 2.5 μ L of 12.5 μ M primer solutions, and 10 μ L sterile distilled water were mixed. As the upper mixed solution, 1 μ L human kidney cDNA (1 ng/mL) as a template, 3 μ L 10 \times LA PCR Buffer, 1 μ L 2.5 mM dNTP solution, 0.5 μ L TaKaRa LA Taq DNA polymerase (Takara Shuzo) and 24.5 μ L sterile distilled water were mixed. One AmpliWax PCR Gem 100 (Takara Shuzo) was added to the prepared lower mixed solution and the mixture was treated at 70°C for 5 minutes and for 5 minutes in an ice and, thereafter, the upper mixed solution was added to prepare a reaction solution for PCR. A tube containing the reaction solution was set at a thermal cycler (Perkin Elmer), which was treated at 95°C for 2 minutes. Further, after repeating 35 times a cycle of 15 seconds at 95°C and 2 minutes at 68°C, treatment was performed at 72°C for 8 minutes. The resulting PCR product was subjected to agarose gel (1%) electrophoresis, 1.0 kb DNA fragment containing MKK3 gene was recovered from the gel and, thereafter, which was inserted into pT7Blue-T vector (Takara Shuzo) to make the plasmid pHMKK3.

[0467] In order to mutate MKK3 into a constitutive active form (from Ser to Glu at 189 position, from Thr to Glu at position 193), a primer set SER-U: 5'-GGCTACTTGGTGGACGAGGTGGCCAAGGAGATGGATGCCGGCTGC-3' [SEQ ID NO:5] and SER-L: 5'-GCAGCCGGCATCCATCTCCTTGGCCACCTCGTCCACCAAGTAGCC-3' [SEQ ID NO: 6] was used to introduce a mutation by QuikChange Site-Directed Mutagenesis Kit (Stratagene), to obtain pcaMKK3.

[0468] 4.8 kb EcoRI-XbaI fragment of the plasmid pFASTBAC1 (GIBCOBRL) and the 1.0 kb EcoRI-XbaI fragment of the above plasmid pcaMKK3 were ligated to make the plasmid pFBcaMKK3.

[0469] The plasmid pFBcaMKK3 and BAC-TO-BAC Baculovirus Expression System (GIBCOBRL) were used to pre-

EP 1 205 478 A1

pare the recombinant baculovirus virusstock BAC-caMKK3.

(3) Preparation of active form p38 MAP kinase

[0470] The Sf-21 cells were seeded on 100 mL Sf-900II SFM medium (GIBCOBRL) to 1×10^6 cells/mL and cultured at 27°C for 24 hours. After each 0.2 mL of the virusstock BAC-HP38 and BAC-caMKK3 of recombinant baculovirus were added, the culturing was further performed for 48 hours. After the cells were separated from the culturing solution by centrifugation (3000 rpm, 10 min), the cells were washed twice with PBS. After the cells were suspended in 10 mL Lysis buffer (25 mM HEPES (pH 7.5), 1% Triton X, 130 mM NaCl, 1 mM EDTA, 1 mM DTT, 25 mM β -glycerophosphate, 20 mM leupeptin, 1 mM APMSF, 1 mM Sodium orthovanadate), the cells were lysed by treating twice in a homogenizer (POLYTRON) at 20000 rpm for 2 minutes. From the supernatant obtained by centrifugation (40000 rpm, 45 minutes), active form p38 MAP kinase was purified using Anti-FLAG M2 Affinity Gel (Eastman Chemical).

(4) Measurement of the enzyme inhibitory activity

[0471] 2.5 μ L of a test compound dissolved in DMSO was added to 37.5 μ L reaction solution (25 mM HEPES (pH 7.5), 10 mM Magnesium Acetate) containing 260 ng active form p38 MAP kinase and 1 μ g Myelin Basic Protein, which was maintained at 30°C for 5 minutes. The reaction was initiated by adding 10 μ L ATP solution (2.5 μ M ATP, 0.1 μ Ci [g - 32 P]ATP). After the reaction was performed at 30°C for 60 minutes, the reaction was stopped by adding 50 μ L 20% TCA solution. After the reaction solution was allowed to stand at 0°C for 20 minutes, an acid insoluble fraction was transferred to GF/C filter (Packard Japan) using Cell Harvester (Packard Japan) and washed with 250 mM H_3PO_4 . After drying at 45°C for 60 minutes, 40 μ L Microscint 0 (Packard Japan) was added and the radioactivity was measured with a TopCount (Packard Japan). The concentration (IC_{50} value) of the test compound necessary for inhibiting uptake of 32 P into an acid insoluble fraction by 50% was calculated with PRISM 2.01 (Graphpad Software). The results are shown in Table 45.

Table 45

Reference Example Compound No.	IC_{50} (μ M)
13-14	0.086
13-15	0.081
13-16	0.060
13-70	0.026
13-74	0.63

Experimental Example 2

Measurement of inhibiting activity of TNF- α production

[0472] After THP-1 cells which had been cultured on PRMI 1640 medium (manufactured by Life Technologies, Inc.) containing 1% inactivated bovine fetal serum (manufactured by Life Technologies, Inc., U.S.A.) and 10 mM HEPES (pH 7.5) seeded on a 96-well plate to 1×10^5 cells/well, 1 μ L test compound dissolved in DMSO was added. After incubation at 37°C for 1 hour in a CO_2 incubator, LPS (Wako Pure Chemicals) was added to the final concentration 5 μ g/mL. After cultured at 37°C for 4 hours in a CO_2 incubator, the supernatant was obtained by centrifugation. The concentration of TNF- α in the supernatant was measured by ELISA (R&D Systems, Quantikine Kit). The concentration (IC_{50} value) of the test compound necessary for inhibiting TNF- α production by 50% was calculated using PRISM 2.01 (Graphpad Software). The results are shown in Table 46.

Table 46

Reference Example Compound No.	IC_{50} (μ M)
13-16	0.14
13-70	0.18
23-60	0.046

EP 1 205 478 A1

[0473] From the above results, it can be seen that Compound (I) has an excellent inhibitory activity against p38 MAP kinase and TNF- α production.

Industrial Applicability

[0474] Compound (I) has an excellent p38 MAP kinase inhibitory activity and TNF- α inhibitory activity and can be used as a prophylactic and therapeutic agent for cytokine-mediated diseases, such as p38 MAP kinase related diseases, TNF- α related diseases and the like.

5

10

15

20

25

30

35

40

45

50

55


SEQUENCE LISTING

5 <110>Takeda Chemical Industries, Ltd.
 <120>p38 MAP Kinase Inhibitors
 <130>2627W00P
 10 <150>JP11-224651
 <151>1999-08-06
 <160>6
 15 <210>1
 <211>62
 <212>DNA
 20 <213>Artificial Sequence
 <400>1
 25 ACCACTCGAG ATGGACTACA AGGAOCAAGA TGACAAGTCT CAGGAGAGGC CCAOGTTCTA 60
 CC 62
 <210>2
 30 <211>35
 <212>DNA
 <213>Artificial Sequence
 35 <220>
 <223>
 <400>2
 40 ACCCGGTACC ACCAGGTGCT CAGGACTOCA TCTCT 35
 <210>3
 45 <211>61
 <212>DNA
 <213>Artificial Sequence
 50 <400>3
 ACAAGAATTC ATAACATATG GCTCATCATC ATCATCATCA TTCCAAGCCA CCGCAOCCA 60
 55 A 61

5 <210>4
 <211>32
 <212>DNA
 <213>Artificial Sequence
 10 <400>4
 TCCCGTCTAG ACTATGAGTC TTCTCCAGG AT 32
 15 <210>5
 <211>45
 <212>DNA
 20 <213>Artificial Sequence
 <400>5
 25 GGCTACTTGG TGGACGAGGT GGCCAAGGAG ATGGATGCOG GCTGC 45
 <210>6
 <211>45
 30 <212>DNA
 <213>Artificial Sequence
 <400>6
 35 GCAGCCGGCA TCCATCTOCT TGGCCACCTC GTCCACCAAG TAGCC 45


45 **Claims**

- 50
1. A p38 MAP kinase inhibitory agent comprising a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof.
 2. A TNF- α production inhibitory agent comprising a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof, excluding a compound of the formula
- 55



wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of an aromatic ring, and R is a hydrogen atom, an acyl group or a monovalent aromatic group having not more than 10 carbon atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring, and a salt thereof.

3. The agent of claim 1 or 2, wherein the 1,3-thiazole compound is a 1,3-thiazole compound substituted at the 4-position by an aromatic group optionally having substituent(s).
4. The agent of claim 1 or 2, wherein the 1,3-thiazole compound is a 1,3-thiazole compound substituted at the 2-position by an aryl group optionally having substituent(s) or an amino group optionally having substituent(s).
5. The agent of claim 1 or 2, wherein the 1,3-thiazole compound is a compound of the formula



wherein R¹ represents a hydrogen atom, a hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), an amino group optionally having substituent(s) or an acyl group; R² represents a pyridyl group optionally having substituent(s); and R³ represents an aromatic group optionally having substituent(s), or a salt thereof.

6. The agent of claim 1 or 2, which is a prophylactic or therapeutic agent of cytokine-mediated diseases.
7. The compound of claim 5, wherein R¹ is

(i) a hydrogen atom,

(ii) a C₁₋₁₀ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₆ cycloalkyl group, a C₆₋₁₄ aryl group or a C₇₋₁₆ aralkyl group [these groups may have substituent(s) selected from the group (substituent group A) consisting of oxo, halogen atom, C₁₋₃ alkylendioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₂₋₆ alkenyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₂₋₆ alkynyl, optionally halogenated C₃₋₆ cycloalkyl, C₆₋₁₄ aryl, optionally halogenated C₁₋₈ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, C₆₋₁₄ aryloxy, C₇₋₁₆ aralkyloxy, mercapto, optionally halogenated C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₇₋₁₆ aralkylthio, amino, mono-C₁₋₆ alkylamino, mono-C₆₋₁₄ arylamino, di-C₁₋₆ alkylamino, di-C₆₋₁₄ arylamino, formyl, carboxy, C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, 5 or 6 membered heterocyclic carbonyl, carbamoyl, thiocarbamoyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₄ aryl-carbamoyl, 5 or 6 membered heterocyclic carbamoyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl, C₁₋₆ alkylsulfanyl, C₆₋₁₄ arylsulfanyl, formylamino, C₁₋₆ alkyl-carbonylamino, C₆₋₁₄ aryl-carbonylamino, C₁₋₆ alkoxy-carbonylamino, C₁₋₆ alkylsulfonylamino, C₆₋₁₄ arylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₆₋₁₄ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₄ aryl-carbamoyloxy, nicotinoyloxy, 5 to 7 membered saturated cyclic amino optionally having 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to one nitrogen atom and carbon atoms (this cyclic amino may have substituents selected from the group consisting of C₁₋₆ alkyl, C₆₋₁₄ aryl, C₁₋₆ alkyl-carbonyl, 5 to 10 membered aromatic heterocyclic group and oxo), 5 to 10 membered aromatic heterocyclic group containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom

in addition to carbon atoms, sulfo, sulfamoyl, sulfinamoyl and sulfenamoyl],

(iii) a monovalent heterocyclic group obtained by removing one arbitrary hydrogen atom from a 5 to 14 membered heterocycle containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms optionally having substituents selected from the above-mentioned substituent group A,

(iv) an acyl group represented by the formula:

$-(C=O)-R^5$, $-(C=O)-OR^5$, $-(C=O)-NR^5R^6$, $-(C=S)-NHR^5$ or $-SO_2-R^7$ wherein R^5 represents (a) a hydrogen atom, (b) a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl group, a C_{3-6} cycloalkyl group, a C_{6-14} aryl group or a C_{7-16} aralkyl group as defined in the above (ii) or (c) a heterocyclic group as defined in the above (iii), R^6 represents a hydrogen atom or a C_{1-6} alkyl group, R^7 represents (a) a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl group, a C_{3-6} cycloalkyl group, a C_{6-14} aryl group or a C_{7-16} aralkyl group as defined in the above (ii), or (b) a heterocyclic group as defined in the above (iii),

(v) an amino group (this amino group may have substituents selected from the group consisting of (a) a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl group, a C_{3-6} cycloalkyl group, a C_{6-14} aryl group or a C_{7-16} aralkyl group as defined in the above (ii), (b) a heterocyclic group as defined in the above (iii), (c) an acyl group as defined in the above (iv), and (d) a C_{1-6} alkylidene group optionally having substituent(s) selected from the above substituent group A), or

(vi) a 5 to 7 membered non-aromatic cyclic amino group optionally containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to one nitrogen atom and carbon atoms (this cyclic amino may have substituent(s) selected from the group consisting of C_{1-6} alkyl, C_{6-14} aryl, C_{1-6} alkyl-carbonyl, 5 to 10 membered aromatic heterocyclic group and oxo);

R^2 represents a pyridyl group optionally having substituent(s) selected from the above substituent group A; and

R^3 represents (a) a C_{6-14} monocyclic or fused polycyclic aromatic hydrocarbon group optionally having substituents selected from the substituent group A or (b) a monovalent aromatic heterocyclic group obtained by removing one arbitrary hydrogen atom from a 5 to 14 membered aromatic heterocycle containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms said 5 to 14 membered aromatic heterocycle optionally having substituents selected from the substituent group A.

8. The agent of claim 5, wherein

R^1 is (a) a C_{6-14} aryl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C_{1-6} alkyl, carboxy C_{2-6} alkenyl, optionally halogenated C_{1-6} alkoxy, C_{1-6} alkoxy-carbonyl- C_{1-6} alkoxy, hydroxy, amino, mono- or di- C_{1-6} alkylamino, carboxy, C_{1-6} alkoxy-carbonyl, mono- or di- C_{1-6} alkyl-carbamoyl, C_{6-14} aryl-carbonylamino, C_{1-3} alkylenedioxy, C_{1-6} alkylthio, C_{6-14} arylthio, C_{1-6} alkylsulfinyl, C_{6-14} arylsulfinyl, C_{1-6} alkylsulfonyl, C_{6-14} arylsulfonyl and nitro,

(b) C_{1-8} alkyl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C_{1-6} alkyl, carboxy C_{2-6} alkenyl, optionally halogenated C_{1-6} alkoxy, C_{1-6} alkoxy-carbonyl- C_{1-6} alkoxy, hydroxy, amino, mono- or di- C_{1-6} alkylamino, carboxy, C_{1-6} alkoxy-carbonyl, mono- or di- C_{1-6} alkyl-carbamoyl and C_{6-14} aryl-carbonylamino,

(c) C_{3-6} cycloalkyl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C_{1-6} alkyl, carboxy C_{2-6} alkenyl, optionally halogenated C_{1-6} alkoxy, C_{1-6} alkoxy-carbonyl- C_{1-6} alkoxy, hydroxy, amino, mono- or di- C_{1-6} alkylamino, carboxy, C_{1-6} alkoxy-carbonyl, mono- or di- C_{1-6} alkyl-carbamoyl and C_{6-14} aryl-carbonylamino,

(d) C_{7-16} aralkyl group,

(e) a 5 to 10 membered aromatic heterocyclic group containing 1 to 4 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms,

(f) a 5 to 10 membered non-aromatic heterocyclic group containing 1 or 2 of one or two kinds of heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, which may have C_{6-14} aryl, C_{1-6} alkyl-carbonyl or oxo,


(g) amino group optionally having 1 or 2 substituent(s) selected from the group consisting of the following (1) to (7) [(1) C_{1-6} alkyl, (2) C_{6-14} aryl, (3) C_{7-16} aralkyl, (4) a 5 or 6 membered heterocyclic group containing 1 or 2 heteroatom(s) selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, (5) C_{1-6} alkyl-carbonyl, C_{3-6} cycloalkyl-carbonyl, C_{6-14} aryl-carbonyl, C_{7-16} aralkyl-carbonyl, C_{1-6} alkyl-carbamoyl or 5 or 6 membered heterocyclic carbonyl group, optionally having 1 to 3 substituent(s) selected from halogen atom, C_{1-6} alkyl, C_{1-6} alkoxy, carboxy, C_{1-6} alkoxy-carbonyl, cyano, tetrazine and the like, (6) C_{6-14} aryl-carbamoyl group optionally having 1 to 3 substituent(s) selected from halogen atom, C_{1-6} alkyl, C_{1-6} alkoxy,

carboxy, C₁₋₆ alkoxy-carbonyl, cyano, nitro and mono- or di-C₁₋₆ alkylamino and (7) di-C₁₋₆ alkylamino-C₁₋₆ alkylidene], or
(h) a carboxy group.

9. The agent of claim 5, wherein R¹ is a C₆₋₁₄ aryl group optionally having C₁₋₆ alkylsulfonyl.
10. The agent of claim 5, wherein R² is a 4-pyridyl group optionally having substituent(s).
11. The agent of claim 5, wherein R³ is a C₆₋₁₀ aryl group optionally having substituent(s).
12. The agent of claim 5, wherein R³ is a phenyl group optionally having substituent(s).
13. The agent of claim 5, wherein R³ is a C₆₋₁₄ aryl group optionally having substituent(s) selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₈ alkoxy, carboxy C₁₋₈ alkoxy, hydroxy, C₆₋₁₄ aryloxy, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkyl-carbonyloxy, mono- or di-C₁₋₆ alkylamino and C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy.
14. The agent of claim 5, wherein R³ is a phenyl group optionally having substituent(s) selected from the group consisting of halogen atom and C₁₋₆ alkyl group.
15. The agent of claim 5, wherein R¹ is (a) an amino group optionally having 1 or 2 acyl represented by the formula: -(C=O)-R⁵ or -(C=O)-NR⁵R⁶ wherein each symbol is as defined above, (b) C₆₋₁₄ aryl group optionally having 1 to 5 substituent(s) selected from C₁₋₆ alkylthio, C₆₋₁₄ arylthio, C₁₋₆ alkylsulfinyl, C₆₋₁₄ arylsulfinyl, C₁₋₆ alkylsulfonyl, C₆₋₁₄ arylsulfonyl and carboxy or (c) C₁₋₆ alkyl group optionally substituted by halogen atom, R² is a pyridyl group, and R³ is a C₆₋₁₄ aryl group optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy and carboxy.
16. The agent of claim 5, wherein R¹ is
 - (i) C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₆₋₁₄ aryl optionally having 1 to 5 substituent(s) selected from halogen atom, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, hydroxy, amino, mono- or di-C₁₋₆ alkylamino, carboxy, C₁₋₆ alkoxy-carbonyl, mono- or di-C₁₋₆ alkyl-carbamoyl and C₆₋₁₄ aryl-carbonylamino,
 - (ii) a 5 membered heterocyclic group,
 - (iii) an amino group having 1 or 2 substituent(s) selected from (1) C₁₋₆ alkyl, (2) C₆₋₁₄ aryl, (3) C₇₋₁₆ aralkyl, (4) 6 membered heterocyclic group and (5) C₁₋₆ alkyl-carbonyl, C₃₋₆ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkyl-carbamoyl or 5 or 6 membered heterocyclic carbonyl, each optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, carboxy and C₁₋₆ alkoxy-carbonyl, or an amino group optionally having di-C₁₋₆ alkylamino-C₁₋₆ alkylidene,
 - (iv) a 5 or 6 membered non-aromatic cyclic amino group optionally substituted by C₁₋₆ alkyl-carbonyl or oxo, or
 - (v) a carboxy group;R² is a pyridyl group; and R³ is a C₆₋₁₀ aryl group optionally having 1 to 3 substituent(s) selected from halogen atom, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, carboxy C₂₋₆ alkenyl, optionally halogenated C₁₋₈ alkoxy, hydroxy, C₇₋₁₆ aralkyloxy and C₁₋₆ alkyl-carbonyloxy (two adjacent alkyl groups as substituents may be bonded to form a 5 membered non-aromatic carbon ring).
17. The agent of claim 5, wherein R¹ is a C₆₋₁₄ aryl group optionally having C₁₋₆ alkylsulfonyl, R² is a pyridyl group, and R³ is a C₆₋₁₄ aryl group optionally having halogen atom(s).
18. The agent of claim 1 or 2, which is a prophylactic or therapeutic agent for asthma, chronic obstructive pulmonary disease (COPD), allergic disease, inflammation, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis, osteoporosis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob dis-

ease, virus infection, atopic dermatitis, AIDS encephalopathy, meningitis, angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney failure, nephritis, malignant tumor, transplantation, dialysis hypotension or disseminated intravascular coagulation.


- 5 19. The agent of claim 1 or 2, which is a prophylactic or therapeutic agent of chronic rheumatoid arthritis or osteoarthritis.
20. N-Ethyl-4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine,
 N-propyl-4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine,
 10 N-butyl-4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine,
 N-benzyl-4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine,
 N-propyl-4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine,
 N-isopropyl-4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine,
 N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-phenylurea,
 15 4-[[[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid,
 methyl 4-[2-[4-(methylthio)phenyl]-5-(4-pyridyl)-1,3-thiazol-4-yl]phenyl ether,
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide,
 4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide,
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide,
 20 4-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone,
 4-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone,
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide,
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide,
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide,
 25 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide,
 4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone,
 4-[4-(4-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone,
 N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]-N'-phenylurea,
 2-hydroxy-N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]propionamide,
 30 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfide,
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfoxide,
 4-[4-(3,4-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylmethylsulfone,
 2-hydroxy-N-[4-(4-methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide,
 4-[[[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid,
 35 3-[[[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amino]carbonyl]benzoic acid,
 4-(4-fluorophenyl)-2-phenyl-5-(4-pyridyl)-1,3-thiazole, methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]
 phenylsulfide,
 methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfoxide,
 methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]phenylsulfone, or a salt thereof.
- 40 21. A method for inhibiting p38 MAP kinase, comprising administering an effective amount of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof to a mammal.
- 45 22. A method for inhibiting TNF- α production, comprising administering an effective amount of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof, excluding a compound of the formula



wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of an aromatic

ring, and R is a hydrogen atom, an acyl group or a monovalent aromatic group having not more than 10 carbon atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring, and a salt thereof, to a mammal.

23. A method for prophylaxis or treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic disease, inflammation, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis, osteoporosis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis, AIDS encephalopathy, meningitis, angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney failure, nephritis, malignant tumor, transplantation, dialysis hypotension or disseminated intravascular coagulation, which method comprises administering an effective amount of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof to a mammal.
24. A method for prophylaxis or treatment of chronic rheumatoid arthritis or osteoarthritis, which method comprises administering an effective amount of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof to a mammal.
25. Use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof for the production of a p38 MAP kinase inhibitor.
26. Use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug, excluding a compound of the formula



wherein Ar is an unsubstituted or substituted aryl group bonded to a thiazole ring by a carbon atom of an aromatic ring, and R is a hydrogen atom, an acyl group or a monovalent aromatic group having not more than 10 carbon atoms, which is bonded to a nitrogen atom by a carbon atom of the aromatic ring, and a salt thereof, for the production of a TNF- α production inhibitor.

27. Use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof for the production of an agent for the prophylaxis or treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic disease, inflammation, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, Crohn's disease, psoriasis, rheumatism, cerebral hemorrhage, cerebral infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis, osteoporosis, toxemia, Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis, AIDS encephalopathy, meningitis, angina pectoris, cardiac infarction, congestive heart failure, hepatitis, kidney failure, nephritis, malignant tumor, transplantation, dialysis hypotension or disseminated intravascular coagulation.
28. Use of a 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s), a salt thereof or a prodrug thereof for the production of an agent for the prophylaxis or treatment of chronic rheumatoid arthritis or osteoarthritis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/05198

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁷ C07D417/04, 417/14, A61K31/4439, 31/5377, A61P43/00, 11/06, 11/00, 37/08, 29/00, 7/06, 9/10, 25/28, 25/16, A61P21/00, 3/10, 19/02, 19/10, 39/02, 1/04, 31/06, 7/08, 9/10, 31/12, 17/04, 9/04, 1/16, 13/12, 35/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁷ C07D417/04, 417/14, A61K31/4439, 31/5377, A61P43/00, 11/06, 11/00, 37/08, 29/00, 7/06, 9/10, 25/28, 25/16, A61P21/00, 3/10, 19/02, 19/10, 39/02, 1/04, 31/06, 7/08, 9/10, 31/12, 17/04, 9/04, 1/16, 13/12, 35/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS, REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, 61425, A2 (CIBA-GEIGY A.-G.), 29 September, 1982 (29.09.82), & US, 4451471, A&FI, 8200877, A& DK, 8201184, A&NO, 8200881, A& GB, 2098203, A&ZA, 8201790, A& ES, 510504, A&AU, 8281667, A& JP, 57-183767, A&IL, 65285, A& DD, 202705, A&ES, 522868, A& ES, 522869, A&ES, 522867, A& ES, 537278, A&ES, 537277, A& ES, 537343, A&ES, 537342, A	1, 3, 6, 18, 19, 25-28
X	EP, 149884, A2 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 31 July, 1985 (31.07.85), & JP, 60-58981, A&JP, 61-10580, A&	1-19, 25-28 20
A		
X	WO, 99/21555, A2 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 21 July, 1999 (21.07.99), & AU, 9896480, A&JP, 11-193281, A&	1-19, 25-28
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 16 November, 2000 (16.11.00)		Date of mailing of the international search report 24 October, 2000 (24.10.00)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

EP 1 205 478 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/05198

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	EP, 1027050, A2	
X	JP, 11-49762, A (JAPAN TOBACCO, INC.), 23 February, 1999 (23.02.99) (Family: none)	1, 4, 6, 18, 19, 25-28
EX	WO, 00/49015, A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 24 August, 2000 (24.08.00) (Family: none)	1, 4, 6, 18, 19, 25-28
PX	WO, 99/64418, A1 (NOVARTIS-ERFINDUNGEN VER- WALTUNGSGESELLSCHAFT MBH), 16 December, 1999 (16.12.99) & AU, 9945063, A	1-6, 8-16, 18, 19 , 25-28

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/05198

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 21-24
because they relate to subject matter not required to be searched by this Authority, namely:
The inventions as set forth in claims 21 to 24 pertain to methods for treatment of the human body by therapy.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.